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The tetrahydrofuran containing acetogenins (THF-ACGs) are a naturally occurring class of compounds 
with potent toxicity against a broad range of tumors, including multidrug resistant (MDR) strains. However, 
the equally high toxicity to normal cells presents a hurdle for their clinical advancement. This study entails 
synthetic and tumor targeting strategies that are relevant to their therapeutic development.  
Chapter 1 presents a review of the synthesis and biological activity of the THF-ACGs. Chapter 2 covers a 
modular approach for the synthesis of libraries of THF-ACGs. This strategy is illustrated in the synthesis 
of C-10 epimers of 4-deoxyannonomontacin (4-DAN), one of the more potent monotetrahydrofuran 
acetogenins. Towards the discovery of synthetically more accessible and tumor-selective analogues, 
Chapter 3 describes the application of this methodology to analogues of 4-DAN where the THF ring is 
substituted by mannose with different chain lengths and/or the butenolide is substituted by simpler 
heterocycles.   
To address the issue of systemic toxicity, Chapter 4 presents tumor-targeting strategies for the THF-
ACGs and their mimics. In the ‘chameleon’ approach the THF moiety was replaced with the 3-O-
carbamoyl-mannose residue, present in bleomycin, a family of clinically used anti-tumor agents and 
believed to be responsible for their tumor selectivity. Therefore, the carbamoyl containing mannose 
residue could confer both drug potency and selectivity. A prodrug strategy in which a naturally occurring 
THF-ACG or synthetic analogue is conjugated via a cleavable linker to a tumor vector, is also described. 




the active cytotoxic agent. As proof of principle, prodrugs comprising a sugar analogue of 4-DAN or the 
naturally occurring acetogenin annonacin, 2-[3-(1,3-dicarboxypropyl)ureido] pentanedioic acid (DUPA),  a 
highly specific vector for prostate specific membrane antigen (PSMA) in prostate cancer (PCa), and a 
traceless disulfide-based linker were synthesized.  
Chapter 5 presents the cytotoxicity data for the new THF-ACGs and structure activity conclusions. Using 
an MTT assay at both 16 and 48 hours, the cell viability of the THF-ACGs and their mimetics were 
evaluated against five cancer cell lines: MDA-MD-231 (triple negative breast), MCF-7 (breast), HCT116 
(colon), PC-3 (PSMA negative prostate cancer) and LNCaP (PSMA positive prostate). THF containing 
analogues generally showed a lower IC50 (ca 0.5-5 micromolar) across the panel of cell lines than ones in 
which the THF is replaced by a mannose. For the analogues with butenolide replacements, the 
thiophene-2-carboxamide residue was the most active substitute and their derivatives showed 
comparable or higher activity than their butenolide parents. The cytotoxicity of sugar mimetics with alkyl 
ether chains of different lengths and positions was also determined. While individual analogues displayed 
low micromolar potency and selectivity across the five cell lines tested, no clear structure activity trends 
emerged. An ACG mimetic in which the THF and butenolide segments were replaced with 3-O-
carbamoyl-mannose and thiophene-2-carboxamide residues respectively, showed potent activity in the 
0.1-10 M range against LNCaP and PC-3. Although not evaluated, the tumor selectivity of this mimetic is 
particularly interesting given its structural similarity to the bleomycins.  
The cytotoxicity activity of the DUPA-linked prodrugs derived from a mannose based ACG mimetic and 
the naturally occurring ACG annonacin was also evaluated. In the 16 h MTT assay against LNCaP 
(PSMA positive), the two prodrugs were more active than their parent drugs. However, against the PSMA 
negative cell lines, MDA-MD-231, MCF-7, HCT116 and PC-3 both prodrugs and their parent drugs 
showed similar activity and were appreciably less active than for LNCaP. The higher toxicity for LNCaP 
over the PSMA negative cell lines, albeit modest (ca 2:1), supports the notion that this selectivity is 
connected to DUPA-PSMA binding, and that PSMA is an internalizing receptor. However, in a 48 h MTT 
assay, while the cytotoxicity of the prodrugs and parent drugs against MDA-MD-231, MCF-7, HCT116 




increased markedly. This unexpected trend for PC-3 does not align with our prodrug hypothesis and may 
be an indication that these DUPA-linked ACGs have a different mechanism of action than their parent 














“Our greatest weakness lies in giving up. The most certain 
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TETRAHYDROFURAN CONTAINING ACETOGENINS: 





1.1.  Introduction and background 
 
Cancer remains a major health challenge despite major advances in early detection, diagnosis and 
treatment. The current lines of treatment involve chemotherapy, surgery, radiation or most commonly, a 
combination of the three. Small organic molecules are a primary line of treatment and usually those have 
been identified from natural sources. Plants have been used since ancient times to treat many diseases: 
between the 1940s and 2014, 175 molecules were approved for the treatment of cancer and 49% of 
those are natural products or modified natural compounds.2 To this end, the naturally occurring 
tetrahydrofuran containing acetogenins (THF-ACGs) are of interest because of their high potencies 
against a broad panel of human cancer cell lines, including several multidrug resistant (MDR) ones and 
their relatively simple structures. However, while certain THF-ACGs show selectivity for certain cancer 
cells, challenges for their clinical use are systemic toxicity and a lack of understanding of their 
mechanisms of action.  
 
1.2. Tetrahydrofuran containing acetogenins 
 
The tetrahydrofuran containing annonaceous acetogenins (THF-ACGs) are a relatively untested family of 
cytotoxic agents isolated from the Annona species. These evergreen trees are usually found in tropical 
and subtropical areas. ACGs can be found in the leaves, roots, seeds, pulp of fruits like graviola, soursop, 
pawpaw, guanabanana, Brazilian pawpaw and 
custard apple. The first compound of this class, 
uvaricin3 1.1, was isolated in 1982 via an activity-
directed fractionalization using 3PS cells in vivo 
(murine leukemia) testing of the extracts. Its 
unusual bioactivity attracted the attention of many, 
hoping to isolate and/or synthesize the future 




class of compounds. Since then, more than 400 compounds have been isolated from natural sources.4,5,6 
Many of them have been synthesized and analogues have been designed and synthesized seeking for 
the “magic bullet”. Many of them have antitumoral effects, as well as antimicrobial, antimalarial, 
antifeedant, antiviral, anthelminthic, antiprotozoal, pesticidal and immunosuppressive.7,2,8 Unfortunately, 
as of 2019, this class of compounds are still strong candidates for the development of new drugs, but the 
lack of understanding of their mode of action makes targeting of specific tumors and designing active and 
selective analogues a tremendous challenge.  
The highly lipophilic THF-ACGs derive from the polyketide pathway and have a C35 or C37 aliphatic chain 
that contains: (i) one, two or three THF tetrahydrofuran rings that can be adjacent or not; (ii) a terminal α, 
β-unsaturated δ-lactone; (iii) a series of oxygenated groups (hydroxyls, acetoxyls, ketones, epoxides) 
and/or double bonds (Figure 1.2).  
 
Figure 1.2. Structural features of the THF containing acetogenins 
 
 
1.3. Synthesis of THF-ACGs 
 
The potent biological activities of the THF-ACGs and their stereochemical complexity have motivated 
considerable interest in their synthesis. Since 1996, over 100 total syntheses have been reported.9, 10, 11 




Convergent, linear and biomimetic strategies for naturally occurring THF-ACGs, derivates, as well as non-
natural analogues have been described. A major emphasis has been the synthesis of the 
stereochemically complex tetrahydrofuran segment which has employed inexpensive chiral starting 
materials, such as carbohydrates and amino acids, and a variety of asymmetric reactions including:  (i) 
oxidative cyclization of hydroxy alkenes, (ii) epoxidation-epoxide opening sequence on 4-alkene-1-ol 
precursor, (iii) iodoetherification of hydroxy alkenes, (iv) ring closing metathesis, (v) Sharpless 
dihydroxylation followed by acid catalyzed cyclization; (vi) base catalyzed cyclization;11d (vii) 
diastereoselective Williamson reaction; (viii) chiral ligand-controlled cyclization; (ix) radical cyclization. 
Table 1.1 exemplifies the more popular strategies.  
 
Table 1.1. Strategies for the tetrahydrofuran ring synthesis 
 



























































































Several approaches for the butenolide segment have also been reported: ((i) ruthenium catalyzed; (ii) Pd 
catalyzed coupling); (iii) sulfonium enolate-elimination or (iv) the aldol-elimination. The ruthenium 
catalyzed ring formation reported by Brown24 is of special interest because it accomplishes both the 












































A number of strategies have been used for the coupling of tetrahydrofuran and butenolide subunits (Table 
1.3): (i) Sonogashira coupling; (ii) Wittig olefination; (iii) cross metathesis; (iv) ring closing metathesis; (v) 
addition of organometals to aldehydes; (vi) Koscienski-Julia coupling; (vii) Nozaki-Hiyama-Kishi reaction; 
(viii) crotylation; (ix) epoxide opening. The Sonogashira and the Grubbs approaches have the broadest 
scope.  
 
Table 1.3. Coupling strategies of the THF and butenolide segments 
 Examples 
 





































































































Table 1.4 lists the more recent publications in the field. These studies have focused on using the 
foregoing methods to synthesize unnatural analogues for biological studies.  
 
Table 1.4. Recent publications on THF-ACGs syntheses 
 
Year Title Notes Ref 
2008 
Synthesis and antitumor activity of C-9 epimers of the 
tetrahydrofuran containing acetogenin 4-deoxyannoreticuin 
Total synthesis 35 
2010 
Synthesis of the Annonacin isolated from Annona 
densicoma 
Total synthesis 36 
2011 
Modular assembly of cytotoxic acetogenin mimetics by click 
linkage with nitrogen functionalities 
Synthesis of analogues 







Critical role of a methyl group on the δ-lactones ring of 
annonaceous acetogenins in the potent inhibition of 
mitochondrial complex I 
Development of 




Structure-activity relationships of hybrid annonaceous 
acetogenins: powerful growth inhibitory effects of their 
connecting groups between heterocycle and hydrophobic 
carbon chain bearing THF ring on human cancer cell lines 
Solamin analogues 
using as butenolide 
replacement N-pyrazole 
39 
2013 Total synthesis of 14,21-diepi-squamocin-K 




New cytotoxic annonaceous acetogenin mimetics having a 








Thiophene-3-carboxamide analogue of annonaceous 
acetogenins as antitumor drug lead 
Substitution of the 
butenolide by a 




Total synthesis of Muricadienin, the Putative Key precursor 
in the Solamin Biosynthesis 
Total synthesis 43 
2015 
Synthesis of dansyl-labeled probe of thiophene analogues of 
annonaceous acetogenins for visualization of cell 
distribution and growth inhibitory activity toward human 
cancer cell lines 











Covergent synthesis of stereoisomers of THF ring moiety of 
acetogenin thiophene analogue and their antiproliferative 
activities against human cell lines 
Synthesis of analogues 
– replacement of 




Total synthesis of two possible diastereomers of natural 6-
chlorotetrahydrofuran acetogenin and its stereostructural 
elucidation 
Total synthesis 47 
2018 
Convergent total synthesis of asimicin via decarbonylative 
radical dimerization 
Total synthesis 48 
2018 
A general diastereoselective strategy for both cis- and trans-
2,6- disubstituted tetrahydropyrans: formal total synthesis of 
(+)-muconin 




It is evident that organic chemists have been fascinated with this class of complex structures since their 
discovery and are excited and intrigued by their wide range of biological activities and potential use in the 
clinic. 
 
1.4. Mode of action 
 
It has been suggested that the ACGs act on cancer cells by inhibition of the NADH-ubiquinone reductase 
(complex I), a membrane-bound protein of the mitochondrial electron-transport system, and the 
nicotinamide adenine dinucleotide (NADH) oxidase, characteristic of the plasma membranes in tumor 
cells.11c Mechanistic studies have focused on action on Complex I. McLaughlin50 has proposed a model in 
which the more lipophilic parts of the molecule, the THF rings and the alkyl chain, are anchored to the 
mitochondrial membrane. Once positioned, the alkyl spacer helps directing the butenolide, or warhead, to 
the active site on the enzyme (Figure 1.3).2 This results in the inhibition of oxidative phosphorylation and 
ATP production. Because cancer cells are estimated to rely on mitochondrial oxidation for 40-75% of the 
required ATP, complex I inhibition may contribute to some degree in the antitumor activity. Alternatively, 
antitumor activity may be the result of triggering the mitochondrial apoptotic pathway. The contribution of 
these different pathways to the overall toxicity could explain the difference in susceptibility of different cell 









The mitochondrial apoptotic pathway entails the efflux of mitochondrial contents into the cytosol as a 
result of the disruption of the mitochondrial membrane, which in turn may be promoted by depletion of 
mitochondrial ATP. In this context, different apoptotic mechanisms have been studied. 
Alteration of the cytosol would affect the endoplasmic reticulum causing release of Ca2+. The inability of 
the cell to restore Ca2+ homeostasis, will trigger caspase activation an eventually cell death. This 
sequence of events that are part of the endoplasmic reticulum stress disorder (ERS) were observed by 
Wu’s group52 when treating the human nasopharyngeal carcinoma (NPC) cells with THF-ACGs.  
Other indicators of the apoptotic pathway are the alteration of the Bcl-2/Bax protein ratio, the activation of 
caspases 3 and 9 and the production superoxide anion and hydrogen peroxide (ROS). All of which were 
reported by Tormo53 when treating Hep2G cells with THF-AGEs. Tormo also reported a dramatic 
decrease in the mitochondrial transmembrane potential (MTP) – a measurement of the mitochondrial 
function, as it is generated by the pumping of electrons across the membrane- and in the mitochondrial 
membrane permeability transition pore (MPTP) – which opening allows calcium homeostasis.  
 
Other signals/targets that have been reported to be altered by the THF-AGEs related to the mitochondrial 
apoptotic pathway are: (i) Notch signaling54. Treatment of gastric cancer cells with THF-ACGs resulted in 
Notch2 up-regulation in a dose dependent manner, which resulted in cell growth inhibition; (ii) The 
hypoxia-inducible factor-1 (HIF-1)55 activates the expression of more than 100 genes involved in 
adaptation and cell survival under hypoxia conditions. It is suggested that hypoxia increases the levels of 
ROS, which in turn inactivate HIF-1α protein, resulting in activation of HIF-1. T47D cells treated with THF-
ACGs inhibited HIF-1 activation with IC50 values from 0.02-31 µM; (iii) Estrogen receptor-α (ERα). 
Annonacin decreased cell survival in ERα positive cells but not on ERα negative cells, suggesting that the 
receptor may play a key role in the mode of action of THF-AGEs. Moreover, annonacin also inhibited 
expression of D1 and Bcl-2 receptors. These in vitro results were confirmed in in vivo assays using cell-
grafted nude mice.  
 




attributed to an increased expression of the P-170 glycoprotein, drug efflux pump in the plasma 
membrane. ACGs may act against MDR cells by their inhibition of ATP production, which is required for 
active efflux. 
The inhibition of NADH oxidase in the plasma membrane of certain tumor cells, involved in ATP 
production for glycolysis, may lead to both necrotic and apoptotic pathways. This may explain the 
selectivity observed against certain cell lines. Another basis for selectivity, could be that the mitochondria 
for certain tumor cells seems to be different from their healthy counterparts. They exhibit comprehensive 
metabolic differences that makes them more sensitive to mitochondrial perturbation than normal cells.56 
In this context, the ACGs are an interesting group of potential clinical agents.  
 
1.5. Activity studies 
In the early stages of extraction and isolation of THF-AGEs from seeds, pulp, leaves or other parts of the 
Annonaceae plants, the potential as cytotoxic agents of this class of compounds was recognized. In order 
to evaluate the extracts, each one of the partition fractions from the extractions of the naturally obtained 
samples were tested using the brine shrimp lethality assay. If the fraction contained the cytotoxic 
compound, shrimp would not survive, and therefore the extract would be further purified to isolate 
individual compounds. That could be considered the first cytotoxicity assessment of THF-ACGs. 
Some research has been focused on the biological evaluation in vitro and in vivo of the crude extracts 
from the plants57,58 and other researchers have isolated compounds from the extracts and studied their 
biological activities. Even though the data collected for the extracts is valuable and seems to be in 
concordance with the one of individual compounds, it is beyond the scope of this discussion and we will 
center our attention in studies of isolated compounds.   
When first discovered, the tetrahydrofuran containing annonaceous acetogenins (THF-ACGs) showed 
potent cytotoxicity against a wide range of human tumor cell lines. The first in vivo study carried out by 




xenografts. Thereafter, the interest in this family of compounds, grew exponentially, resulting in the 
isolation of 400 compounds in 27 years in the search of the ‘magic bullet’ against tumor cells. Even 
though in vitro studies have proven useful to identify potential cytotoxic compounds or “magic bullets” 
have not been so successful when carried out in vivo. In solid tumors, other factors need to be considered 
such as pH differences or gradient of nutrition concentrations. Those have a great impact in the cell 
viability, the metabolism and the sensitivity to treatment60 and may be the reason why these compounds 
have not yet been advanced to clinical studies.  
Although these compounds showed potential in the cell studies, there has been a gradual loss of interest 
in this class of compounds due to the challenges with systemic toxicity. In particular there is a concern in 
neuronal toxicity. It has been reported that in regions where there is a high consumption of herbal tea and 
fruits from plants of the Annonaceae family61 there is a high rate of parkinsonism. Targeting compounds 
to cancer cells could address these issues.  
 
1.5.1. In vitro 
The lack of a stablished protocol towards the evaluation of the compounds, makes the makes the 
reproducibility and comparison of newly acquired data challenging. Based on the comparison of different 
reports, the activity seems to vary with incubation time. Holschneider62  treated different cell lines with 
bullatacin for 48 and 72 h observing ED50s of 10 vs 10-7 µg/mL for OC-194 cells and 50 vs 4 µg/mL for 
OVCAR-3 cells, respectively. Cytotoxicities vary with incubation time and across different cell lines. To 
this date there is not an explanation as to why some cell lines are more affected by THF-ACGs than 
others. Elucidation of the mode of action could bring some insight to this matter. The disparity of data 






Table 1.5. Example of the data disparity among different cell assays in THF-ACGs 
 
Compound Cell line 
ED50  (µg/mL) IC50  (µg/mL) 
48 h 72 h 5 days 
 
Bullatacin 




A-549 1.3x10-13 3.3x10-2 
























  4.8 x 10-3 
MKN-45   5.3x10-2 
 
 
1.5.2. In vivo  
 
Not many in vivo evaluations of the THF-ACGs have been published. The first one was the activity-
directed fractionation of P388 murine leukemia assay on uvaricin. The Upjohn company reported that 
treating mice with 25 µg/kg and 1.4 mg/kg would increase their life span by 124-157%, respectively.3,59 
The abovementioned data showed that bullatacin and other isolated derivatives were potential antitumor 
agents based on their efficacy in normal mice with L1210 murine leukemia and immunodeficient mice 




In another study, the in vivo activity of annonacin was examined using mouse lung carcinoma (LLC) 
tumor cells in BDF-1 mice.66 The difference of this study with the ones that had been published before is 
that the ratio of activity towards the tumor vs activity towards the host was much higher than in previous 
cases: at a dose of 10 mg/kg of annonacin no mice died while three and five out of six died in the 
controls. This seemed to suggest that annonacin was less toxic towards the host than other compounds.  
In a separate study also on annonacin, mice bearing MCF-7 xenografts were treated with 50 mg/kg/day 
for 21 days and the tumor size was measured every 3 to 4 days. It was observed that the size of the 
tumor decreased in 7 to 22 days. In 2012, Fan et al67 evaluated 5 compounds: squamostatiin A, 
squamostatiin E, 4-deoxyannoreticuin, desacetyluvaricin, bullatacin were tested the against S180 and 
Hep9 xenograpft bearing mice. Their findings agreed with their in vitro results: (i) the two bis-THF 
compounds, showed the highest antitumor inhibition of between 64 and 71% at a dose of 60 µg/kg; (ii) out 
of the two bis-THF compounds, the one with adjancent THF showed higher activity and (iii) bullatacin at 
higher doses showed the highest activity but also more adverse effects.  
The above examples suggest that treatment of mice with THF-ACGs in vivo reduced tumor size without 
affecting the host. However, in the studies below, treatment of mice with THF-AGEs would not stop tumor 
growth (at low dosages) and/or would cause host death (at high dosages).  
The data published in 1994 by Montz and coworkers63 proved that using a murine ovarian 
terotocarcinoma (MOT) model in C3HeB/Fej mice, the injection of bullatacin made no difference in the 
MOT-related animal death at non-lethal dose ranges for both, single dose administration or if the dosage 
was divided over time. At low dosages the tumor growth was not inhibited and at higher dosages 
bullatacin killed the host.  
In the most recent in vivo study, in 2013, Li60 injected H22 hepatoma cells bearing mice with 
annosquamin B, bullatacin and annosquatin B. They established that: (i) a single injection of 100 µg/kg 
did not influence healthy mice; (ii) treatment of tumor bearing mice with 5 doses of 25-50 µg/kg produced 
61% reduction of the tumor size, whereas the other two compounds reduced the tumor size by 53.7 and 




kidney tissue damage proved by an increase in calcium concentration, ROS production and Bax/Bcl-2 
ratio in rats.  
Table 1.6 summarizes the in vivo data published in recent years and most of the examples have been 
discussed above.  
Table 1.6. Summary of in vivo studies of THF-AGCs 
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Both the in vivo and in vitro reports demonstrate how toxic this family of compounds is to all type of cells 
and supports our claim that in order to become clinical agents, these compounds need to be targeted at 
cancer cells.   
 
1.6. SAR studies  
 
Several studies on structure activity relationships (SARs) in THF-ACGs have been published,12, 69 
establishing the structural elements required for toxicity: a cyclic ether core, a butenolide, a hydrophobic 
spacer which connects one end to the cyclic ether core to the butenolide, and a hydrocarbon tail, which is 
attached to the other end of the cyclic ether core (Figure 1.2). However, predicting the effects of structural 
modification is challenging as SAR studies have been based on different assays, primarily mitochondrial 
and cytotoxicity assays, and it is often difficult to compare data from different researchers. In addition, as 
discussed in the Mode of Action section, new mechanisms of action are being elucidated and SAR data 




On the mitochondrial and cytotoxic assays, the role of the butenolide is the more extensively studied. 
However, it is still uncertain if its presence is necessary for the compounds to remain active. In an early 
study, Takada and coworkers70 used a bis THF model to evaluate whether inverting the (S) configuration 
of the lactone found would affect the inhibitory potency of complex I. Their study concluded that the R- 
configuration analog was as potent as the natural occurring one. Based on those findings, Takada 
expanded the study using a bullatacin-like structure (Figure 1.4).70 He concluded that: (i) removing the 
alcohol from position 4 in bullatacin 1.67 did not affect inhibitory potency, see 1.68; (ii) removing the 
methyl 1.69 had no effect in the potency; (iii) the bulkier n-butyl derivative, 1.70 retained an activity in the 
same order of magnitude as the parent drug.  
 
Figure 1.4. Takada studies on the modification of the butenolide 
 
Based on those results, it was suggested that the recognition of the butenolide (or any butenolide 
substituent) by the enzyme is weak and that could be a consequence of a large cavity binding domain in 
complex I.  
Hoppen71 substituted the butenolide by the natural target of the mitochondrial complex I (NADH-
ubiquinone oxidoreductase), quinone.  In the inhibitory studies, it was found that the lactone could be 
substituted by the quinone ring and the compound would still be active. These findings led to the idea that 
both ubiquinone and the anonnaceous acetogenins are competitive inhibitors of the same binding site of 
complex I. Hocquemiller72 explored the possible replacements of the butenolide by synthesizing a library 




quinazoles or benzimidazoles. Some of the modifications resulted in analogues with high activities, 
however, it must be noted that alteration of the structure may result in a completely different mechanism 
of action. 
In more recent years, other groups have substituted the butenolide for simpler heterocycles such as 
thiophene,39, 42, 44, 46 piperazine41 or N-methylpyrazole39 and have obtained analogues with maintained or 
increased activities. The thiophene and piperazine cases will be discussed in Chapter 3. These studies 
suggest that a butenolide-like structure may be necessary for complex I targeting. 
Other SAR studies propose the middle of the hydrophobic spacer as the ideal position for conjugation for 
tumor targeting or for introduction of a fluorescent group or radiolabel for imaging. Others12 have 
evaluated the length of the hydrophilic spacers as well as the polarity of the tetrahydrofuran and its 
surroundings and was determined that it was a fundamental feature to maintain activity. 
There is controversy regarding the hydroxyl groups in the hydrophilic spacer. Some claim that activity 
varies depending on the position of the hydroxyls,73 Chen67 suggested that two hydroxyls flanking the 
THF and a third one somewhere else are necessary, others proposed that hydroxylation at position 4 
could be involved in a unique intramolecular interaction with the butenolide,74 and Takada’s70 results (see 
Figure 1.3) seem to indicate that removal of the hydroxyl at position 4 does not compromise the activity of 
the compound.   
Even though much progress has been made in elucidating the role of the structural elements of the THF-
ACGs there is a need for a wider library of molecules to expand SAR trends and elucidate new pathways. 



















2.1. Introduction and background 
 
The tetrahydrofuran containing acetogenins (THF-AGEs) exhibit high activities and selectivities for certain 
tumors, but they are also too potent to normal cells. Therefore, there is an interest in developing novel 
synthetic analogues that may present higher selectivity towards tumors. THF-AGEs can be obtained from 
natural resources, but it is challenging because of the difficult purification that results in low yields. In 
order to easily access a library of compounds for structure-activity relationship studies and clinical 
development is important to develop a synthetic method. That method should be convergent to allow 
synthetic modification at late stages and tolerate a broad range of functional groups. 
The mono THF-AGE 4-deoxyannomontacin (4-DAN), 2.1 was selected as a model to develop new 
synthetic strategies as its structure is relatively simple and it shows high potency against a wide range of 
human tumor cell lines in an MTT 7-day assay (Figure 2.1). 
 
Figure 2.1. Structure of 4-deoxyannomontacin (7-day MTT assays) 
 
4-DAN was first isolated from Goniothalamus giganteus in 1997 by McLaughin75 and coworkers. The only 
total synthesis was reported in 1999 by the Wu group.76 The key reaction in this synthesis was the 
Sonogashira coupling of vinyl iodide 2.5 and alkyne 2.9, in which diimide reduction25 on the enyne 
product gave 4-DAN. 
Iodide 2.5 was obtained in 13 steps starting from compound 2.3 in a 22% overall yield. Aldehyde 2.3 was 
obtained from D-glucose 2.2. After elongation of the side chain using a Wittig-Horner reaction and 
reduction of the alkene, the resulting ester was treated with propane-1,3-dithiol in the presence of 
BF3.Et2O to give the lactone-diol. Then, it was protected in situ to afford a lactone that was reduced with 





alkenes. After photoisomerization of the alkene, only Z was obtained. The alcohol was converted to the 
tosylester and the alkene was subjected to asymmetric dihydroxylation using AD-mix-β. With the diol in 
hand the THF ring was constructed using an intramolecular Williamson etherification on substrate 2.4.  
 
 
Scheme 2.1. The Wu approach to 4-DAN 
 
The free alcohol was protected with MOM. After deprotection of the isopropylidene, epoxide formation 




iodide 2.5 using tributyltin hydride followed by iodine. Alkyne 2.9 was obtained from methyl ester 2.6 and 
ethyl (S)-(-)-lactate using an aldol-cyclization tandem previously reported.77 Then, the epoxide was 
introduced using the terminal alkene as substrate and upon elimination, the racemic mixture was 
obtained. The CoIII-Salen catalyzed hydrolytic kinetic resolution of epoxide 2.7 delivered the resolved 
oxirane that was treated with n-butyl lithium and trimethylsilylacetylene to deliver silyl 2.8. Desylation of 
the alkyne yielded lactone 2.9. Overall 4-DAN was synthesized in an overall yield of 15% from over 17 
steps starting from 2.3 and 2.8.   
In earlier studies in our laboratory, 4-deoxyannoreticuin (4-DAR), 2.10 and 2.11, a very closely related 
analog of 4-DAN, showed that the configuration at the position corresponding to C-10 in 4-DAN did not 
impact on cytotoxicity against several cell lines. Therefore we decided, for synthetic convenience, to 
prepare 4-DAN as a mixture of C-10 epimers 2.12.35 (Figure 2.2). 
   
 
Figure 2.2. 4-deoxyannorecticuin (2.10 and 2.11) and 4-deoxyannomontacin (2.12) 
 
 
2.2. Synthetic strategy 
 
Our synthetic plan follows a modular approach, involving a cross metathesis (CM) strategy that was first 




(S) and (R)-deoxyannoreticuin, 2.10 and 2.11, and the mannose containing analogues of the THF-ACGs, 
2.18. (Figure 2.3).78, 77, 79  
 




 Synthesis of 4-deoxyannoreticuin (2008)35: 
 
 
 Synthesis of mannose containing analogues (2013)79: 
 
 




This approach was later applied to analogues of the mono-THF solamin by Konno et al.81 (Figure 2.4). 
Starting with either (+)-muricatacin or (-)-muricatacin, 2.28a and 2.28b, they were able to synthesize three 
different allylic alcohols, 2.24, 2.25 and 2.16. that were then subjected to a CM with the butenolide 
counterparts, 2.26 and 2.27, respectively, to deliver the three known natural compounds cis-solamin A 
2.21, cis-solamin B 2.22, and reticulatacin 2.23.  
 
Konno’s work on solamin type acetogenins (2010)81: 
 
 











Figure 2.5. CM approach to the synthesis of the C-10 epimeric mixture of 4-DAN 
 
For their synthesis of the THF-alkene, 2.16, (-)-muricatacin 2.28b was converted into the α,β-unsaturated 
ester and then cyclized back to yield the allylic alcohol. Then, it was converted to the epoxide, that was 
subsequently converted into the diol and subjected to oxidative cleavage. The resulting aldehyde was 
then treated with vinyl magnesium bromide and after removal of the protecting group, compound 2.16 
was obtained in 8 steps with an overall yield of 4%. 
Konno’s group obtained the butenolide partners, 2.26 and 2.27 by subjecting trans-3-pentenenitrile to an 
osmium catalyzed dihydroxylation followed by acid catalyzed hydrolysis-lactonization that yielded the 
racemic mixture of the hydroxylactone 2.29. The mixture was then separated by using a lipase-mediated 
kinetic transesterification. Our approach to the butenolide 2.30 segment must be different because of the 
presence of a hydroxyl group in the hydrophobic spacer. In both cases, the convergent nature of this CM 
strategy is particularly attractive because of its synthetic efficiency and flexibility for later modification in 
the synthesis of analogues. 
Towards the synthesis of the epimeric mixture of 4-DAN, 2.12, we applied the same strategy developed in 






2.3.1. THF alkene, 2.16 
The synthesis of the THF allylic alcohol 2.16 started with the known alcohol 2.31 that underwent a 
Johnson Claisen rearrangement to deliver unsaturated ester 2.3224 (Scheme 2.2). LiAlH4 reduction on 
2.32 provided the hydroxyalkene82 2.33, which was subjected to Sharpless dihydroxylation with AD-mix β 
to give triol 2.34 in excellent yields.82 Treatment of 2.34 with 2,2-DMP and p-TsOH furnished the 
isopropylidene derivative 2.35. Comparison of the NMR data of the (R)-MTPA Mosher ester of 2.35 with 
the diastereomeric mixture of R-Mosher esters from racemic 2.35 (obtained via OsO4 dihydroxylation on 
2.33), indicated that the enantiomeric excess of 2.34 was greater than 95%. Next, PCC oxidation on 2.35 
provided aldehyde 2.36, which was reacted with methyl (triphenylphosphoranylidene) acetate to yield the 
Wittig product 2.37, exclusively as the E-isomer. DIBAL-H reduction of 2.37 gave the primary alcohol 
2.38. The key step in the synthesis of the THF ring was the iodoetherification reaction on 2.38. Previous 
studies from our group83,84,78 have shown that the iodocyclization of related isopropylidene alkenes lead to 
2,5-disubstituted THFs with high selectivity for the trans isomer.17, 78 Accordingly, exposure of 2.38  to NIS 
and catalytic silver triflate afforded the tetrahydrofuran ring 2.39 as a single trans isomer, in 89% yield.78 
After FCC purification, compound 
2.39 formed crystalline needles 
which were subjected to X-ray. 
The presence of the heavy atom 
allowed for the determination of 
the absolute configuration of the 
ring as a the enantiopure trans 
form (Figure 2.6). Finally, 
treatment of iodohydrin 2.39 with 
dimethylsulfonium methylide 
provided the tetrahydrofuran 
alkene 2.16 in 60% yield, via an 




in situ, tandem epoxide formation-epoxide opening-elimination sequence of reactions. Compound 2.16 
was obtained in 8 steps from 2.32 with a 6% overall yield. Protection of the diol using MOMCl afforded 
compound 2.40.  
 
 
Scheme 2.2. Synthesis of THF alkene 2.16 
 
 
2.3.2. Butenolide alkene, 2.30 
The synthesis of the diastereomeric mixture of butenolide 2.30 started with known compound 2.41.85 This 
compound was prepared as the racemic mixture via the esterification of undecenoic acid with methanol 
and the treatment of the resulting methyl 10-undecenoate ester with mCPBA. Copper (I) iodide assisted 
epoxide opening with 4-pentenylmagnesium bromide and protection of the resulting alkenol as the 
TBDPS ether, yielded 2.42. An stablished two step aldol-elimination sequence on 2.42 and the known 





Scheme 2.3. Synthesis of butenolide 2.30 
 
2.3.3. CM of THF and butenolide alkenes 
 
Coupling of 2.16 (or MOM substituted 2.40) and 2.30 in DCM at rt in the presence of 10 mol% of Grubbs 
second-generation catalyst gave compounds 2.44 and 2.45, respectively. Selective reduction of 2.44 and 
2.45 using diamide conditions afforded 2.46 and 2.47. Subsequent removal of the silyl protecting group 
with in situ generated methanolic HCl afforded 4-DAN as a mixture of C-10 epimers 2.12 and selective 
deprotection of the TBDPS group in the presence of MOM using HF/pyridine delivered compound 2.48. 
Compound 2.48 is relevant for the potential selective functionalization that the synthetic material can 









Scheme 2.4. CM reaction and synthesis of C-10 epimers of 4-DAN 
 
 
2.3.4. Comparison of naturally obtained 4-DAN and synthetic C-10 epimers  
 
To confirm the authenticity of our synthetic mixture C-10 epimers, 2.12, we compared the 1H and 13C 
NMR to the ones of naturally occurring 4-DAN reported in the literature,75 2.1 (Table 2.1, Figures 2.7 and 
2.8). As previously observed for analogous epimers at C-9 of 4-DAR, NMR data for the C-10 epimers 
showed as a single compound. Within the limits of experimental measurements, this data was essentially 
identical to that of the natural product. This outcome is not surprising given the remoteness of the C-10 





Table 2.1. Naturally obtained vs synthetic 4-DAN 
 
Position Naturally obtained (4-DAN) Synthesized (2.12) 
 1H (δ ppm) 13C (δ ppm) 1H (δ ppm) 13C (δ ppm) 
1 - 174.00 - 174.16 
2 - 134.25 - 134.47 
3 2.26 t (7.0) 25.13 2.23 t (7.9) 25.36 
10 3.58 m 71.88 3.55 broad s 71.88 
17, 22 3.40 q (5.5) 74.01 3.37 broad q (5.5) 74.01 
18, 21 3.80 q (7.5) 82.66,82.61 3.77 broad q (6.2) 82.66, 82.61 
34 0.88 t (7.5) 14.07 0.85 t (6.3) 14.35 
35 6.99 t (1.5) 148.88 6.96 broad s 148.88 
36 5.00 qq (7.2) 77.41 4.97 broad q (6.7) 77.6 
 
 
Figure 2.7. 1H chemical shifts of 4-DAN both naturally obtained and synthesized 
3 10 17&22 18&21 34 35 36
Naturally obtained 2.26 3.58 3.4 3.8 3.8 0.88 6.99
Synthetic 2.23 3.55 3.37 3.77 3.77 0.85 6.96
Difference in ppm 0.03 0.03 0.03 0.03 0.03 0.03 0.03






Figure 2.8. 13C chemical shifts of 4-DAN both naturally obtained and synthesized 
 
 
The use of a cross coupling reaction towards the synthesis of THF-ACGs was first established in our 
laboratory. CM is a versatile reaction that is compatible with a wide variety of functional groups. Since 
then, other groups have adopted this strategy (see Chapter 1). Here, we established a modular strategy 
for the synthesis of 4-DAN. By using different CM alkene partners, this protocol can be applied towards 








1 2 3 10 17&22 18&21 34 35 36
Naturally obtained 174 134.25 25.13 71.88 74.01 82.66 82.61 14.07 148.88
Synthetic 174.16 134.47 25.36 71.88 74.01 82.66 82.61 14.35 148.88




















Moisture and oxygen sensitive reactions were performed under an argon atmosphere. Solvents were 
purified by standard procedures or used directly from commercial sources. Thin layer chromatography 
(TLC) was done on 0.25 mm thick precoated silica gel HF254 aluminum sheets. Chromatograms were 
observed under UV (short and long wavelength) light and were visualized by heating plates that were 
dipped in a solution of ammonium (VI) molybdate tetrahydrate (12.5 g) and cerium (IV) sulfate 
tetrahydrate (5.0 g) in 10 % aqueous sulfuric acid (500 mL). Flash column chromatography (FCC) was 
performed using silica gel 60 (230-400 mesh) and employed a stepwise solvent polarity gradient, 
correlated with TLC mobility. 1H and 13C NMR spectra were obtained on a Bruker 400, 500 and 600 MHz 
spectrometer. Chemicals shifts are relative to the deuterated solvent peak and are in parts per million 
(ppm). X-ray diffraction data were collected on a Bruker X8 Kappa Apex II diffractometer.  Crystal data, 
data collection and refinement parameters are summarized in Table S1-I.  The structure was solved using 
direct methods and standard difference map techniques and was refined by full-matrix least-squares 
procedures on F2 with SHELXTL86 (Version 2014/7). The absolute configuration was established by 




A mixture of 5% Ac2Cl in MeOH (0.5 mL) was added at rt to a solution of 2.46 (30 mg, 0.035 mmol) in 
CH2Cl2 (1 mL). The mixture was stirred at this temperature for 4 h, diluted with CH2Cl2 and washed with 
saturated aqueous NaHCO3. The organic layer was dried (Na2SO4), filtered, and concentrated under 
reduced pressure. FCC of the residue afforded 2.12 (15 mg, 68%). Rf = 0.2 (60% EtOAc/hexanes). 1H 




3H), 1.95 (m, 3H), 1.67 (m, 4H), 1.43-1.38 (m, 7H), 1.39 (d, partially buried, J = 6.8 Hz, 3H), 1.38-1.20 (s, 
38H), 0.88 (t, J = 6.3 Hz, 3H); 13C NMR (CDCl3, 500 MHz)  δ 174.1, 149.1, 134.5, 82.8, 82.8, 77.7, 74.3, 
74.2, 72.2, 37.7, 37.6, 33.7, 33.6, 32.1, 29.9 (4 signals), 29.8 (2 signals), 29.6, 29.5, 29.3, 29.0, 27.6, 




To a solution of Me3SI (2.23 g, 10.4 mmol) in THF (11 mL) at -78 °C was added n-BuLi (3.6 mL, 9.1 
mmol) under N2. The mixture was warmed to rt, maintained at this temperature for 1 h, then recooled to -
78 °C. A solution of compound 2.39 (0.5 g, 1.2 mmol) in THF (12 mL) was then introduced and the 
mixture stirred at -78 °C for 2 h. A solution of sulfonium ylide in THF (11 mL), Me3SI (1.88 g, 9.1 mmol) 
and n-BuLi (2.9 mL, 7.3 mmol) was prepared at -78 oC and then warmed to rt. Then, that portion was 
added to the main reaction at -78 °C, let warm up to rt, and stirred for 2 h. The reaction was then 
quenched with saturated aqueous NH4Cl and extracted with EtOAc. The organic phase was dried 
(Na2SO4) filtered and evaporated under reduced pressure. The residue was subjected to FCC to give 
2.16 (220 mg, 60%) as a clear oil. Rf = 0.57 (50% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 5.76 (m, 
1H), 5.31 (d, J = 18.6 Hz, 1H), 5.17 (m, 1H), 3.92 (m, 1H), 3.82 (m, 2H), 3.38 (m, 1H), 2.93 (br s, 1H), 
2.67 (br s, 1H), 1.93 (m, 2H), 1.64 (m, 2H), 1.34 (m, 2H), 1.21 (s, 20H), 0.74 (t, J = 6.9 Hz, 3H); 13C NMR 
(CDCl3, 500 MHz) δ 136.8, 117.4, 83.1, 82.4, 75.8, 74.2, 33.5, 32.1, 29.9 (2 signals), 29.8 (4 signals), 







To a solution of diisopropylamine (23.2 mL, 0.16 mmol) in anhydrous THF (290 mL) at -78 oC was added 
n-BuLi (46.3 mL, 2.5 M in hexane, 0.12 mol). The mixture was warmed to 0 oC and stirred at this 
temperature for 10 min, then re-cooled to -78 oC. A solution of 2.42 (11.6 g, 0.02 mol) in anhydrous THF 
(115 mL) was then added and the mixture maintained at -78 oC for 1 h, at which time a solution of 2.43 
(11.07 g, 0.07 mmol) in anhydrous THF (115 mL) was slowly added. After 30 min, the reaction was 
diluted with saturated aqueous NH4Cl and extracted with ethyl ether. The organic phase was dried 
(Na2SO4) and concentrated under reduced pressure. FCC of the residue (20% EtOAc/hexanes) afforded 
mixture of products (11.3 g). To the solution of this material in a mixture of MeOH (28 mL) and 2-propanol 
(280 mL) was added TsOH.H2O (0.34 g, 1.79 mmol) at 0 oC. The reaction mixture was stirred at rt for 20 
h, then concentrated under reduced pressure. The residue was purified by FCC (15-20 % 
EtOAc/hexanes) to afford the derived lactone 2.30 as a yellow oil (6.4 g). To a solution of the material 
obtained in the previous step (6.4 g) in CH2Cl2 (280 mL) was added Et3N (8.46 mL, 0.06 mol) and MsCl (2 
mL, 0.02 mol) at 0 oC. After stirring at rt for 14 h, the reaction was diluted with saturated aqueous NH4Cl 
and extracted with ethyl ether. The organic phase was dried (Na2SO4) and concentrated under reduced 
pressure. The residue was purified by FCC to afford 2.30 (3.21 g, 52% after two steps from 2.42). 1H 
NMR (CDCl3, 500 MHz) δ 7.65-7.63 (m, 4H), 7.42-7.31 (m, 6H), 6.94 (s, 1H), 5.76-5.67 (m, 1H), 4.96 (m, 
1H), 4.87 (m, 1H), 4.83 (m, 1H), 3.67 (m, 1H), 2.22 (m, 2H), 1.91 (m, 2H), 1.16 (m, 3H), 1.15-1.07 (m, 
18H), 1.03 (s, (H); 13C NMR (CDCl3, 500 MHz)  δ 149.0, 139.2, 136.1, 135.0, 130.0, 129.5, 127.9, 127.5, 
114.3, 77.3, 36.4, 36.3, 33.9, 29.7, 29.4, 29.3, 29.1, 27.5, 27.3, 26.7, 25.3, 25.0, 24.6, 19.6, 19.4. HRMS 
(ESI) calcd C35H51O3Si for (M+H)+ 546.3529, found 546.3529.  
 
 
Ethyl (E)-heptadec-4-enoate (2.32) 
A mixture of compound 2.3182 (7.7 g, 34.0 mmol) in toluene (80 mL), triethyl orthoacetate (56.09 mL, 0.3 
mol) and propionic acid (0.51 mL, 6.8 mmol), was heated at 125 °C under nitrogen for 4 h. The reaction 
was then quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The organic phase was 




EtOAc/hexanes) to give product 2.32 (9.86 g, 98%) as a yellow oil. 1H NMR (CDCl3, 500 MHz) δ 5.37-
5.21 (m, 1H), 5.46-5.38 (m, 1H), 4.12-4.08 (m, 2H), 2.34-2.29 (d, J = 25.0 Hz, 2H), 2.29-2.27 (t, J = 11.6 
Hz, 2H), 1.95-1.91 (q, J = 20.4 Hz, 2H), 1.22 (s, 20H), 0.86-0.84 (t, J = 13.7 Hz, 3H); 13C NMR (CDCl3, 
500 MHz) δ 59.2, 33.4, 31.5, 30.9, 28.7, 28.1, 26.9, 21.7. HRMS (ESI) calcd for C19H37O2 (M+H)+ 





LAH (2.63 g, 69.3 mmol) was added over 30 min to a solution of 2.32 (10.3 g, 34.7 mmol) in THF (400 
mL) at 0 °C. The mixture was stirred at 0 °C under nitrogen for 1.5 h. Then, water (20 mL) and 1 M 
aqueous NaOH (20 mL) was slowly added, sequentially, to the reaction mixture, after which anhydrous 
Na2SO4 was added until a granular precipitate was obtained. The suspension was filtered, and the filtrate 
was concentrated under reduced pressure. The residue was subjected to FCC (5% EtOAc/hexanes) to 
give 2.33 (8.08 g, 91%) as a white solid (MP: 31-33⁰C). Rf = 0.4 (10% EtOAc/hexanes). 1H NMR (CDCl3, 
500 MHz) δ 5.45-5.34 (m, 2H), 3.64 (m, 2H), 2.05 (m, 2H), 1.95 (m, 2H), 1.62 (m, 2H), 1.30-1.23 (br s, 
20H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 131.5, 129.5, 62.8, 32.8, 32.7, 32.1, 29.9 (3 





Methanesulfonamide (2.0 g, 45.3 mmol), AD-mix β (18.5 g, 0.023 mol) in 1:1 (v/v) water:t-BuOH (100 mL) 
was stirred for 1 h until the mixture was homogeneous. The mixture was cooled to 0 °C for 30 min at 
which time an orange precipitate was formed. A solution of compound 2.33 (6.16 g, 0.17 mmol) in t-BuOH 




with Na2SO3, filtered, extracted with EtOAc. The organic phase was concentrated in vacuo and the solid 
residue recrystallized from ethyl acetate to give 2.34 (6.71 g, 95%) as white crystals (MP: 66-69⁰C). Rf = 
0.15 (75% EtOAc/hexanes). 𝛼𝐷
25 = 15.3. 1H NMR (CDCl3, 500 MHz) δ 3.72 (m, 2H), 3.47 (m, 2H), 3.08 (br 
s, 1H), 2.33 (br s, 1H), 2.30 (br s, 1H), 1.77 (m, 2H), 1.58-1.42 (m, 4H), 1.28 (br s, 20H), 0.90 (t, J = 7.1 
Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 74.9, 74.6, 63.2, 33.8, 32.1, 31.1, 29.9 (2 signals), 29.8 (2 
signals), 29.6, 29.2, 25.9, 22.9, 14.3. HRMS (ESI) calcd for C17H36O3Na (M+Na)+ 311.2555, found 
311.2562.  The enantiomeric purity of 2.34 was determined to be greater than 95% by Mosher ester 




To a solution of 2.34 (8.55 g, 29.3 mmol) in CH2Cl2 (58 mL) was added 2,2-dimethoxypropane (4.32 mL, 
35.1 mmol) and p-TsOH (0.56 g, 2.93 mmol). The mixture was stirred for 1 h, then quenched with 
saturated aqueous NaHCO3 and extracted with CH2Cl2. The organic phase was dried (Na2SO4), filtered 
and concentrated under reduced pressure. FCC of the residue (10-15% EtOAc/hexanes) afforded 2.35 
(9.23 g, 96%) as a clear oil. Rf = 0.36 (35% acetone/hexanes). 1H NMR (CDCl3, 500 MHz) δ 3.65 (m, 2H), 
3.59 (m, 2H), 2.24 (br s, 1H), 1.71 (m, 2H), 1.56-1.20 (m, 22H), 1.37 (s, partially buried, 6H), 0.86 (t, J = 
7.1 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 108.2, 81.2, 81.1, 62.9, 32.9, 32.1, 29.9 (2 signals), 29.8 (3 
signals), 29.7 (2 signals), 29.5, 27.5, 27.4, 26.3, 22.8, 14.3. HRMS (ESI) calcd for C20H40O3Na (M+Na)+ 







 (R)-MTPA ester of 2.35 (2.35a) 
To a stirred solution of 2.35 (50 mg, 0.15 mmol) and (R)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl 
chloride (77 mg, 0.30 mmol) in CH2Cl2 (10 mL) at 0 oC, DMAP (ca 2 mg) and DCC (63 mg, 0.30 mmol) 
were added. The reaction was brought to rt and stirred for an additional 1 h at which time the mixture was 
diluted with ethyl ether. The resulting suspension was filtered over Celite and the filtrate was washed with 
brine and water. The organic phase was dried (Na2SO4), filtered and concentrated in vacuo. The crude 
mixture was purified by FCC to give the R-MTPA-ester 2.35a as a white solid. Rf = 0.78 (30% 
acetone/hexanes). 1H NMR (C6D6, 500 MHz) δ 7.68 (m, 2H), 7.09-6.96 (m, 3H), 4.10 (m, 1H), 4.05 (m, 
1H), 3.49 (m 1H), 3.42 (s, 3H), 3.41 (partially buried m, 1H), 1.65-1.55 (m, 6H), 1.29 (s, 3H), 1.28 (s, 3H), 
1.26 (m, 20H), 0.91 (t, J = 5.7 Hz, 3H); 13C NMR (C6D6, 500 MHz) δ 166.9, 133.5, 130.1, 130.0, 129.2, 
129.0, 128.8, 128.7, 127.9, 125.6, 123.7, 108.5, 81.6, 81.0, 66.4, 55.7, 33.5, 32.7, 30.6, 30.5 (2 signals), 
30.4 (2 signals), 30.2, 29.5, 28.0, 27.9, 27.1, 26.1 (2 signals), 26.0, 23.5, 14.7, 1.7. HRMS (ESI) calcd for 
C30H47F3O5Na (M+Na)+ 567.3268, found 567.3249. 
 
 (R)-MTPA Ester of (+/-) 2.35 (2.35b) 
 
2.33 (0.1 g, 0.3 mmol) was dissolved in a mixture of water and acetone (1:1, 2 mL). The reaction was 
cooled down to 0 oC and osmium tetroxide in t-butanol (2.5% wt, 0.7 mL, 0.06 mmol) was added. Then, 
N-methylmorpholine (0.04 mL, 0.4 mmol) was added and the reaction was stirred for 2 h at 0 oC. The 
reaction was quenched with Na2SO3 (17 mg, 0.06 mmol) and stirred for 2 h. The product was extracted 




Rf = 0.2 (70% EtOAc/hexanes). The isopropylidene was installed using the same conditions as for the 
chiral compound 2.35 and the primary alcohol was then converted to the R-MTPA-ester, 2.35b, was 
purified using FCC (30-40% EtOAc/hexanes). Rf = 0.8 (35% acetone/hexanes). 1H NMR (C6D6, 400 MHz) 
δ 7.66 (m, 2H), 7.05 (m, 3H), 4.07 (m, 2H), 3.89 (m, 1H), 3.50 (m, 1H), 3.47 (m, 1H), 3.38 (m, 3H), 3.33 
(m, 3H), 1.55 (m, 2H), 1.40 (br s, 16H), 0.8 (m, 2H), 0.7 (m, 2H), 0.4 (m, 3H); 13C NMR (C6D6, 400 MHz) δ 
165.4, 165.3, 132.0, 128.6, 128.5, 128.5, 127.7, 127.5, 127.4, 127.1, 127.0, 126.9, 126.7, 126.6, 126.1, 
124.5, 121.7, 107.0, 84.1, 83.8, 80.1, 79.5, 64.9, 64.9, 60.9, 55.7, 54.1 (2 signals), 51.1, 48.9, 32.0, 31.3, 
31.2, 30.2, 29.0 (2 signals), 28.9 (3 signals), 28.6, 28.0, 26.5, 26.4, 25.5, 25.3, 25.2, 24.6 (3 signals), 
24.5, 23.6 (2 signals), 21.9, 13.2, 12.6.   
    
 
(4R,5R)-4,5-O-isopropylidene-heptadecanal (2.36) 
A suspension of powdered, freshly activated molecular sieves (7 g), Fluorosil (7 g), Celite (7 g), 
CH3COONa (2.54 g, 31.2 mmol), PCC (6.61 g, 31 mmol) and 2.35 (6.84 g, 20.8 mmol) in CH2Cl2 (19 mL) 
was stirred under nitrogen for 1 h. At that time the mixture was diluted with ether and filtered over 
Fluorosil. The filtrate was concentrated under reduced pressure and the residue subjected to FCC to give 
2.36 (4.42 g, 64%) as a yellow oil. Rf = 0.45 (15% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 9.74 (s, 
1H), 3.54 (m, 2H), 2.57 (m, 2H), 1.90 (m, 1H), 1.68 (m, 1H), 1.46 (m, 2H), 1.34-1.19 (m, 20H), 1.34 (s, 
partially buried, 6H), 0.86 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 202.1, 108.4, 81.0, 80.0, 40.7, 
33.0, 32.1, 29.9 (2 signals), 29.8, 29.7, 27.5, 27.4, 26.3, 25.3, 22.9, 14.3. 
 
 




To a solution of compound 2.36 (5.06 g, 15.5 mmol) in CH3CN (150 mL) was added methyl 
(triphenylphosphoranylidene) acetate (15.5 g, 46.5 mmol). The mixture was heated at reflux for 1.5 h, 
then filtered over Celite.  The filtrate was concentrated under reduced pressure and the residue purified 
by FCC to give 2.37 (4.67 g, 76%) as a clear oil. Rf = 0.85 (15% EtOAc/hexanes). 1H NMR (CDCl3, 500 
MHz) δ 6.94 (m, 1H), 5.81 (m, 1H), 3.68 (s, 3H), 3.55 (m, 2H), 2.36 (m, 1H), 2.25 (m, 1H), 1.76 (m, 2H), 
1.45 (m, 2H), 1.32-1.10 (m, 20H), 1.32 (s, partially buried 6H), 0.82 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 
500 MHz) δ 167.2, 148.8, 121.4, 108.2, 81.0, 80.2, 51.6, 33.1, 32.1, 31.4, 29.9, 29.8 (3 signals), 29.7, 




To a solution of compound 2.37 (1.4 g, 3.54 mmol) in CH2Cl2 (70 mL) was added a solution of 1 M 
DIBAL-H in hexane (2.16 mL, 10.6 mmol) at -78 °C under nitrogen. The mixture was warmed to rt and 
stirred at this temperature for an additional 1.5 h. Then water (10 mL) and 1 M aqueous NaOH (1 mL) 
was slowly added, sequentially, to the reaction mixture after which anhydrous Na2SO4 was added until a 
granular precipitate was obtained.  The mixture was filtered over Celite and the filtrate was concentrated 
under reduced pressure. FCC of the residue (10% EtOAc/hexanes) afforded 2.38 (0.7 g, 56%) as a clear 
oil. Rf = 0.53 (25% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 5.66 (m, 2H), 4.06 (m, 2H), 3.57 (m, 
2H), 2.23 (m, 1H), 2.10 (m, 1H), 1.69 (s, 1H), 1.56 (m, 4H), 1.32 (s, partially buried, 6H), 1.18 (m, 20H), 
0.81 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 132.5, 129.6, 108.1, 81.2, 81.1, 63.9, 33.1, 32.6, 
32.1, 30.0, 29.9, 29.8 (2 signals), 29.7, 29.5, 29.0, 27.5 (2 signals), 26.4, 22.9, 14.3. HRMS (ESI) calcd 








To a solution of compound 2.38 (390 mg, 1.10 mmol) in CH3CN (100 mL) was added NIS (100 mg, 4.40 
mmol) and AgOTf (6 mg, 0.02 mmol). The mixture was stirred at rt for 3 h, then diluted with a saturated 
solution of Na2S2O3 and extracted with EtOAc. The organic phase was dried (Na2SO4), filtered and 
evaporated in vacuo. FCC of the residue gave 2.39 (430 mg, 89%) as a white solid (MP: 47-49⁰C). Rf = 
0.33 (25% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 4.23 (m, 1H), 4.11 (m, 1H), 4.00 (m, 1H), 3.95 
(m, 2H), 3.46 (m, 1H), 2.85 (t, J = 13.1 Hz, 1H), 2.41 (m, 1H), 2.10 (m, 2H), 1.99-1.73 (m, 2H), 1.42 (m, 
2H), 1.28 (s, 20H), 0.85 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 500 MHz)  δ 84.1, 83.1, 74.0, 68.0, 39.3, 
34.3, 33.9, 32.1, 29.9 (2 signals), 29.8 (2 signals), 29.6, 28.2, 25.8, 22.9, 14.4 HRMS (ESI) calcd for 




THF alkene MOM protected (2.40) 
2.16 (0.150 g, 0.4 mmol) were dissolved in 8 mL CH2Cl2. Then, MOMCl (0.14 mL,1.84 mmol) and DIPEA 
(0.41 mL, 2.3 mmol) were added at 0 oC and the solution was stirred overnight. The reaction was then 
quenched with water and extracted with DCM (3x). The organic phase was dried (NaSO4), concentrated 
in vacuo and purified via FCC (10% EtOAc/hexanes) to afford compound 2.40 (0.18 g, quant) as a white 
solid. Rf = 0.5 (20% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 5.71 (m, 1H), 5.28 (m, 1H), 5.24 (m, 
1H), 4.82 (m, 1H), 4.65 (m, 4H), 3.99 (m, 3H), 3.37 (d, J = 2.8 Hz, 6H), 1.89 (m, 2H), 1.66 (m, 2H), 1.39 
(m, 4H), 1.23 (m, 20H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 135.0, 118.9, 96.9, 94.2, 
81.8, 81.1, 79.7, 79.4, 55.9, 55.5, 32.1, 31.3, 30.0, 29.9 (2 signals), 29.8, 29.6, 28.3, 28.2, 25.8, 22.9, 






Methyl 10-hydroxyhexadec-15-enoate (2.41a) 
To a suspension of CuBr (I) (3.70 g, 0.26 mol) in THF (300 mL) at 0 oC was added 4-pentenylmagnesium 
bromide (24 mL, 1M, 0.13 mol) over 5 min. A solution of 2.4185 (10.6 g, 43 mmol) in anhydrous THF (60 
mL) was then introduced, dropwise over 5 min. The reaction was stirred 0 oC for 10 min and saturated 
aqueous NH4Cl was added and the mixture extracted with ethyl ether. The organic phase was washed 
with brine, dried (Na2SO4), filtered and evaporated under reduced pressure. The residue was purified to 
give the derived alcohol 2.41a (10.2 g, 70%). Rf = 0.15 (10% EtOAc /hexanes). 1H NMR (CDCl3, 500 
MHz) δ 5.77 (m, 1H), 4.92 (m, 1H), 4.91 (m, 1H), 3.63 (s, 3H), 3.53 (br s, 1H), 2.26 (m, 2H), 2.03 (m, 2H), 
1.34-1.26 (m, 2H); 13C NMR (CDCl3, 500 MHz) δ 174.6, 139.1, 114.6, 72.1, 51.7, 37.6, 37.5, 34.3,  29.8, 
29.6, 29.4, 29.3 (2 signals), 29.1, 25.8, 25.3, 25.1.  
 
 
Methyl 10-((tert-butyldiphenylsilyl)oxy)hexadec-15-enoate (2.42) 
A portion of the material from the previous step (7.31 g, 0.024 mol), TBDPSCl (6.24 mL, 0.024 mol) and 
imidazole (8.33 g, 0.12 mol) in anhydrous THF (200 mL) were heated at reflux under nitrogen for 4 h. The 
mixture was then diluted with water, extracted with ethyl ether and washed with brine. The organic phase 
was dried (Na2SO4), filtered, and evaporated under reduced pressure. The residue was purified by FCC 
to afford 2.42 (9.37 g, 89%) as a clear oil. Rf = 0.75 (10% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 
7.64 (m, J = 7.6 Hz, 4H), 7.36 (m, 6H), 5.72 (m, 1H), 4.89 (m, 1H), 4.87 (m, 1H), 3.67 (m, partially buried, 
1H), 3.64 (s, 3H), 2.27 (t, J = 7.5 Hz, 2H), 1.91 (m, 2H), 1.08-1.25 (m, 20H), 1.04 (s, 9H); 13C NMR 
(CDCl3, 500 MHz) δ 174.4, 139.1, 136.0, 134.8, 129.4, 127.4, 114.2, 73.2, 51.5, 36.3, 36.1, 34.1, 33.7, 
29.6, 29.4, 29.2, 29.1, 29.0, 27.1, 25.0, 24.8, 24.4, 19.4. HRMS (ESI) calcd for C33H51O3Si (M+H)+ 





THF-butenolide alkene (2.44) 
A mixture of 2.16 (0.1 g, 0.3 mmol) and 2.30 (0.28 g, 0.51 mmol) in CH2Cl2 (2 mL) was purged with 
nitrogen for 30 min. Grubbs 2nd generation catalyst (25 mg, 0.03 mmol) was then introduced and the 
reaction stirred for 16 h at rt, after which DMSO (0.05 mL) was added and stirring continued for 30 min. 
The mixture was then concentrated in vacuo. FCC of the residue (40% EtOAc/hexanes) afforded 2.44 
(136 mg, 54%) as a clear oil. Rf = 0.65 (40% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 7.63 (m, 4H), 
7.40-7.30 (m, 6H), 6.94 (s, 1H), 5.67 (m, 1H), 5.30 (m, 1H) 4.96 (m, 1H), 3.84-3.77 (m, 3H), 3.80 (m, 1H), 
3.38 (m, 1H), 2.47 (br s, 1H), 2.28 (br s, partially buried, 1H), 2.21 (m, 2H), 1.90 (m, 4H), 1.63 (m, 2H), 
1.45 (m, 3H), 1.33 (m, 10H), 1.22-1.14 (m, 30H), 1.00 (s, 9H), 0.85 (t, J = 6.6 Hz, 3H); 13C NMR (CDCl3, 
500 MHz) δ 174.1, 149.0, 136.1, 134.9, 134.5, 129.6, 128.3, 127.6, 82.9, 82.7, 77.7, 75.9, 74.2, 73.3, 
36.4, 36.3, 33.8, 32.5, 32.5, 32.1, 29.9 (4 signals), 29.8 (3 signals), 29.6, 29.4, 29.3, 28.7, 27.6, 27.3, 





A mixture of 2.40 (0.180 g, 0.45 mmol) and 2.30 (0.4 g, 0.73 mmol) in CH2Cl2 (4 mL) was purged with 
nitrogen for 30 min. Grubbs 2nd generation catalyst (31 mg, 0.04 mmol) was then introduced and the 
reaction stirred for 16 h at rt, after which DMSO (0.05 mL) was added and stirring continued for 30 min. 
The mixture was then concentrated in vacuo. FCC of the residue in 40% EtOAc/hexanes afforded 2.45 







A solution of sodium acetate (0.62 g, 3 mmol) in water (12 mL) was added via a syringe pump, over 4 h, 
to a mixture of 2.44 (85 mg, 0.10 mmol), p-toluenesulfonylhydrazide (1.25 g, 3 mmol) and DME (12 mL) at 
reflux. After cooling to rt, the reaction mixture was poured into water and extracted with EtOAc. The 
organic extract was washed with 2M HCl, water and brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure. FCC of the residue (1-5% acetone/DCM) gave 2.46 (0.04 g, 47%). Rf = 0.68 (2% 
acetone/dichloromethane). 1H NMR (CDCl3, 500 MHz) δ 7.63 (m, 4H), 7.45-7.29 (m, 6H), 6.94 (s, 1H), 
4.95 (m, 1H), 3.76 (m, 2H), 3.66 (m, 1H), 3.36 (m, 2H), 2.21 (m, 2H), 1.96 (m, 4H), 1.85 (br s, 2H), 1.36 
(d, partially buried, J = 6.8 Hz, 3H), 1.34 (m, 10H), 1.25 (m, 36H), 1.00 (s, 9H), 0.85 (t, J = 7.1, 3H); 13C 
NMR (CDCl3, 500 MHz) δ 174.1, 149.0, 136.1, 135.0, 134.5, 129.5, 127.5, 82.8, 74.2, 73.4, 36.5, 36.4, 
33.7 (2 signals), 32.1, 31.8, 29.9 (2 signals), 29.8 (3 signals), 29.6, 29.4, 29.3, 28.9, 27.5, 27.3, 25.8, 
25.8, 25.4, 25.0, 22.9 (2 signals), 19.6, 19.4, 14.3, 11.7. HRMS (ESI) calcd for C53H86O6SiNa (M+Na)+ 




A solution of sodium acetate (1.89 g, 0.023 mol) in water (57 mL) was added via a syringe pump, over 4 
h, to a mixture of 2.45 (0.2 g, 0.21 mmol), p-toluenesulfonylhydrazide (1.7 g, 9.28 mmol) and DME (57 
mL) at reflux. After cooling to rt, the reaction mixture was poured into water and extracted with EtOAc. 
The organic extract was washed with 2 M HCl, water and brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure. FCC of the residue gave 2.47 (4 mg, 47%). Rf = 0.4 (20% EtOAc/hexanes). 1H 




(m, 2H), 3.99 (m, 2H), 3.70 (m, 1H), 3.51 (m, 2H), 3.39 (m, 6H), 2.20 (m, 2H), 1.94 (m, 2H), 1.45 (m, 6H), 
1.41 (m, 9H), 1.38 (m, 36H), 1.06 (s, 9H), 0.90 (t, J = 7.1 Hz, 3H). HRMS (ESI) calcd for C57H94O8SiNa 

















3.1. Introduction and background  
THF-AGCs show potent activity against human cancer cell lines and therapeutic potential in animal 
studies. However, their equally high toxicity to normal cells has limited their clinical development. Towards 
more clinically viable analogues, we are interested in THF-ACGs that are easily accessed and more 
selective to tumor cells. Accordingly, we designed a series of compounds based on the SAR trends for 
the THF-ACGs discussed in Chapter 1. The potently active mono-THF-ACG 4-DAN was used as a 
template for these structures. The modifications that we propose are: (i) replacement of the butenolide by 
simpler non-chiral heterocycles or alkyl chains; (ii) substitution of the THF ring with a carbohydrate 
moiety; (iii) variations in the hydrophobic spacer that connects the THF core or its replacement to the 
butenolide or butenolide substitute (Figure 3.1). While certain of these individual modifications have been 
previously shown to deliver compounds with similar activity to naturally occurring THF-ACGs, hybrid 
structures that combine two or more such changes have not been widely tested. For instance, we have 
shown that the THF core could be replaced with a cyclic sugar and other researchers have replaced the 
butenolide with simple heterocycles, but the activity of analogues that combine both of these 
modifications is unknown. Such hybrids are of interest in that they may be more easily prepared than less 
modified analogues. 
 





As discussed earlier, previous studies from this laboratory on 4-deoxyannoreticuin,35 showed that both C-
10 epimers were similarly active. Based on this result, for synthetic simplicity we decided to prepare our 
new analogues of DAN as an epimeric mixture at the corresponding C-9 carbinol in 4-DAN.  
 
3.2. Butenolide substitutes 
3.2.1. Piperazine 
Zen and others88 have evaluated ACG mimetics like AA005 3.1, in which the bis-THF ring is replaced with 
an ethylene glycol ether moiety (Figure 3.2). These simplified mimetics presented activities comparable to 
the natural products. More recently, the same group examined even simpler mimics in which the 
butenolide in these acyclic analogues was replaced with simple achiral heterocycles (cf 3.2).41 These 
compounds still showed low micromolar activity. We are particularly interested in the analog containing a 
terminal piperazine, 3.3, not just because it exhibited the most potent antiproliferation activity but also 
because the secondary amine provides a handle for prodrugs.   
 
 






Kojima also investigated small heterocycles as butenolide substitutes. In the initial study, an amide linked 
N-methylpyrazole, showed selectivity towards the same cell lines as the alkyl-linked equivalent, but with 
higher potencies (Figure 3.3).39 In a later study, other amide-linked heterocycles, including furan or 
thiophene were evaluated.42, 44, 46 Both the thiophene-3-carboxamide and thiophene-2-carboxamide 
showed high potencies across a panel of 39 cell lines. The 3-carboxamide derivative was used in vivo 
studies and inhibited tumor growth of the NCI-H23 xenografts implanted in mice. Following this study, we 
decided to replace the butenolide in 4-DAN with a thiophene-2-carboxamide moiety. Our analogues differ 
from Kojima’s with respect to the length of the hydrophobic chain that connects the THF and the 










Other groups have examined simpler replacements, such as a n-butyl ester in the case of squamocin 
(Figure 3.4).89 This analog was several orders of magnitude less active than squamocin but was still in 
the low micromolar range. Interestingly, its activity against complex I was comparable to the natural 
product. To probe whether the carbonyl group of the ester was important for activity, we targeted the n-
butyl ether derivative of 4-DAN, 3.7.  
 
 
Figure 3.4. Simple n-alkyl derivative 
 
3.3. Tetrahydrofuran substitutes 
3.3.1. Mannose replacement 
Several reviews have been published on the modification of the THF ring.90,91,92  Our group has showed 
that replacing the THF core with a sugar residue delivered compounds with low micromolar level activity 




Replacement of the THF ring with a carbohydrate is attractive as stereochemically diverse sugars are 
readily available, the sugar motif may act as a vector for tumor targeting, and their heavily hydroxylated 




Figure 3.5. Activity of DAR 3.8 and mannose analog 3.9 
 
Mannose was chosen as a THF replacement because its framework can be relatively easily 
functionalized, and is a potential tumor vector, for example to glucose transporters (GLUT), which are 
overexpressed on tumor cells, or other mannose specific receptors.93 In our initial study on sugar 
analogues of DAR, the alkyl chain was attached at the O6 position of mannose. To further develop these 
mannose-derived ACG mimetics, we were interested in the effect of altering the length and position of the 
alkyl chain. This is important as related modifications in the hydrophobic chains in the natural THF-ACGs 
Cell Line Jurkat (µM) HeLa (µM) MDA-MB-231 (µM) PC-3 (µM) 
DAR (3.8) 17.79 20.99 34.16 43.05 
Mannose analog of 
DAR (3.9) 




are known to affect both potency and selectivity. Accordingly, the new sugar analogues of 4-DAN 3.10 - 




Figure 3.6. THF replacement analogues 
 
 
3.4. Hybrid structures 
An important question is whether the aforementioned SARs regarding THF and butenolide replacements 
are additive.  With that in mind, hybrid compounds which both the THF ring and the butenolide are 
replaced with mimicking entities, were of interest (Figure 3.7). To probe this question, we targeted hybrid 
structures comprising the 6-O-undecyl mannose residue and piperazine or thiophene moieties as THF 
and butenolide replacements, respectively (cf 3.15 and 3.16). 
 
 






3.5. Modification of the hydrocarbon spacer 
It has been proposed that the hydrophobic spacer connecting the THF and the butenolide controls the 
active spatial arrangement between the THF and the butenolide.91 Consistent with this hypothesis, 14- 
and 12- carbon chains appear to be optimal for the mono and bis-THF ACGs, respectively.11c The position 
and number of hydroxyl groups also impacts on activity. Some studies suggest that having too many 
alcohols in the middle chain can lower the activity of the compounds as an increase in hydrophilicity may 
decrease mitochondrial uptake. Against this background we targeted the deoxygenated sugar-piperazine 
hybrid structure 3.17 (Figure 3.8).    
 
 




3.6. Synthetic strategy 
The overall synthetic plan for these new analogues follows the CM approach described in Chapter 2 for 4-
DAN. Thus, the THF-alkene 3.18 (2.16 in Chapter 2), or one of its mannose substitutes 3.19-3.23, were 


























3.7.1. Mannose alkenes 
For efficiency, the synthesis of the different mannose alkenes was conducted in a divergent fashion from 
a known precursor, 1-propenyl 2,3-O-isopropylidene mannopyranoside 3.32. This material can be 
obtained in multi-gram quantity, in a straightforward fashion, over three steps from D-mannose: (i) acid 
promoted glycosidayion of mannose with allyl alcohol, (ii) isopropylidenation of the product 3.30 to give 
the bis-O-isopropylidene 3.31, and (iii) selective removal of the 4,6-O-isopropylidene  (Scheme 3.1). The 
yield over these three steps was 35%. 
 
 




Alkylation of 3.32 using one equivalent of base in THF provided a separable mixture of 3.19 (27%) and 
3.20 (13%). For a streamlined synthesis of 3.19, the primary alcohol on 3.32 was first selectively 
protected as the its TBDPS ether. Then, protection of the secondary alcohol by treatment with ethyl vinyl 
ether and PPTS and desilylation of the resulting product provided 3.33. Alkylation of 3.33 with undecyl 
bromide and treatment of the product under mildly acidic conditions yielded 3.19 (65%). Similarly, 
butylation on 3.33 afforded 3.21 (58%) and methylation on 3.20 and 3.33 afforded 3.23 (64%) and 3.22 
(90%), respectively. 
 
3.7.2. Butenolide replacements 
The precursor for the butenolide replacements was alkenol 3.35, which was obtained from the LAH 
reduction of ester 3.34 (Scheme 3.2). Alkenes 3.25 and 3.26, the CM precursors for the piperazine and 
butyl ether analogues, were obtained from butylation and mesylation on 3.35, respectively. 
 
 




Reaction of 3.26 with ethanolic ammonia and amidation of the resulting amine 3.36 with thiophene 2-
carboxylic acid provided 3.27, the CM precursor for the thiophene analogues. 
 
3.7.3. Cross metathesis and final products 
The CM reactions for the THF analogues were performed under similar conditions to those used in the 
synthesis of 4-DAN in Chapter 2. 77, 80 Thus, reaction of THF alkene 3.18 with 2 equivalents of alkenes 
3.25-2.37, in the presence of 10 mol% of 2nd generation Grubbs catalyst, in DCM at room temperature 
for 20 h afforded CM products 3.37, 3.38 and 3.39 in 40, 27, 23% yields, respectively. Hydrogenation of 
these products provided the reduced derivatives, which were transformed via straightforward substitution, 










For the synthesis of the mannose containing analogs, 3.10-3.14, modified CM conditions using Grubbs I 
catalyst at 40 oC were needed (Scheme 3.4).94 The mannose butenolide metathesis products 3.40-3.44 
were obtained in 25-96% yields. Subsequently, the alkene in the CM product was selectively reduced with 
diimide as described in the earlier synthesis of 4-DAN, and the isopropylidene and silyl protecting groups 
on the sugar were removed using acidic conditions to afford 3.10-3.14. The yields for the deprotection 
steps were low as these reactions were not optimized. In the later compounds, after optimization, these 
yields were higher. 
 
 
Scheme 3.4. Synthesis of mannose containing compounds 
 
CM between the 6-O-undecenyl-mannose alkene 3.19 and the mesylate containing alkenes, 3.26 and 
3.28, and the thiophene alkene 3.27 provided 3.45, 3.46 and 3.47 respectively (Scheme 3.5)  
Hydrogenation of 3.45 and 3.46, treatment of the reduced derivatives with piperazine, and acid promoted 
removal of isopropylidene and TBDPS protecting groups provided the mannose-piperazine hybrid 
compounds 3.15 and 3.17 respectively. Similarly, hydrogenation of 3.47 and removal of protecting groups 





Scheme 3.5. Route to hybrid analogues 
 
3.8 Summary 
In Chapter 3, the CM methodology that was used for the synthesis of the 4-DAN in Chapter 2, was 
applied to THF analogues of 4-DAN with butenolide substitutes, 3.3, 3.4 and 3.7. It has been shown that 
the butenolide residue in other ACGs or mimetics thereof, can be replaced with heterocycles such as 
thiophene or piperazine without loss in activity. Biological evaluation of such heterocyclic analogues of 
DAN is needed to determine the generality of this trend. The CM methodology was also applied to ACG 
analogues in which the THF moiety is replaced with a mannose residue, and the butenolide is preserved 
or replaced with piperazine or thiophene residues, i.e. 3.10-3.17. These carbohydrate-derived structures 
which follow from earlier studies in this laboratory and the aforementioned observations on butenolide 
replacement, are attractive for their relatively easy accessibility and for the potential of the sugar motif to 




would expand the SARs for these less well-known carbohydrate analogues and pave the way to their 
possible development as therapeutic agents. The development of potentially more tumor selective ACGs 










Compound 3.37b (29 mg, 0.033 mmol) was dissolved in CH2Cl2 (2 mL) and treated with 5% AcCl in 
MeOH (0.5 mL). The reaction was stirred for 24 h and then quenched with a saturated solution of 
NaHCO3 in MeOH. The mixture was filtered and concentrated in vacuo. FCC of the residue (10% 
MeOH/DCM) afforded 3.3 (3 mg, 14%). Rf = 0.6 (10% MeOH/DCM). 1H NMR (CD3OD, 600 MHz) δ 3.72 
(m, 2H), 3.51 (m, 1H), 3.33 (m, 2H), 3.16 (m, 4H), 2.72 (m, 4H), 2.35 (m, 2H), 1.98 (m, 2H), 1.66 (m, 2H), 
1.50-1.28 (m, 50H), 0.98 (t, J = 8.7 Hz, 3H); 13C NMR (CD3OD, 600 MHz) δ 84.0, 75.3, 72.6, 59.4, 50.3, 
45.0, 38.6, 34.4, 33.3, 31.0, 30.8, 30.7 (2 signals), 29.8, 26.9, 23.9, 14.6. HRMS (ESI) calcd for 




Compound 3.38b (31 mg, 0.034 mmol) was dissolved in CH2Cl2 (2 mL) and treated with 5% AcCl in 
MeOH (0.5 mL). The reaction was stirred for 20 h and then quenched with a saturated solution of 
NaHCO3 in MeOH. The mixture was filtered and concentrated in vacuo. FCC of the residue (10% 
MeOH/DCM) afforded 3.4 (7 mg, 33%). Rf = 0.4 (60% EtOAc/hexanes). 1H NMR (CDCl3, 600 MHz) δ 
7.40 (m, 1H), 7.38 (m, 1H), 7.00 (m, 1H), 5.88 (br s, 1H), 3.73 (m, 2H), 3.60 (m, 1H), 3.34 (m, 4H), 3.28 
(m, 2H), 2.24 (m, 2H), 1.91 (m, 3H), 1.55-1.00 (m, 50H), 0.95 (t, J = 6.6 Hz, 3H); 13C NMR (CDCl3, 600 
MHz) δ 161.8, 139.1, 129.6, 127.8, 127.6, 82.6, 74.0 (2 signals), 72.0 (2 signals), 59.0, 40.0, 37.5, 37.1, 




28.0, 27.1, 26.9, 25.6 (3 signals), 25.5, 24.9, 24.5, 24.1, 22.7, 21.9, 19.8, 14.1, 13.6, 12.6, 11.4. HRMS 
(ESI) calcd for C39H72NO5S (M+H)+ 666.5131, found 666.5127.  
 
 
THF-butyl ether (3.7) 
Compound 3.39 (50 mg, 0.047 mmol) was dissolved in EtOAc (4 mL). The solution was degassed for 30 
min and Pd/C (10%, 5 mg) was introduced. Then, it was stirred under H2 atmosphere for 20 h. The 
solution was filtered over Celite, concentrated in vacuo. FCC of the residue (30-35% EtOAc/hexanes) 
yielded 3.39a (42 mg, 84%). Rf = 0.4 (40% EtOAc/hexanes).  
Compound 3.39a (42 mg, 0.049 mmol) was dissolved in CH2Cl2 (2 mL) and treated with 5% AcCl in 
MeOH (0.5 mL). The reaction was stirred overnight and then quenched with a saturated solution of 
NaHCO3 in MeOH. The mixture was filtered and concentrated in vacuo. FCC of the residue (5% 
MeOH/DCM) afforded 3.7 (15 mg, 51%). Rf = 0.4 (60% EtOAc/hexanes). 1H NMR (CDCl3, 600 MHz) δ 
3.76 (m, 2H), 3.37 (m, 1H), 3.37 (m, 6H), 1.95 (m, 2H), 1.66 (m, 2H), 1.56-1.39 (m, 54H), 0.88 (t, J = 7.4 
Hz, 3H), 0.84 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 600 MHz) δ 82.6, 74.0 (2 signals), 72.0, 71.0, 70.6 (2 
signals), 37.5 (3 signals), 33.5 (2 signals), 31.9 (2 signals), 29.8, 29.7 (4 signals), 29.6 (3 signals), 29.5 (2 
signals), 29.4, 28.7, 26.2, 25.7, 25.6 (3 signals), 25.5, 22.7, 19.4, 19.2, 14.1. HRMS (ESI) calcd for 
C38H77O5 (M+H)+ 613.5771, found 613.5760.  
 
 




Compound 3.40a (35 mg, 0.036 mmol) was dissolved in CH2Cl2 (2 mL) and treated with 5% AcCl in 
MeOH (0.5 mL). The reaction was stirred for 24 h and then quenched with a saturated solution NaHCO3 
in MeOH. The mixture was filtered and concentrated in vacuo. FCC of the residue (5-10% MeOH/DCM) 
afforded 3.10 (5 mg, 20%). Rf = 0.5 (5% MeOH/DCM). 1H NMR (CDCl3, 600 MHz) δ 5.96 (s, 1H), 4.97 (m, 
1H), 4.80 (s, 1H), 3.90 (s, 1H), 3.81 (m, 1H), 3.76-3.36 (m, 13H), 2.24 (m, 2H), 1.45-1.20 (m, 42H), 1.37 
(partially buried d, J = 6.8 Hz, 3H), 0.86 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 600 MHz) 148.9, 134.3, 99.5, 
72.2, 71.9, 71.8, 71.7, 70.8, 70.5, 69.1, 67.8, 37.5, 31.9, 29.7, 29.6 (2 signals), 29.5 (2 signals), 29.3 (3 
signals), 29.2, 29.1, 27.4, 26.1, 26.0, 25.6, 25.5, 25.2, 22.7, 19.2, 14.1. HRMS (ESI) calcd for C37H69O9 
(M+H)+ 657.4942, found 657.4930.  
 
 
4-O-Undecyl mannoside-butenolide (3.11) 
Compound 3.41 (60 mg, 0.064 mmol) was transformed to 3.41a following the reduction protocol 
described for preparation of 3.40a.  FCC in 1-5% (acetone/DCM) delivered 3.41a (35 mg, 58%). Rf = 0.3 
(5% acetone/DCM). 1H NMR (CDCl3, 600 MHz) δ 7.59 (m, 4H), 7.31 (m, 6H), 6.90 (s, 1H), 4.99 (m, 2H), 
4.18 (m, 1H), 4.10 (m, 1H), 3.77 (m, 2H), 3.65-3.42 (m, 4H), 3.31 (m, 1H), 2.17 (m, 2H), 2.03 (br s, 1H), 
1.61-1.03 (m, 51H), 0.97 (s, 9H), 3.43 (t, J = 6.7 Hz, 3H.   
Compound 3.41a (27 mg, 0.028 mmol) was dissolved in CH2Cl2 (2 mL) and treated with 5% AcCl in 
MeOH (0.5 mL). The reaction was stirred overnight and then quenched with saturated solution of 
NaHCO3 in MeOH. The mixture was filtered and concentrated in vacuo. FCC of the residue (5-10% 
MeOH/DCM) afforded 3.11 (4 mg, 17%). Rf = 0.5 (5% MeOH/DCM). 1H NMR (CDCl3, 600 MHz) δ 6.95 (s, 
1H), 5.00 (m, 1H), 4.78 (s, 1H), 3.90 (m, 1H), 3.80 (m, 1H), 3.75-3.48 (m, 8H) 3.37 (m, 1H), 2.23 (m, 2H), 
1.54-1.22 (m, 42H), 1.28 (partially buried d, J = 5.0 Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 




29.9, 29.8 (2 signals), 29.7 (2 signals), 29.6, 29.5, 29.4, 29.3, 27.6, 26.3, 26.2, 25.8, 25.7, 25.4, 22.9, 
19.4, 14.3. HRMS (ESI) calcd for C37H68O9Na (M+Na)+ 679.4761, found 679.4754.  
 
 
6-O-Butyl mannoside-butenolide (3.12) 
Compound 3.42a (60 mg, 0.07 mmol) was dissolved in CH2Cl2 (5 mL) and treated with 5% AcCl in MeOH 
(1 mL). The reaction was stirred for 24 h and then quenched with a saturated solution of NaHCO3 in 
MeOH. The mixture was filtered and concentrated in vacuo. FCC of the residue (5-10% MeOH/DCM) 
afforded 3.12 (5 mg, 14%). Rf = 0.6 (5% MeOH/DCM). 1H NMR (CDCl3, 600 MHz) δ 6.95 (s, 1H), 4.97 (m, 
1H), 4.78 (s, 1H), 3.87 (m, 1H), 3.90-3.60 (m, 5H), 3.50 (m, 4H), 3.38 (m, 1H), 2.35 (m, 2H), 2.22 (m, 3H), 
1.65-1.10 (m, 28H), 0.87 (m, 3H); 13C NMR (CDCl3, 600 MHz) δ 174.1, 149.1, 136.1, 134.4, 99.7, 72.1, 
72.0, 71.9, 71.6 (2 signals), 70.7, 70.3, 69.7, 67.9, 37.6, 32.1, 31.7, 29.8 (2 signals), 29.6, 29.5, 29.4, 29.3 
(2 signals), 29.2, 29.0, 28.7, 27.5 (2 signals), 27.2, 27.1, 26.1 (2 signals), 25.7, 25.6, 25.3, 25.0, 23.9 (2 




6-O-Methyl mannoside-butenolide (3.13) 
Compound 3.43a (54 mg, 0.06 mmol) was dissolved in CH2Cl2 (2 mL) and treated with 5% AcCl in MeOH 
(0.5 mL). The reaction was stirred for 24 h and then quenched with a saturated solution of NaHCO3 in 
MeOH. The mixture was filtered and concentrated in vacuo. FCC of the residue (5-10% MeOH/DCM) 




1H), 4.94 (m, 1H), 4.57 (s, 1H), 3.64-3.18 (m, 11H), 3.28 (partially buried s, 3H), 2.10 (m, 2H), 1.26 (m, 
27H). HRMS (ESI) calcd for C27H48O9Na (M+Na)+ 539.3196, found 539.3190.   
 
 
6-O-Methyl-4-O-undecyl mannoside-butenolide (3.14) 
Compound 3.44a (27 mg, 0.027 mmol) was dissolved in CH2Cl2 (2 mL) and treated with 5% AcCl in 
MeOH (0.5 mL). The reaction was stirred for 24 h and then quenched with a saturated solution of 
NaHCO3 in MeOH. The mixture was filtered and concentrated in vacuo. FCC of the residue (60-80% 
EtOAc/hexanes) afforded 3.14 (3 mg, 16%). Rf = 0.5 (60% EtOAc/hexanes). 1H NMR (CD3OD, 500 MHz) 
δ 7.13 (s, 1H), 4.93 (m, 1H), 4.54 (s, 1H), 3.70 (m, 1H), 3.55 (m, 3H), 3.50-3.30 (m, 5H), 3.25 (m, 2H), 
3.24 (partially buried s, 3H), 2.11 (m, 2H), 1.44 (m, 6H), 1.16 (m, 42H), 0.77 (t, J = 7.5 Hz, 3H). HRMS 




6-O-Undecyl mannoside-piperazine (3.15) 
Compound 3.45b (62 mg, 0.063 mmol) was dissolved in CH2Cl2 (5 mL) and treated with 5% AcCl in 
MeOH (1 mL). The reaction was stirred for 24 h and then quenched with a saturated solution of NaHCO3 
in MeOH. The mixture was filtered and concentrated in vacuo. FCC of the residue (10% MeOH/DCM) 
afforded 3.15 (7 mg, 18%). Rf = 0.3 (20% MeOH/DCM). 1H NMR (CD3OD, 600 MHz) δ 4.58 (s, 1H), 3.65-
3.24 (m, 11H), 3.18 (m, 4H), 2.88 (m, 4H), 2.48 (m, 2H), 1.64-1.04 (m, 46H), 0.88 (m, J = 7.5 Hz, 3H); 13C 




signals), 33.2, 31.0 (2 signals), 30.9 (3 signals), 30.8, 30.7 (2 signals), 30.6, 27.5 (2 signals), 26.9 (2 




6-O-Undecyl mannoside-thiophene (3.16) 
3.46 (70 mg, 0.07 mmol) was dissolved in EtOH (2 mL). Then 10% wt (0.7 mg) Pd/C was added and the 
mixture was maintained under H2 for 16 h (2x). The mixture was filtered over Celite and the filtrate 
evaporated in vacuo. The residue was dissolved in DCM (2 mL) and treated with 5% AcCl in MeOH (0.4 
mL) for 4 h. Additional 5% AcCl in MeOH (0.2 mL) was added over 9 h. The mixture was neutralized with 
K2CO3 in MeOH, filtered through Celite and purified by FCC (60-100% EtOAC/hexanes) to yield 3.16 (14 
mg, 65%).1H NMR (CDCl3, 600 MHz) δ 7.46 (d, J = 3.6 Hz, 1H), 7.42 (d, J = 4.9 Hz, 1H), 7.04 (dd, J1 = 
4.9 Hz, J2 = 3.8 Hz, 1H), 5.99 (br s, 1H), 4.79 (s, 1H), 3.88 (br s, 1H), 3.79-3.63 (m, 6H), 3.54 (m, 1H), 
3.45 (m, 2H), 3.37 (m, 3H), 1.56 (m, 6H), 1.36 (m, 6H), 1.38-1.22 (m, 37H), 0.85 (t, J = 6.8 Hz, 3H); 13C 
NMR (CDCl3, 600 MHz) δ 162.1, 139.3, 129.8, 128.1, 127.8, 99.7, 72.3, 72.1, 71.9, 70.7, 67.9, 40.2, 37.6 
(2 signals), 32.1, 29.8 (4 signals), 29.7 (2 signals), 29.6 (2 signals), 29.5, 29.4 (2 signals), 27.1, 26.2, 
25.8, 25.6, 22.9, 14.3. HRMS (ESI) calcd for C39H71NO8SNa (M+Na)+ 736.4793, found 736.4782.  
 
 
6-O-Undecyl mannoside-deoxypiperazine (3.17) 
Compound 3.47b (44 mg, 0.067 mmol) was dissolved in CH2Cl2 (2 mL) and treated with 5% AcCl in 




NaHCO3. The mixture was filtered and concentrated in vacuo. FCC of the residue (5% MeOH/DCM) 
afforded 3.17 (15 mg, 38%). Rf = 0.2 (10% MeOH/DCM). 1H NMR (CD3OD, 600 MHz) δ 4.62 (s, 1H), 3.66 
(m, 3H), 3.58 (m, 3H), 3.44 (m, 3H), 3.33 (m, 1H), 3.12 (m, 4H), 2.65 (br s, 4H), 2.41 (br s, 2H), 1.53-1.44 
(m, 6H), 1.21 (m, 42H), 0.82 (t, J = 6.8 Hz, 3H); 13C NMR (CD3OD, 600 MHz) δ 101.7, 73.5, 72.9, 72.8, 
72.3, 72.0, 69.0, 68.8, 59.3, 51.2, 44.9, 33.3, 31.0, 31.0 (3 signals), 30.9 (4 signals), 30.8, 30.7 (3 





3.32 (1.30 g, 5 mmol) and TBAI (0.32 g, 1 mmol) were dissolved in THF (36 mL) under a N2 atmosphere. 
The reaction was cooled to 0 oC and NaH (0.22 g, 5.5 mmol) was added. The reaction was warmed 
slowly to rt, then recooled to 0 oC and bromoundecane (1.23 mL, 5.5 mmol) added. The mixture was 
stirred for 2 h, quenched and purified via FCC (40-50% EtOAc/hexanes), to give: 0.2 g of dialkylated 
material, 3.19 (0.16 g, 13%), 3.20 (0.34 g, 26%), 3.32 (0.50 g, 38% bsrm) and 4,6-di-O-undecenyl 
derivative (0.20 g, 7%). 
Compound 3.19 was also prepared from 3.33. Compound 3.33 (1.51 g, 4.5 mmol) and TBAI (0.29 g, 0.9 
mmol) were dissolved in DMF (22 mL) under a N2 atmosphere. The mixture was cooled to 0 oC and NaH 
(0.2 g, 5.0 mmol) was added. The reaction was warmed to rt over 30 min. Then, it was cooled down to 0 
oC and undecenyl bromide (1.18 mL, 5 mmol) was added. The reaction was stirred overnight at rt, then 
cooled to 0 oC and quenched slowly with water. The mixture was extracted with ethyl ether and the 
organic phase washed with brine, dried (NaSO4) and evaporated in vacuo. The residue was resuspended 
in MeOH and treated with PPTS (ca 0.5 g, pH 3-4). The mixture was stirred for 1 h, then, quenched with 
saturated NaHCO3 in MeOH. The solution was filtrated and concentrated under pressure. FCC of the 




5.28 (m, 1H), 5.20 (m, 1H), 5.03 (s, 1H), 4.20-4.10 (m, 3H), 3.99 (m, 1H), 3.73-3.60 (m, 4H), 3.47 (m, 2H), 
2.93 (br s, 1H), 1.57 (m, 2H), 1.50 (s, 3H), 1.33 (s, 3H), 1.33-1.23 (m, 16 H), 0.85 (t, J = 6.0 Hz, 3H); 13C 
NMR (CDCl3, 500 MHz) δ 133.7, 118.2, 109.7, 96.5, 78.2, 75.5, 72.3, 71.8, 71.7, 68.3, 68.0, 32.1, 29.8 (3 
signals), 29.7, 29.5, 28.1, 26.3 (2 signals), 22.9, 14.34. HRMS (ESI) calcd for C23H42O6Na (M+Na)+ 




1H NMR (CDCl3, 500 MHz) δ 5.86 (m, 1H), 5.26 (m, 1H), 5.19 (m, 1H), 5.04 (s, 1H), 4.20-4.11 (m, 3H), 
3.94 (m, 1H), 3.74 (m, 2H), 3.71 (m, 1H), 3.60 (m, 1H), 3.44 (m, 1H), 3.36 (m, 1H), 1.52 (m, 5H), 1.51 
(partially buried s, 3H), 1.33 (s, 3H), 1.23 (m, 14H), 0.85 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 
133.6, 118.2, 109.4, 96.4, 78.8 (2 signals), 75.9, 71.8, 68.6, 68.3, 62.9, 32.1, 30.3, 29.8, 29.7, 29.6, 28.2, 




Compound 3.21 was obtained from compound 3.33 (0.33 g, 0.99 mmol) following the procedure for 3.19 
with 1-bromobutane (0.16 mL, 1.48 mmol) as the alkylating agent. After purification via FCC (20-30% 
EtOAc/hexanes) 3.21 (0.18 g, 58%) was obtained. Rf = 0.75 (20% EtOAc/hexanes). 1H NMR (CDCl3, 500 
MHz) δ 5.88 (m, 1H), 5.28 (m, 1H), 5.19 (m, 1H), 5.03 (s, 1H), 4.18 (m, 1H), 4.13 (s, 2H), 3.98 (m, 1H), 




1.32 (partially buried s, 3H), 0.89 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 133.6, 118.1, 109.7, 
96.5, 78.2, 75.5, 71.9, 71.7, 71.6, 68.3, 68.0, 31.8, 28.1 (2 signals), 26.3, 19.4, 14.1. HRMS (ESI) calcd 




3.33 (0.74 g, 2.2 mmol) and TBAI (0.24 g, 0.74 mmol) were dissolved in DMF (20 mL) under a N2 
atmosphere. The reaction was cooled to 0 oC and NaH (0.13 g, 0.01 mmol) was added. The reaction was 
warmed up slowly over 30 min. Then, it was cooled down to 0 oC and CH3I (0.3 mL, 4.8 mmol) was 
added. The mixture was stirred overnight. The solution was brought to 0 oC, quenched slowly with water. 
Then, it was extracted using ethyl ether (3x100 mL) and washed with brine. The crude residue was 
resuspended in MeOH and treated with PPTS (ca 0.5 g, pH 3-4). The mixture was stirred for 1 h. Then, 
quenched with saturated NaHCO3 in methanol and the solvent was evaporated in vacuo. FCC yielded 
3.22 (0.55 g, 90%). Rf = 0.38 (20% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 5.88 (m, 1H), 5.28 (m, 
1H), 5.19 (m, 1H), 5.04 (s, 1H), 4.19 (m, 1H), 4.12 (m, 2H), 3.67 (m, 3H), 3.59 (m, 1H), 3.38 (s, 3H), 2.68 
(br s, 1H), 1.49 (s, 3H), 1.32 (s, 3H); 13C NMR (CDCl3, 500 MHz) δ 133.5, 118.0, 96.5, 78.0, 75.4, 72.9, 







NaH (58 mg, 1.45 mmol) was added at 0 oC to a solution of 3.20 (0.28 g, 0.9 mmol), TBAI (66 mg, 0.18 
mmol) in DMF (15 mL). The mixture was stirred for 30 min, and CH3I (0.09 mL, 1.45 mmol) was added. 
The reaction was stirred for 3-4 h at rt, then cooled to 0 oC and quenched with water. The mixture was 
extracted with ethyl ether (3x25 mL) and the organic phase was dried (Na2SO4) and evaporated under 
reduced pressure. The residue was purified via FCC (10-15% EtOAc/hexanes) to give 3.23 (0.27 g, 64%). 
Rf = 0.9 (20% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 5.86 (m, 1H), 5.25 (m, 1H), 5.16 (m, 1H), 
5.05 (s, 1H), 4.17 (m, 2H), 4.10 (m, 1H), 3.96 (m, 1H), 3.76 (m, 1H), 3.64-3.53 (m, 3H), 3.44 (m, 1H), 3.36 
(partially buried s, 3H), 3.34 (m, 1H), 1.52 (m, 2H), 1.50 (partially buried s, 3H), 1.31 (partially buried s, 
3H), 1.22 (br s, 16H), 0.84 (t, J = 6.7 Hz, 3H); 13C NMR (CDCl3, 600 MHz) δ 133.8, 117.8, 109.3, 96.6, 
79.0, 76.3, 76.0, 71.7 (2 signals), 68.4, 68.0 (2 signals), 67.9, 59.4, 32.1, 30.2, 29.8, 29.6, 29.5, 28.2, 




Compound 3.25 was prepared following the procedure described for 3.21. For 3.25: 1H NMR (CDCl3, 500 
MHz) δ 7.67 (m, 4H), 7.42-7.34 (m, 6H), 5.73 (m, 1H), 4.93 (m, 1H), 4.90 (m, 1H), 3.69 (m, 1H), 3.40 (m, 
4H), 1.94 (m, 2H), 1.56 (m, 4H), 1.40-1.07 (m, 22H), 1.05 (br s, 9H), 0.90 (t, J = 7.4 Hz, 3H); 13C NMR 
(CDCl3, 500 MHz)  δ 139.3, 136.2, 135.8, 135.0, 129.7, 129.6, 127.8, 127.6, 114.4, 73.4, 71.2, 70.9, 36.5, 
36.3, 33.9, 32.1, 30.0, 29.9, 29.7 (3 signals), 29.2, 27.3, 27.1, 26.4, 25.1, 24.6, 19.6 (2 signals), 14.2. 
HRMS (ESI) calcd for C36H59O2Si (M+H)+ 551.4279, found 551.4263. 
 
 
10-((tert-Butyldiphenylsilyl)oxy)hexadec-15-en-1-yl methanesulfonate (3.26) 
To a solution of compound 3.35 (1.0 g, 2.14 mmol) at 0 oC in CH2Cl2 (30 mL) was added Et3N (0.35 mL, 




reaction was diluted with H2O and extracted with ethyl ether (3x100 mL). The organic phase was washed 
with brine, dried (Na2SO4) and evaporated in vacuo. FCC of the residue afforded 3.26 (0.84 g, 69%) as a 
yellow oil. Rf = 0.5 (20% EtOAc/hexanes).1H NMR (CDCl3, 500 MHz) δ 7.65 (m, 4H), 7.41-7.32 (m, 6H), 
5.72 (m, 1H), 4.91 (m, 1H), 4.88 (m, 1H), 4.20 (t, J = 6.6 Hz, 2H), 3.67 (m, 1H), 2.98 (s, 3H), 1.91 (m, 2H), 
1.72 (m, 2H), 1.40-1.06 (m, 20H), 1.02 (br s, 9H); 13C NMR (CDCl3, 500 MHz) δ 139.3, 136.1, 129.6, 
127.6, 114.4, 73.4, 70.4, 37.6, 36.5, 36.3, 34.0, 29.9, 29.8, 29.6, 29.5, 29.3, 29.2, 29.1, 27.3, 25.6, 25.1, 
24.6, 19.6. HRMS (ESI) calcd for C33H52O4SSiNa (M+Na)+ 595.3253, found 595.3246.  
 
 
10-Hydroxyhexadec-15-en-1-yl methanesulfonate (3.26a) 
A 5% solution of acetyl chloride in MeOH (1.7 mL) was added to a mixture of 3.26 (1.0 g, 1.75 mmol) and 
DCM (17 mL). The mixture was stirred for 16 h at rt, then neutralized with methanolic sodium bicarbonate. 
The mixture was filtered and concentrated in vacuo. FCC of the residue (20-30% EtOAc/hexanes) yielded 
3.26a (0.39 g, 66%). Rf = 0.5 (20% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 5.77 (m, 1H), 4.97 (m, 
1H), 4.93 (m, 1H), 4.20 (t, J = 6.0 Hz, 2H), 3.56 (m, 1H), 2.99 (s, 3H), 2.06 (m, 2H), 1.70 (m, 2H), 1.39-
1.34 (m, 20H); 13C NMR (CDCl3, 500 MHz) δ 139.1, 114.5, 72.0, 70.4, 37.6, 37.5, 37.4, 33.9, 29.7, 29.6, 





10-Iodohexadec-15-en-1-yl methanesulfonate (3.26b) 
A mixture of 3.26a (0.38 g, 1.15 mmol), Ph3P (0.33 g, 1.26 mmol) and imidazole (90 mg, 1.38 mmol) 
benzene (12 mL) was stirred for 15 min at rt. Then, iodine (0.15 g, 1.26 mmol) was introduced and stirring 




The organic phase was dried (Na2SO4) and evaporated in vacuo. The residue was purified via FCC (15% 
EtOAc/hexanes) to yield 3.26b (0.31 g, 61%). Rf = 0.6 (20% EtOAc/hexanes). 1H NMR (CDCl3, 600 MHz) 
δ 5.78 (m, 1H), 4.98 (m, 1H), 4.92 (m, 1H), 4.20 (t, J = 6.0 Hz, 2H), 4.08 (m, 1H), 2.98 (s, 3H), 2.05 (m, 
2H), 1.84 (m, 2H), 1.75-1.63 (m, 4H), 1.52 (s, 2H), 1.43 (m, 6H), 1.31 (m, 8H); 13C NMR (CDCl3, 600 




Amine 3.36 (0.26 g, 0.52 mmol) and 2-thiophene carboxylic acid (0.10 g, 0.78 mmol) were azeotroped 
and dissolved in DCM (26 mL) Then, EDCI (0.30 g, 1.58 mmol), dry Et3N (0.29 mL, 2.10 mmol) and 
catalytic DMAP (13 mg, 0.10 mmol) were added. The reaction was stirred for 16 h. Then, it was extracted 
using more DCM (3x10 mL) and it was washed with water (3x). The organic phase was dried (Na2SO4) 
and evaporated and FCC of the residue yielded 3.27 (0.22 g, 69%). Rf = 0.7 (20% EtOAc/hexanes). 1H 
NMR (CDCl3, 600 MHz) δ 7.65 (m, 4H), 7.45 (m, 2H), 7.42 (m, 6H), 7.04 (d, J = 6.0 Hz, 1H)  5.90 (br s, 
1H), 5.71 (m, 1H), 4.90 (m, 1H), 4.88 (m, 1H), 3.67 (m, 1H), 3.40 (m, 2H), 1.90 (m, 2H), 1.57 (m, 4H), 
1.36 (m, 6H), 1.15 (m, 12H), 1.08 (s, 9H); 13C NMR (CDCl3, 500 MHz) δ 139.3, 136.2, 135.0, 129.8, 
129.6, 128.0, 127.8, 127.6, 114.4, 73.4, 40.3, 36.5, 36.3, 33.9, 30.0, 29.9, 29.7, 29.7, 29.5, 29.2, 27.3, 




Hexadec-15-en-1-yl methanesulfonate (3.28) 
Compound 3.26b (0.31 g, 0.07 mmol) was stirred with zinc (0.26 g, 4.05 mmol) and methanol (15 mL). 
The reaction was quenched with water, extracted with ethyl ether (3x10 mL) and purified via FCC to 




5.80 (m, 1H), 4.98 (m, 1H), 4.91 (m, 1H), 4.21 (t, J = 6.0 Hz, 2H), 2.99 (s, 3H), 2.02 (m, 2H), 1.73 (m, 2H), 
1.39-1.30 (m, 4H), (br s, 18H). 13C NMR (CDCl3, 600 MHz) δ 139.5, 114.3, 70.4, 37.6, 34.0, 29.8, 29.8, 




To a solution of 3.34 (3.3 g, 0.01 mmol) in MeOH (50 mL) was added PPTS (0.24 g, 0.96 mmol). The 
reaction mixture was stirred for 4 h and then quenched with a saturated solution of NaHCO3 in MeOH. 
The mixture was concentrated in vacuo. FCC of the residue in 50-60% EtOAc/hexanes gave 3.35 (2.19 g, 
95% brsm). Rf = 0.34 (50% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 5.86 (m, 1H), 5.30 (m, 1H), 
5.22 (m, 1H), 5.05 (s, 1H), 4.17 (m, 3H), 3.98 (m, 1H), 3.83 (m, 2H), 3.74 (m, 1H), 3.64 (m 1H), 2.51 (br s, 
1H), 2.04 (m, 1H), 1.51 (s, 3H), 1.34 (s, 3H); 13C NMR (CDCl3, 500 MHz) δ 133.5, 128.6, 118.4, 109.9, 




3.32 (2.19 g, 8.41 mmol), TBDPSCl (2.37 mL, 9.25 mmol) and imidazole (1.14 g, 16.82 mmol) were 
dissolved in THF (84 mL) and stirred overnight. The solvent was evaporated in vacuo and the mixture 
was redissolved in ethyl ether and water and extracted (3x100 mL). The combined organic phase was 
washed with brine, dried (Na2SO4) and the solvent was evaporated in vacuo. FCC of the residue afforded 
product 3.32a (1.7 g, 56% brsm). Rf = 0.4 (20% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 7.72 (m, 
4H), 7.44 (m, 6H), 5.90 (m, 1H), 5.28 (m, 1H), 5.22 (m, 1H), 5.06 (s, 1H), 4.18 (m, 3H), 3.99 (m, 1H), 3.95 




(CDCl3, 500 MHz) δ 135.8, 135.7, 133.6, 133.0, 130.0 (2 signals), 127.9 (2 signals), 118.1, 109.7, 96.3, 
78.3, 75.5, 71.0, 69.6, 68.0, 64.8, 28.1, 27.0, 26.3, 19.4. HRMS (ESI) calcd for C28H38O6SiNa (M+Na)+ 






PPTS (ca 1 g) was added to a mixture of 3.32a (1.7 g, 3.4 mmol), ethyl vinyl ether and DCM solution (1:1, 
100 mL) until a pH of 4. The reaction was stirred for 2 h and quenched with methanolic NaHCO3. The 
solution was filtered and evaporated to give crude 3.32b (ca 1.42 g). Rf = 0.69 (20% EtOAc/hexanes). 1H 
NMR (CDCl3, 500 MHz) δ 7.71 (m, 4H), 7.38 (m, 6H), 5.90 (m, 1H), 5.26 (m, 1H), 5.21 (m, 1H), 5.08 (m, 
1H), 4.90 (m, 1H), 4.24-3.99 (m, 3H), 3.96-3.75 (m, 3H), 3.74 (m, 2H), 3.74-3.68 (m, 2H), 1.52 (s, 3H), 
1.26 (s, 3H), 1.20 (m, 4H), 1.04 (s, 9H), 0.80 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 136.1, 
135.8 (2 signals), 134.0, 133.9, 133.8 (2 signals), 133.5, 133.3, 129.8 (2 signals), 129.7 (2 signals), 127.8 
(2 signals), 127.7, 118.1, 118.0, 109.4, 109.3, 100.9, 100.0, 96.1, 95.9, 79.1, 78.7, 76.0 (2 signals), 73.3, 
73.2, 69.8 (2 signals), 67.7, 67.6, 63.6, 62.9, 61.8, 61.0, 28.2, 28.1, 27.0, 26.6 (2 signals), 22.9, 21.2, 




A mixture of crude 3.35b (ca 1.42 g), TBAF (0.1 M in THF, 50 mL, 5 mmol) and THF (100 mL) was stirred 
overnight at rt. The solvent was then evaporated in vacuo. FCC of the residue yielded 3.36 (0.7 g, 85%). 




5.10 (m, 1H), 4.95 (m, 1H), 4.29 (m, 1H), 4.14 (m, 2H), 3.95 (m, 1H), 3.78 (m, 3H), 3.64 (m, 3H), 1.47 (s, 
3H), 1.26 (m, 6H), 1.23 (m, 3H); 13C NMR (CDCl3, 500 MHz) δ 133.7, 133.6, 118.2 (2 signals), 109.5, 
109.4, 101.3, 100.9, 78.9, 78.5, 76.3, 76.0, 73.5, 72.8, 69.0, 68.7, 68.3, 68.2, 62.2, 62.1, 62.0, 28.3, 28.2, 




LAH (0.1 g, 2.7 mmol) was slowly added to a solution of compound 3.34 (0.92 g, 1.8 mmol) in CH2Cl2 (18 
mL) at 0 oC. The mixture was warmed to rt and stirred for an additional 1 h. Then, water (10 mL) and 
NaOH (1 mL, 1M), were added, subsequently. Na2SO4 was added to dry the H2O and the mixture was 
filtered over Celite. The filtrated was concentrated in vacuo and then was subjected to FCC to afford 
compound 3.35 (0.71 g, 85%). Rf = 0.2 (10% EtOAc/hexanes). 1H NMR (CDCl3, 600 MHz) δ 7.65 (m, 
4H), 7.34 (m, 6H), 5.72 (m, 1H), 4.92 (m, 1H), 4.88 (m, 1H), 4.10 (m, 1H), 3.68 (m, 1H), 3.62 (m, 2H), 
1.92 (m, 2H), 1.54 (m, 4H), 1.38-1.17 (m, 8H), 1.02 (s, 9H). HRMS (ESI) calcd for C32H50O2SiNa (M+Na)+ 




Ethanol (ca 200 mL) was saturated with ammonia gas at 0 oC by bubbling for 30 minutes. 3.26 (0.65 g, 
1.13 mmol) was placed in a high-pressure tube and the saturated ammonia solution (150 mL) was added. 
The vessel was closed, and the reaction was heated at approximately 80 oC for 4 h. The reaction was 
brought to rt and the solvent was concentrated in vacuo. The residue was purified via FCC (10% 
MeOH/DCM) to afford 3.36 (0.48 g, 94%). Rf = 0.32 (20% MeOH/DCM). 1H NMR (CDCl3, 600 MHz) δ 
7.63 (m, 4H), 7.36 (m, 6H), 5.70 (m, 1H), 4.88 (m, 1H), 4.85 (m, 1H), 4.10 (m, 1H), 3.10 (m, 2H), 1.90 (m, 




134.9, 129.5, 127.5, 114.3, 73.3, 40.1, 39.4, 36.4, 36.3, 33.9, 29.8, 29.7, 29.6, 29.2, 29.1, 27.8, 27.2, 





Nitrogen was bubbled through a solution of 3.18 (96 mg, 0.29 mmol) and 3.26 (0.33 g, 0.58 mmol) in dry 
CH2Cl2 (3 mL) for 30 min and at rt. At that point Grubbs 2nd generation catalyst (25 mg, 10 mol%) was 
added and the mixture stirred for 20 h. Then, the reaction was quenched with DMSO (0.05 mL). After 
stirring for an additional 30 in the solution was evaporated in vacuo. FCC of the residue afforded 3.37 (45 
mg, 40%). Rf = 0.35 (40% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 7.64 (m, 4H), 7.34 (m, 6H), 
5.67 (m, 1H), 5.30 (m, 1H), 4.19 (t, J = 6.7 Hz, 2H), 3.79 (m, 3H), 3.66 (m, 1H), 3.38 (m, 1H), 2.97 (s, 3H), 
2.40 (br s, 1H), 2.24 (br s, 1H), 1.90 (m, 4H), 1.72-1.06 (m, 46H), 1.06 (s, partially buried, 9H), 0.85 (t, J = 
7.1 Hz, 3H); 13C NMR (CDCl3, 600 MHz) δ 135.9, 129.4, 127.4, 82.7, 82.5, 74.0, 73.1, 70.2, 37.4, 36.3, 
33.6, 31.9, 29.6 (3 signals), 29.4, 29.3 (2 signals), 29.1, 29.0, 28.4, 27.1, 25.6, 25.4, 24.8, 22.7,19.4, 14.1. 
HRMS (ESI) calcd for C51H86O7SSiNa (M+Na)+ 893.5761, found 893.5743.   
 
 
THF-mesylate (3.37a)  
A solution of compound 3.37 (45 mg, 0.05 mmol) in EtOAc (2 mL) and Pd/C (20 mg, 10% wt) was purged 
with N2 for 30 min. Then, the mixture was stirred under a hydrogen atmosphere (balloon) for 20 h. The 
reaction was then purged with N2 and filtered through a bed of Celite to yield 3.37a (45 mg, quantitative). 
1H NMR (CDCl3, 600 MHz) δ 7.64 (m, 4H), 7.36 (m, 6H), 4.19 (t, J = 6.6 Hz, 2H), 3.76 (m, 2H), 3.67 (m, 




13C NMR (CDCl3, 600 MHz) δ 136.1, 135.0, 129.5, 127.5, 82.8, 74.2 (2 signals), 73.4, 70.4, 37.5, 36.5, 
36.4, 33.7, 33.6, 32.1, 29.9 (2 signals), 29.8 (3 signals), 29.6 (2 signals), 29.5, 29.3, 29.2, 28.9, 27.3, 25.8 




THF-piperazine (3.37b)  
To a solution of compound 3.37a (45 mg, 0.05 mmol) in dry CH3CN (2 mL) was added piperazine (0.22 g, 
0.26 mmol) and the mixture was refluxed for 4 h. The mixture was evaporated under reduced pressure. 
FCC of the residue yielded 3.37b (29 mg, 64%). Rf = 0.57 (10% MeOH/DCM). 1H NMR (CDCl3, 500 MHz) 
δ 7.63 (m, 4 H), 7.34 (m, 6H), 3.76 (m, 2H), 3.66 (m, 1H), 3.36 (m, 2H), 3.11 (br s, 4H), 2.64 (br s, 4H), 
2.39 (m, 2H), 1.96 (m, 2H), 1.62-1.22 (m, 18H), 1.01 (br s, partially buried), 1.00 (s, partially buried, 9H), 
0.84 (t, J = 6.7 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 136.1, 135.0, 129.6, 127.6, 82.8, 74.4, 73.4, 58.5, 
50.7, 44.0, 36.7, 36.4, 33.6, 32.1, 29.9, 29.9, 29.9, 29.8, 29.7, 29.7, 29.7, 29.6, 29.6, 29.1, 29.0, 27.5, 
27.3, 26.6, 25.8, 25.7, 25.0, 24.9, 22.9, 19.6, 14.4. HRMS (ESI) calcd for C54H95N2O4Si (M+H)+ 862.6983, 
found 862.6940.   
 
 
THF-thiophene-alkene (3.38)  
Following the procedure described for 3.37, CM of 3.18 (60 mg, 0.18 mmol) and 3.27 (0.22 g, 0.36 mmol) 
yielded 3.38 (43 mg, 27%). Rf = 0.47 (40% EtOAc/hexanes). 1H NMR (CDCl3, 600 MHz) δ 7.42 (m, 4H), 
7.39 (m, 1H), 7.37 (m, 1H), 7.32 (m, 6H), 7.04 (m, 1H), 6,02 (br s, 1H), 5.67 (m, 1H), 5.30 (m, 1H), 3.80 
(m, 3H), 3.66 (m, 1H), 3.39 (m, 3H), 2.59 (br s, 1H), 2.43 (br s, 1H), 1.90 (m, 4H), 1.54-1.15 (m, 46H), 




129.5, 128.1, 127.9, 127.7, 127.5, 82.8, 82.6, 74.1, 73.2, 40.2, 36.4, 36.2, 33.62, 32.4 (2 signals), 32.0, 
29.8 (5 signals), 29.7 (2 signals), 29.6, 29.5 (2 signals), 29.4, 29.2, 28.6, 27.2, 27.1, 25.8, 25.0, 24.5, 





Compound 3.38 (43 mg, 0.047 mmol) was dissolved in EtOAc (2 mL). The solution was degassed for 30 
min and Pd/C (40 mg, 10%) was introduced. Then, the reaction was stirred under H2 atmosphere for 20 h. 
The solution was filtered over Celite and concentrated in vacuo. NMR indicated the presence of alkene, 
so the hydrogenation procedure was repeated. Then, FCC (40-50% EtOAc/hexanes) of the crude product 
gave 3.38a (31 mg, 72%). Rf = 0.5 (40% EtOAc/hexanes). 1H NMR (CDCl3, 600 MHz) δ 7.64 (m, 4H), 
7.46 (d, J = 1.1 Hz, 1H), 7.45 (d, J = 1.1 Hz, 1H), 7.35 (m, 6H), 7.04 (d, J = 1.3 Hz ,1H), 5.98 (br s, 1H), 
3.76 (m, 2H), 3.66 (m, 1H), 3.39 (m, 4H), 1.96 (m, 3H), 1.65 (m, 3H), 1.56 (m, 3H), 1.35-1.12 (m, 47H), 
1.09 (s, 9H), 0.86 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 600 MHz) δ 162.0, 139.3, 136.1, 135.0, 134.9 (2 
signals), 129.8, 129.6, 129.5, 128.2, 128.0, 127.7, 127.6, 127.5, 82.9, 72.2 (2 signals), 73.4, 73.3, 40.2, 
36.4, 32.1, 29.9 (2 signals), 29.8 (2 signals), 29.6 (3 signals), 29.5, 28.9, 28.6, 27.3, 27.1, 25.8, 25.0, 




THF-butyl ether-alkene (3.39) 
Following the procedure for 3.37, CM of alkenes 3.18 (86 mg, 0.26 mmol) and 3.25 (0.13 g, 0.52 mmol) 
yielded 3.39 (50 mg, 23%). Rf = 0.51 (40% EtOAc/hexanes). 1H NMR (CDCl3, 400 MHz) δ 7.63 (m, 4H), 




8H), 1.23 (br s, 44H), 1.01 (s, 9H), 0.89 (t, J = 7.3 Hz, 3H), 0.84 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 500 
MHz) δ 139.3, 136.1, 135.0, 129.5, 127.6, 114.3, 73.4, 71.2, 70.9, 36.5, 36.3, 33.9, 32.1, 30.0, 29.9, 29.7 
(3 signals), 29.1, 27.3, 26.4, 25.0, 24.7, 19.6 (2 signals), 14.2.   
 
 
6-O-Undecyl mannoside-butenolide-alkene (3.40) 
Nitrogen was bubbled through a solution of 3.19 (57 mg, 0.14 mmol) and butenolide 3.24 (39 mg g, 0.07 
mmol) in dry CH2Cl2 (1 mL) for 30 min and at rt. At that point Grubbs 1st generation catalyst (25 mg, 10 
mol%) was added and the mixture refluxed for 6 h. Then, the reaction was quenched with DMSO (0.05 
mL). After stirring for an additional 30 min the solution was evaporated in vacuo. FCC of the residue 
afforded 3.40 (54 mg, 96%) as an E/Z mixture (E/Z~3/1). Rf = 0.38 (20% EtOAc/hexanes x 2). 1H NMR 
(CDCl3, 500 MHz) δ 7.59 (m, 4H), 7.31 (m, 6H), 6.90 (m, 1H), 5.60-5.41 (m, 2H), 4.97 (s, 1H), 4.92 (m, 
1H), 4.10-3.84 (m, 4H), 3.61-3.56 (m, 5H), 3.39 (m, 2H), 2.93 (m, 1H), 2.17 (t, J = 7.7 Hz, 2H), 1.85 (m, 
2H), 1.52-1.18 (bm, 45H), (s, 9H), 0.80 (t, J = 6.7 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 174.1, 149.0, 
136.3 (2 signals), 136.1, 135.1, 134.9 (2 signals), 134.5, 129.6, 127.6, 124.9, 124.6, 109.7, 96.3, 96.0, 
75.6, 75.5, 73.3, 72.3, 71.8, 71.7, 71.6, 68.0 (2 signals), 36.5, 36.3, 32.4, 32.1, 29.9, 29.8 (2 signals), 29.7 
(2 signals), 29.5, 29.4, 29.3, 29.2, 28.1 (2 signals), 27.5, 27.3, 26.3, 25.4, 25.0, 24.7 (2 signals), 22.9, 
19.6, 19.4, 14.3. HRMS (ESI) calcd for C56H88O9SiNa (M+Na)+ 955.6090, found 955.6088. 







6-O-Undecyl mannoside-butenolide (3.40a) 
To a solution of 3.40 (70 mg, 0.078 mmol) and TsNHNH2 (0.98 g, 5.26 mmol) in DME (7.8 mL) at reflux, 
was added a solution of NaOAc (0.53 g, 6.51 mmol) in H2O (10 mL) over 4 h. The mixture was then 
cooled, diluted with EtOAc, and washed with water. The organic phase was dried (Na2SO4), filtered and 
concentrated in vacuo. FCC in 1-5% (acetone/DCM) delivered 3.40a (35 mg, 48%). Rf = 0.42 (5% 
acetone/DCM). 1H NMR (CDCl3, 500 MHz) δ 7.64 (m, 4H), 7.34 (m, 6H), 6.94 (s, 1H), 4.96 (m, 2H), 4.12 
(m, 2H), 3.66 (m, 6H), 3.37 (m, 3H), 2.93 (m, 1H),  2.21 (m, 2H), 1.49-1.09 (bm, 51H), 1.08 (s, 9H), 0.85 
(t, J = 7.5 Hz, 3H). HRMS (ESI) calcd for C56H90O9SiNa (M+Na)+ 957.6252, found 957.6225. 
 
 
4-O-Undecyl mannoside-butenolide-alkene (3.41) 
Following the procedure described for 3.40, CM for 3.20 (0.21 g, 0.52 mmol) and 3.24 (0.150 g, 0.26 
mmol) yielded 3.41 (6 mg, 25%) as an E/Z mixture (E/Z~4/1). Rf = 0.4 (30% EtOAc/hexanes). 1H NMR 
(CDCl3, 500 MHz) δ 7.59 (m, 4H), 7.28 (m, 6H), 6.90 (s, 1H), 5.56-5.40 (m, 2H), 5.40 (m, 1H), 4.99 (s, 
1H), 4.92 (m, 1H), 4.16 (m, 1H), 4.05 (m, 2H), 3.82-3.75 (m, 5H), 3.56 (m, 1H), 3.43 (m, 1H), 3.31 (m, 
1H), 2.16 (m, 2H), 2.05-1.80 (m, 2H), 1.60-1.10 (bm, 45H), 1.10 (s, 9H), 0.82 (t, J = 6.7 Hz, 3H); 13C NMR 
(CDCl3, 500 MHz) δ 174.1, 149.0, 136.3 (2 signals), 136.1, 134.9 (2 signals), 134.4, 129.5, 127.5, 124.8, 
109.3, 96,2, 95.9, 78.8, 76.0, 71.7, 68.5, 68.0, 62.9, 36.4, 36.3, 32.4, 32.1, 30.2, 28.8, 29.7 (2 signals), 






6-O-Butyl mannoside-butenolide-alkene (3.42) 
Following the procedure described for 3.40, the CM of 3.21 (0.12 g, 0.37 mmol) and 3.24 (80 mg, 0.18 
mmol) yielded 3.42 (60 mg, 80%) as an E/Z mixture (E/Z~4/1). Rf = 0.2 (30% EtOAc/hexanes). 1H NMR 
(CDCl3, 500 MHz) δ 7.63 (m, 4H), 7.37 (m, 6H), 6.94 (s, 1H), 5.61-5.44 (m, 2H), 5.00 (s, 1H), 4.96 (m, 
1H), 4.12-3.88 (m, 4H), 3.71-3.60 (m, 5H), 3.50 (m, 2H), 2.91 (br s, 1H),  2.20 (m, 2H), 1.90 (m, 2H), 1.55-
1.10 (m, 33H), 1.00 (s, 9H), 0.86 (m, 3H); 13C NMR (CDCl3, 500 MHz) 149.1, 136.1, 129.6, 127.6, 124.9, 
109.7, 96.1, 75.6, 73.3, 72.0, 71.9, 71.8, 68.1, 68.0, 36.5, 36.3, 32.5, 31.9, 29.8, 29.5, 29.4, 29.2, 28.1, 
27.6, 27.4, 27.3, 26.3, 25.4, 25.1, 24.8 (2 signals), 19.7, 19.5 (2 signals), 14.1. 
 
 
6-O-Butyl mannoside-butenolide (3.42a) 
Compound 3.42 (0.1 g, 0.12 mmol) was transformed to 3.42a following the reduction protocol described 
for preparation of 3.40a. FCC in 1-5% (acetone/DCM) delivered 3.42a (60 mg, 61%). Rf = 0.42 (5% 
acetone/DCM). 1H NMR (CDCl3, 500 MHz) δ 7.68 (m, 4H), 7.28 (m, 6H), 6.90 (s, 1H), 4.91 (m, 2H), 4.08 
(m, 2H), 3.63 (m, 6H), 3.45 (m, 2H), 3.35 (m, 1H), 3.00 (br s, 1H), 2.15 (m, 2H), 1.49-1.10 (m, 37H), 1.02 
(s, 9H), 0.79 (t, J = 7.7 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 174.1, 149.1, 136.1, 135.0, 134.9, 134.5, 
129.9, 129.6, 127.5, 126.7, 109.7, 97.3, 78.1, 75.6, 73.4, 71.9, 71.8, 71.5,68.0, 36.5 (2 signals), 31.8, 






6-O-Methyl mannoside-butenolide-alkene (3.43) 
Following the procedure described for 3.40, the CM of 3.22 (91 mg, 0.33 mmol) and 3.24 (90 mg, 0.17 
mmol) yielded 3.43 (0.12 g, 92%) as an E/Z mixture (E/Z~3/1). Rf = 0.2 (30% EtOAc/hexanes). 1H NMR 
(CDCl3, 500 MHz) δ 7.64 (m, 4H), 7.34 (m, 6H), 6.94 (s, 1H), 5.65-5.45 (m, 2H), 5.10 (s, 1H), 5.02 (m, 
1H), 4.08-3.91 (m, 4H), 3.68 (m, 4H), 3.58 (m, 1H), 3.39 (m, 3H), 2.67 (br s, 1H), 2.22 (m, 2H), 1.89-1.13 
(m, 27H), 1.01 (s, 9H); 13C NMR (CDCl3, 600 MHz)  δ 174.1, 149.0, 136.3, 136.2 (3 signals), 136.1, 134.9 
(2 signals), 134.5, 129.6, 129.5, 127.6, 127.5 (2 signals), 125.2, 125.0, 109.4, 98.3, 96.4, 96.0. 73.3, 72.0 
(2 signals), 70.4, 70.3, 69.9, 69.8, 69.5, 68.3, 68.0, 67.8, 56.1, 36.5, 36.3, 32.4 (2 signals), 32.1, 31.1, 
29.9 (2 signals), 29.8, 29.7 (2 signals), 29.5, 29.4, 29.3, 29.2, 28.0, 27.5, 27.2, 26.6, 26.3 (2 signals), 




6-O-Methyl mannoside-butenolide (3.43a) 
Compound 3.43 (66 mg, 0.084 mmol) was transformed to 3.43a following the reduction protocol 
described for preparation of 3.40a. FCC in 1-5% (acetone/DCM) delivered 3.43a (60 mg, 91%). Rf = 0.28 
(5% acetone/DCM). 1H NMR (CDCl3, 500 MHz) δ 7.59 (m, 4H), 7.30 (m, 6H), 6.90 (s, 1H), 4.92 (m, 2H), 
4.09 (m, 2H), 3.61 (m, 6H), 3.33 (m, 1H), 3.32 ( partially buried s, 3H), 2.16 (m, 2H), 1.46-1.10 (m, 33H), 
1.03 (s, 9H); 13C NMR (CDCl3, 500 MHz) δ 174.1, 149, 136.1, 134.9 (2 signals), 134.5, 129.5, 127.5, 
109.7, 97.3, 78.2, 75.6, 73.3, 73.0, 70.5, 68.5, 68.0, 59.7, 36.4, 29.8, 29.7, 29.5, 29.4, 29.3, 28.0, 27.5, 





6-O-Methyl-4-O-undecyl mannoside-butenolide-alkene (3.44) 
Following the procedure described for 3.40, CM of 3.23 (0.12 g, 0.29 mmol) and 3.24 (80 g, 0.14 mmol) 
yielded 3.44 (60 mg, 44%) as an E/Z mixture (E/Z~3/1). Rf = 0.8 (20% EtOAc/hexanes). 1H NMR (CDCl3, 
500 MHz) δ 7.63 (m, 4H), 7.35 (m, 6H), 6.94 (s, 1H), 5.60-5.45 (m, 2H), 5.03 (s, 1H), 4.96 (m, 1H), 4.15 
(m, 1H), 4.08 (m, 2H), 3.86 (m, 1H), 3.78 (m, 1H), 3.59 (m, 4H), 3.46 (1H), 3.41 (s, 3H), 3.36 (m, 4H), 
2.22 (m, 2H), 1.89 (m, 2H), 1.57-1.49 (m, 45H), 1.08 (s, 9H), 0.86 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3, 
600 MHz) δ 171.2, 149.1, 146.6 (2 signals), 139.3, 136.7, 136.2, 135.0, 134.8, 129.6, 129.0, 127.6, 124.9, 
114.4, 109.3, 104.2, 96.7, 96.6, 96.2, 79.1, 73.4, 73.3, 71.8, 62.8, 59.5, 36.5, 36.4, 33.9, 32.1, 30.2, 29.9, 
29.7 (2 signals), 29.6, 29.4, 29.3 (2 signals), 29.2, 28.2, 27.4, 27.3, 26.5, 26.3, 25.1 (2 signals), 25.0, 
24.6, 22.9, 19.6, 19.4, 14.3. HRMS (ESI) calcd for C57H90O9SiNa (M+Na)+ 969.6246, found 969.6237. 
 
 
6-O-Methyl-4-O-undecyl mannoside-butenolide (3.44a) 
Compound 3.44 (60 mg, 0.063 mmol) was transformed to 3.44a following the reduction protocol 
described for preparation of 3.40a. FCC in 1-5% (acetone/DCM) delivered 3.44a (27 mg, 45%). Rf = 0.5 
(2% acetone/DCM). 1H NMR (CDCl3, 500 MHz) δ 7.64 (m, 4H), 7.34 (m, 6H), 6.94 (s, 1H), 4.98 (s, 1H), 
4.97 (m, 1H), 4.15 (m, 1H), 4.07 (m, 1H), 3.78 (m, 1H), 3.62 (m, 5H), 3.46 (m, 1H), 3.36 (partially buried s, 
3H), 3.34 (m, 2H), 2.22 (m, 2H), 1.50-1.08 (m, 51H), 1.01 (s, 9H), 0.85 (t, J = 7.5 Hz, 3H); 13C NMR 
(CDCl3, 500 MHz) δ 174.1, 149.0, 136.1, 135.0 (2 signals), 130.0 (2 signals), 128.0, 109.3, 97.3, 79.1, 
77.6, 76.4, 76.2, 73.4, 71.8, 71.7, 68.2, 67.7, 59.5, 36.5 (2 signals), 32.1, 30.3, 29.9, 29.8 (3 signals), 





6-O-Undecyl mannoside-mesylate-alkene (3.45) 
Following the procedure described for 3.40, CM of 3.19 (0.3 g, 0.72 mmol) and 3.26 (0.2 g, 0.35 mmol) 
yielded 3.45 (0.160 g, 48%) as an E/Z mixture (E/Z~4/1). 1H NMR (CDCl3, 600 MHz) δ 7.65 (m, 4H), 7.35 
(m, 6H), 5.65-5.46 (m, 2H), 5.02 (s, 1H), 4.21 (t, J = 5.0 Hz, 2H), 4.13 (m, 3H), 3.90 (m, 1H), 3.69 (m, 4H), 
3.63 (m, 1H), 3.49 (m, 2H), 2.99 (s, 3H), 2.91 (br s, 1H), 1.9 (m, 2H), 1.73 (m, 2H), 1.57-1.24 (m, 46H), 
1.05 (s, 9H), 0.87 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 600 MHz) δ 136.3, 136.2, 135.0 (2 signals), 129.6, 
128.6, 127.6 (2 signals), 125.0, 109.7, 96.2, 75.6, 73.4, 72.3, 71.9, 71.7, 70.4, 68.1, 37.6, 36.6, 36.4, 
32.5, 32.1, 31.2, 29.8, 29.7(2 signals), 29.6, 29.4, 29.3, 29.2, 28.1, 27.3, 26.3, 25.6, 25.1, 24.8, 22.9, 
19.7, 14.3; HRMS (ESI) calcd for C54H90O10SSiNa (M+Na)+ 958.5916, found 958.5917.   
 
 
6-O-Undecyl mannoside-mesylate (3.45a) 
Compound 3.45 (0.16 g, 1 mmol) was transformed to 3.45a following the reduction protocol described for 
preparation of 3.37a (0.16 g, quant). 1H NMR (CDCl3, 600 MHz) δ 7.65 (m, 4H), 7.38 (m, 6H), 4.96 (s, 
1H), 4.21 (t, J = 6.0 Hz, 2H), 4.13 (m, 2H), 3.68 (m, 6H), 3.45 (m, 3H), 2.99 (s, 3H), 2.94 (s, 1H), 1.73 (m, 
2H), 1.55-1.13 (m, 50H), 1.01 (s, 9H), 0.88 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 600 MHz) δ 136.1, 135.0, 
129.6, 127.6, 109.7, 97.3, 78.1, 75.6,73.4, 72.3,71.9, 71.6, 70.4, 68.1, 68.0, 37.6, 36.5, 32.1, 29.8 (3 







6-O-Undecyl mannoside-piperazine (3.45b) 
Following the procedure for the synthesis of 3.37b, 3.45a (0.16 g, 0.16 mmol) was converted to 
piperazine 3.45b (62 mg, 40%). 1H NMR (CDCl3, 600 MHz) δ 7.64 (m, 4H), 7.35 (m, 6H), 4.95 (s, 1H), 
4.10 (m, 2H), 3.65 (m, 5H), 3.47 (m, 4H), 3.19 (br s, 4H), 2.72 (br s, 4H), 2.39 (m, 2H), 1.50-1.09 (m, 
52H), 1.01 (s, 9H), 0.86 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 600 MHz) δ 136.1, 135.0 (2 signals), 129.6, 
127.6, 109.7, 97.3, 78.2, 75.6, 73.4, 72.3, 71.7, 71.4, 68.1, 68.0, 58.4, 50.3, 43.8, 36.5 (2 signals), 32.1, 
29.9 (2 signals), 29.8 (2 signals), 29.7 (2 signals), 29.6, 28.1, 27.5, 27.30, 26.6, 26.3 (2 signals), 25.1 (2 
signals), 22.9, 19.6, 14.4.  
 
 
6-O-Undecyl mannoside-thiophene-alkene (3.46) 
Following the procedure described for 3.40, CM for 3.19 (0.1 g, 0.24 mmol) and 3.27 (0.29 g, 0.48 mmol) 
yielded 3.41 (6 mg, 25%). FCC gave a mixture of CM product and thiophene dimer (~300 mg), which was 
treated with 5% AcCl in MeOH (1.5 mL) in DCM (15 mL). The reaction was stirred for 1 h at rt and then 
quenched with a solution of methanolic NaHCO3. The mixture was filtered and concentrated in vacuo. 
FCC of the residue (5% MeOH/DCM) afforded 3.46 (100 mg, 44% after two steps). 1H NMR (CDCl3, 600 
MHz) δ 7.59 (m, 4H), 7.41 (d, J = 3.7 Hz, 1H), 7.38 (d, J = 0.9 Hz, 1H), 7.33 (m, 2H), 7.28 (m, 4H), 6.99 
(m, 1H), 5.88 (br s, 1H), 5.59-5.36 (m, 2H), 4.91 (m, 1H), 4.03 (m, 1H), 3.94-3.53 (m, 8H), 3.46-3.29 (m, 
4H), 3.10 (m, 1H), 2.78 (br s, 1H), 2.50 (br s, 1H), 1.87 (m, 2H), 1.33-1.03 (m, 40H), 0.97 (s, 9H), 0.81 (t, 





6-O-Undecyl mannoside-10-deoxy-mesylate-alkene (3.47) 
Following the procedure described for 3.40, CM for 3.19 (0.28 g, 0.67 mmol) and 3.28 (0.11 g, 0.33 
mmol) yielded 3.47 (0.12 g, 48%) as an E/Z mixture (E/Z~4/1). Rf = 0.4 (20% EtOAc/hexanes). 1H NMR 
(CDCl3, 600 MHz) δ 5.71-5.68 (m, 2H), 5.01 (m, 1H), 4.19 (t, J = 7.5 Hz, 2H), 4.12 (m, 3H), 3.92 (m, 1H), 
3.68 (m, 3H), 3.60 (m, 1H), 3.45 (m, 2H), 2.97 (s, 3H), 2.95 (m, 1H), 2.01 (m, 2H), 1.72 (m, 2H), 1.59-1.26 
(m, 44H), 0.85 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 600 MHz) δ 136.5, 124.9, 109.7, 96.1, 78.2, 75.6, 
72.3, 71.8, 71.7, 70.4, 68.1, 68.0, 37.6, 32.5, 32.1, 29.9 (2 signals), 29.8 (2 signals), 29.7, 29.7 (2 




6-O-Undecyl mannoside-10-deoxy-mesylate (3.47a) 
3.47 (0.117 g, 0.16 mmol) was dissolved in ethyl acetate (3 mL) and degassed for 30 minutes. At that 
time, Pd/C (11 mg, 10% wt) was added and the reaction was stirred overnight under hydrogen 









Following the procedure for 3.37b, compound 3.47a (85 mg, 0.011 mmol) was converted into piperazine 
3.47b (44 mg, 30%). 1H NMR (CDCl3, 500 MHz) δ 4.96 (s, 1H), 4.12 (m, 1H), 4.10 (s, 1H), 3.66 (m, 4H), 
3.61 (m, 1H), 3.47 (m, 2H), 3.40 (m, 1H), 2.89 (t, J = 5.0 Hz, 4H), 2.40 (br s, 4H), 2.28 (m, 1H), 1.70 (br s, 
4H), 1.55 (m, 4H), 1.50 (s, 3H), 1.33 (s, 3H), 1.23 (br s, 33H), 0.85 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 
500 MHz) δ 109.6, 97.3, 78.2, 75.6, 72.3, 71.8, 71.5, 68.1, 68.0, 59.7, 54.7, 46.2, 32.1, 29.9 (2 signals), 























4.1. Introduction and background 
Traditional cancer therapies are designed to interfere with cell pathways involved in proliferation or cell 
survival.95 Those therapies are effective against cancer cells, but invariably. Therefore, tumor-specific 
cytotoxic agents are desirable.96 Herein, we describe targeting strategies for THF-ACGs. For reasons 
stated earlier, 4-DAN was used for proof of principle.   
Two studies on the targeting of THF-AGEs to cancer cells have been reported. In one, the authors 
explore folate targeted, β-cyclodextrin derived, nano-suspensions, (a biphasic system of pure drug 
particles of less than 1 nanometer in an aqueous vehicle) in vivo.97 The conjugates showed enhanced 
cytotoxicity and cell uptake for folate receptor-positive 4T1 cells. In 4T1 tumor bearing mice, the 
acetogenin nanosuspensions aggregated in tumors and enhanced drug uptake only in the tumor site. In 
the other study, biotin-conjugated acetogenins showed higher potency and selectivity in a cellular assay, 
than the parent drugs.68  
We have designed two strategies for tumor-targeted THF-ACGs. The first is a prodrug approach in which 
an ACG or an ACG mimetic is attached to a vector that binds to a tumor specific receptor. Upon cellular 
internalization the cytotoxic agent will be released. The other strategy is a ‘chameleon’ approach, in which 
the sugar ring of a sugar containing ACG mimetic is “disguised” as a tumor vector. Advantages of the 
chameleon strategy over the prodrug approach are (i) simpler synthetic chemistry; (ii) the drug and the 
vector entity are one in the same and potential problems with release of the active drug before delivery to 
the cellular target do not arise. However, designing a chameleon molecule can be more challenging than 
a prodrug as precise site modification may be needed (vide infra). 
 
4.2. The ‘chameleon’ approach 
The mannose structures described in earlier chapters are relevant to the chameleon approach. As 
discussed previously, mannose replacements are not only of interest for their easy synthetic accessibility, 
but also because they are potentially tumor vectors. For example, certain GLUTs that are overexpressed 




molecules.98 In addition, the 3-O-carbamoyl mannose subunit of the bleomycin family of clinical agents, 
has been shown to be primarily responsible for the tumor selectivity of the bleomycins (Figure 4.1). 
93c,99,100 
 
4.2.1. Design  
The design of our chameleon analogues is based on the following hypothesis: replacement of the THF 
moiety in 4-DAN with a 3-O-carbamoylmannose residue will confer tumor selectivity but will not abrogate 
potency. This design is challenging because the domain responsible for selectivity essentially overlaps 
with a segment of the molecule that impacts on potency. In this regard, questions are: (i) will the presence 
of the 3-O-carbomyl moiety reduce cytotoxicity; (ii) will the 6-O-alkyl chain on the mannose residue lower 
tumor selectivity. In comparison, the prodrug constructs, while involving more complex synthetic 
chemistry, are simpler to design as the domains for potency and selectively are remote and therefore 
likely to function independently .  
 
 






Regioselective benzoylation on the triol 4.3 using dibutyltin oxide and 4-methoxybenzyl isocyanate 
afforded the PMB protected carbamate, 4.4 (Scheme 4.1). Treatment of 4.4 with ceric ammonium nitrate 
(CAN) afforded the deprotected carbamate 4.5. Cross metathesis of 4.5 and thiophene alkene 4.6 (3.27 
in Chapter 3) provided the heterodimer in 41% yield. Hydrogenation and removal of the silyl protecting 
group delivered 4.7 in 67% after two steps.  
 
 








4.3. The prodrug approach  
This strategy uses a prodrug that is 
comprised of an ACG or an ACG mimetic 
that is conjugated via a cleavable linker to a 
vector for a tumor-specific cell surface 
receptor (Figure 4.2). Upon recognition by 
the tumor cell, the prodrug is internalized and 





The underlying hypothesis is that the tumor-specific vector on the prodrug will facilitate delivery to tumor 
but not to normal cells. Once internalized, the linkage will be cleaved, and the liberated drug will kill the 
cell. The mechanism for drug release is critical as this should be a pathway that is tumor specific to 
prevent drug release before delivery to the drug target. The use of a traceless linker is important as the 
released drug entity is identical to the parent drug, thus assuring activity.   
 
 
Figure 4.3. Example of a prodrug construct using 4-DAN as the parent drug 




For proof of principle, our vector target is PSMA which is overexpressed on prostate cancer cells and the 
linker is a previously validated disulfide-based construct (Figure 4.3). Details of the choice and synthesis 
of the specific drug, tumor receptor, vector and linker are presented in the following sections.  
 
4.3.2. Drugs  
One of the analogues of 4-DAN, 4.9 (3.10 in Chapter 3) was selected as the drug entity as it is easily 
prepared and was active against several important tumor cell lines (Figure 4.4). The synthesis of the 
derived prodrug 4.10 lays the groundwork for prodrugs from other drugs like ACG mimetic 4.11 (3.16 in 
Chapter 3), and the naturally occurring ACG annonacin 4.13 (Figure 4.4).  
 
 




Figure 4.5. DUPA derived vector 
4.3.2.  Receptor 
 
Prostate-specific membrane antigen (PSMA) is a type II cell surface glycoprotein and is the most well 
established highly restricted prostate epithelial cell membrane antigen.101 This highly restricted prostate-
related antigen is an integral cell membrane protein. Moreover, the expression level of PSMA has been 
shown to increase as the stage and the grade of the tumor progresses. There is a high interest in PSMA 
as a target for prostate-specific imaging and antitumor agents.102 Furthermore, recent studies have 
demonstrated that PSMA is also expressed in nonprostatic tumor neovasculature and it is almost absent 
in the vasculature of healthy tissues.101 Accordingly much effort has been made in developing PSMA-
targeted agents.103  
 
4.3.3. Vector  
2-[3-(1,3-dicarboxypropyl)ureido] pentanedioic acid (DUPA), is a 
PSMA-specific ligand and enters PSMA expressing cells via 
endocytosis.103b DUPA has shown promise for targeting human 
lymph node prostate cancer (LNCaP) cells with many different 
therapeutic warheads.103a The specificity of DUPA conjugates 
for prostate cancers was evaluated by studying the uptake of 
DUPA-targeted 99mTc radioimaging agents by human prostate 
cancer (LNCaP) tumors in athymic nude mice. It was found that the retention of the agent was limited to 
PCa xenograft and kidneys.104 Unlike murine kidneys, human kidneys express low levels of PSMA, These 
data suggested that DUPA might constitute an ideal ligand for prostate cancer-targeted therapy.103a 
Following a known procedure,105 glutamate salts 4.16 and 4.17 were coupled using triphosgene to deliver 
urea 4.18. Selective removal of the benzyl protecting group provided  4.19, which was treated with 4.20 to 
deliver 4.21. Chloride present under these conditions apparently led to substitution of the tosylate. 




presence of triisobutylsilane gave the tris-carboxylic acid 4.23.106 The material was stored and 
deprotected only as needed, under nitrogen, to avoid the formation of the disulfide derivative.  
 
 




The linker should be such that the drug is only released after the prodrug has been internalized, and not 
before. In addition, a traceless linker is attractive as this allows for release of a drug entity that is identical 
to the parent drug. The linker used in our prodrug 4.24 is susceptible to cleavage by thiolates, which are 
in much higher concentration in cells than in plasma. The proposed release mechanism107 is shown in 












Figure 4.6. Structure of the linker 4.24 (left) and release mechanism of the prodrug (right) 
 
Our initial synthesis of 4.24 followed the Wender protocol.108 This synthesis started with the reaction of 2-
mercaptoethanol 4.25 and 2,2’-dipyridyl disulfide 4.26 to give the mixed disulfide 4.27. As reported by 
Satyam, we found the isolation of the pure product to be tedious, especially in a large scale.107 Therefore, 
4.27 was prepared by first treating 2-mercapthopyridine 4.28 with sulfuryl chloride and reacting the crude 
material with 4.25. This provided much improved yields (40% vs 10%). Reaction of 4.27 with p-
nitrophenylchloroformate 4.29 afforded 4.24. 
 





4.4. C11 mannose derivatives 
4.4.1. Sugar-butenolide Prodrug Synthesis 
The free alcohol in alkene 4.30 was protected as the MOM derivative 4.31, which was then subjected to 
CM with butenolide alkene 4.32 under the previously described conditions to afford 4.33. Reduction of the 
double bond and selective deprotection of the TBDPS ether, provided alcohol 4.34 for vector conjugation. 
Treatment of 4.34 with nitrophenylcarbonate 4.24 in the presence of DMAP gave 4.35. Next, removal of 
the isopropylidene and MOM protecting groups by treatment of 4.35 with methanolic HCl in 
dichloromethane yielded the derived triol. Disulfide exchange on this material with in situ generated 
DUPA-derived thiol 4.15 delivered prodrug 4.10 in 80% yield from the sugar disulfide precursor (Scheme 





















4.4.2. Sugar-thiophene Prodrug Synthesis 
The methodology developed for the synthesis of compound 4.10 was applied to 4.11 as the parent drug, 
towards the synthesis of prodrug 4.12. Cross metathesis of alkenes 4.31 and 4.36 (3.27 in Chapter 3) 
delivered 4.37. After reduction of the double bond, selective deprotection of the silyl group, linker 
conjugation and removal of acetal protecting groups afforded protecting group afforded the pyridyl 
disulfide precursor 4.37b to prodrug 4.12.  
 




4.5. Annonacin prodrugs 
Using the naturally obtained compound avoids a challenging 
synthesis. However, the purification of the natural extract may not be 
trivial. Furthermore, executed complex reactions on the natural 
product may also be problematic. In this context, total synthesis is 
advantageous as such reactions can be more straightforwardly 
performed on synthetic precursors.  
A crude sample of annonacin from Annona muricata was provided by 
Professor Mohindra Seepersaud of the University of The West Indies, St Augustine. Details for extraction 
of this material and our protocol for the further purification of annonacin are described in the following 
section. 
 
4.5.1. Isolation, purification and characterization of annonacin 
 
Approximately 1.5 kg of mature and semi-mature fruits’ seeds were blended and extracted with ethanol 
(Figure 4.9). The extract was then partitioned in DCM and water and using the brine lethality test (BST) 
the organic extract was found to be more active.  
The extraction process was repeated two more times on the crude initial extract and crude compound 
was extracted every time. Each of the extracts were purified using dichloromethane and increasing 
amounts of methanol. We performed two subsequent purifications on 25 g of this sample (Figure 4.10). 
The first purification was done using 60-100% EtOAc/hexanes to 20% methanol/EtOAc. The second 
column involved only increasing amounts of methanol (up to 6%) in dichloromethane. This sequence 
provided 1.22 g of pure annonacin, 4.13, whose NMR data was essentially identical to that reported 
(Figure 4.9, 4.10, Table 4.1).109 





Figure 4.9. Extraction of annonacin 
. 
 
TLC 1 semipurified TLC 2 purified 
  
10% MeOH/DCM (2x) 10% MeOH/DCM (2x) 





Figure 4.11. 1H NMR of annonacin reported in the literature  
.




The 13C of the extracted annonacin and the one reported in the literature are comparable. See table 
below:           
     Table 4.1. 13C of literature reported  









1 174.6 174.32 
2 131.1 131.05 
3 22-38 22.58-37.18 
4 71.6 70.25 
5 29.5 29.77-29.12 
6 29.5 29.77-29.13 
7 29.5 29.77-29.14 
8 29.5 29.77-29.15 
9 29.5 29.77-29.16 
10 69.8 69.85 
11 29.5 29.77-29.12 
12 29.5 29.77-29.13 
13 29.5 29.77-29.14 
14 29.5 29.77-29.15 
15 73.9 74.17 
16 82.6 82.72 
17 22-38 22.58-37.18 
18 22-38 22.58-37.18 
19 82.7 82.63 
20 74.1 74.85 
21 29.5 29.77-29.12 
22-29 29.5 29.77-29.13 
30 29.5 29.77-29.14 
31 29.5 29.77-29.15 
32 14.1 14.13 
33 151.8 152.09 
34 77.9 78.14 




4.5.2. Annonacin prodrug synthesis 
With pure annonacin in hand we followed the same route used for the mannose-derived prodrug.  
Annonacin, 4.13, was reacted with linker 4.24. For solubility reasons, pyridine was used as a co-solvent 
with dichloromethane. This reaction provided a complex mixture comprising mono- and di-substituted 
carbonates and unreacted annonacin (Figure 4.13). To purify the complex mixture a first purification was 
needed to remove the impurities from the linker and di-substituted annonacins. The mixture of 
monosubstituted derivatives was separated into two fractions using methanol/dichloromethane. These 
fractions were each further separated into two fractions using acetone/hexane to give four fractions (1.1, 
1.2, 2.1 and 2.2).  
 





Fractions 1.2 and 2.2 were assigned the structures 4.38 and 4.39, respectively from the 1HNMR and 
HRMS data. Similarly, the compounds in fractions 1.1 and 2.1 were determined to be the other two mono-
carbonate regioisomers, 4.40 and 4.41. Unfortunately, it was not possible to distinguish between these 
two structures. Nevertheless, as fraction 1.1 was the only material that was obtained in significant 
amounts, it was subjected to the disulfide exchange reaction with 4.15. NMR analysis indicated that the 
product was either 4.14 which is derived from 4.41, or the regioisomer that comes from 4.40 (Figures 
4.14-4.16 and Appendix). 
 






Figure 4.14. Fraction 1.1 (4.40 or 4.41)  
 





Figure 4.16. Fraction 2.2 (4.39)  
 
 
Using the naturally obtained annonacin as the drug of choice for the prodrug strategy was challenging 
because of the chemistry per se, but because selective installation of the linker in annonacin was poor 
and purification of the product mixture was extremely difficult. In this context use of a suitably protected 







Scheme 4.7. En route to the synthesis of 4-DAN prodrug 
 
 
4.6. Conclusions  
The syntheses of two classes of potentially tumor-selective molecules were developed, sugar-derived 
agents (termed “chameleon: analogues), in which a mannose based ACG mimetic was modified to 
resemble the sugar recognition element in the bleomycin family of antitumor agents, and prodrugs 
derived from ACGs or ACG mimetics. The chameleon molecule is appealing because it does not require 
complex vector conjugation steps and it avoids a potential problem with prodrugs, i.e.drug release before 
delivery to the tumor target. However, the potency of the modified sugar residue or its effectiveness as a 
tumor selective ligand remains to be tested. The prodrug synthesis was applied to two synthetic 




because it facilitates release of the original unmodified drug. Therefore, retention of drug potency is very 
likely, but as mentioned above, drug release before delivery to the tumor target could be problematic. For 
both classes of these ACG-based drugs, their high degree of hydrophobicity could compromise selectivity 
because of non-specific cellular uptake. The cytotoxic properties of these potential tumor selective 
























Triol 4.3 (53 mg, 0.14 mmol) and Bu2SnO (45 mg, 0.18 mmol) were heated in toluene at reflux for 1 h, 
then the solvent was evaporated. The residue was dissolved in DMF (1 mL) and PMBNCO (22 µL, 0.15 
mmol) was added. The reaction mixture was stirred at rt for 1 h and quenched with MeOH (0.05 mL) and 
stirred for additional 30 min. The solvent was removed in vacuo and the residue was purified via FCC to 
deliver 4.4 (57 mg, 75%). Rf = 0.55 (5% MeOH/DCM). 1H NMR (CDCl3, 600 MHz) δ 7.23 (m, 2H), 6.88 
(m, 2H), 5.91 (m, 1H), 5.33 (m, 1H), 5.23 (m, 1H), 5.03 (m, 1H), 4.87 (br s, 1H), 4.33 (m, 2H), 4.22 (m, 
1H), 4.02 (m, 2H), 3.94 (m, 1H), 3.78 (m, 4H), 3.73 (m, 2H), 3.48 (m, 2H), 1.60 (m, 4H), 1.30 (m, 14H), 




Compound 4.4 (57 mg, 0.11 mmol) and CAN (0.27 g, 0.49 mmol) were dissolved in a 3:1 mixture of 
CH3CN:H2O (3 mL) and stirred for 30 min. Then, it was diluted with saturated NaHCO3 and stirred for 
additional 30 min. The mixture was then filtered through Celite, extracted with EtOAc and dried (Na2SO4). 
FCC of the residue afforded 4.5 (33 mg, 75%). Rf = 0.2 (5% MeOH/DCM). 1H NMR (CDCl3, 600 MHz) δ 
5.83 (m, 1H), 5.23 (m, 1H), 5.13 (m, 1H), 4.85 (m, 1H), 4.78 (br s, 1H), 4.12 (m, 1H), 3.91 (m, 3H), 3.69 
(m, 3H), 3.41 (m, 2H), 1.51 (m, 2H), 1.19 (m, 16H), 0.81 (t, J = 6.7 Hz, 3H); 13C NMR (CDCl3, 600 MHz) δ 







Nitrogen was bubbled through a solution of 4.5 (33 mg, 0.08 mmol) and 4.6 (0.1 g, 0.17 mmol) in dry 
CH2Cl2 (3 mL) for 30 min and at rt. At that point Grubbs 1st generation catalyst (12 mg, 0.015 mmol) was 
added and the mixture heated for 2.5 h at 40 oC. Then, the reaction was quenched with DMSO (0.05 mL). 
After stirring for an additional 30 min the solution was evaporated in vacuo. FCC of the residue afforded 
0.312 g Rf = 0.25 (30% EtOAc/hexanes). FCC afforded heterodimer 4.5a (0.44 g, 41%). Rf = 0.15 (5% 
MeOH/DCM). 1H NMR (CDCl3, 600 MHz) δ 7.58 (m, 4H), 7.40 (m, 1H), 7.32 (m, 1H), 7.28 (m, 6H), 6.99 
(m, 1H), 5.94 (br s, 1H), 5.55-5.36 (m, 2H), 4.91 (m, 1H), 4.78 (br s, 1H), 4.03 (m, 1H), 3.94-3.82 (m, 2H), 
3.63 (m, 4H), 3.43 (m, 3H), 3.35 (m, 2H), 1.86 (m, 2H), 1.51 (m, 4H), 1.30 (m, 4H), 1.29-1.26 (m, 34H), 





A mixture of 4.5a (0.44 g, 0.44 mmol) and 10% Pd/C (0.05 g) in EtOH (2 mL) was stirred for 16 h under a 
H2 atmosphere, then filtered over Celite. The filtrate was then evaporated in vacuo and the residue 
subjected to FCC to give 4.5b (0.44 g, quantitative). Rf = 0.15 (5% MeOH/DCM). 1H NMR (CDCl3, 600 
MHz) δ 7.69 (m, 4H), 7.50 (m, 1H), 7.47 (m, 1H), 7.38 (m, 6H), 7.09 (m, 1H), 6.01 (br s, 1H), 4.98 (m, 
1H), 4.83 (s, 1H), 4.04 (br s, 1H), 3.99 (t, 1H), 3.77-3.67 (m, 4H), 3.50 (m, 3H), 3.44 (m, 3H), 1.61 (m, 








A crude sample of 4.5b (40 mg, 0.052 mmol) was dissolved in DCM (2 mL) and treated with 5% AcCl in 
MeOH (0.6 mL) for 4 h. Additional 5% AcCl in MeOH (0.3 mL) was then introduced and stirring continued 
for 4 h The reaction was then quenched with saturated K2CO3 in methanol, filtered and evaporated in 
vacuo. FCC of the residue (80-100% EtOAc/hexanes and 5-10% MeOH/EtOAc) afforded 4.7 (20 mg, 
67%). Rf = 0.3 (5% MeOH/DCM). 1H NMR (CDCl3, 600 MHz) δ 7.51 (dd, J1 = 3.66 Hz , J2 = 1.08 Hz, 1H), 
7.47 (dd, J1 =  4.98 Hz, J2 = 1.14 Hz, 1H), 7.08 (dd, J1 = 4.98 Hz , J2 = 3.72 Hz, 1H), 6.04 (br s, 1H), 4.98 
(m, 1H), 4.83 (s, 1H), 4.03 (br s, 1H), 3.96 (t, J = 2.58 Hz, 1H), 3.79-3.69 (m, 4H), 3.59 (m, 1H), 3.45 (m, 
2H), 3.41 (m, 3H), 1.60 (m, 6H), 1.30-1.10 (m, 40H), 0.88 (t. J = 6.8 Hz, 3H); 13C NMR (CDCl3, 600 MHz) 
162.1, 157.5, 139.3, 136.1, 129.8, 128.1, 127.8, 99.8, 75.8, 72.3, 72.1, 70.9, 69.9, 68.1, 40.3, 37.6 (3 
signals), 37.5, 32.1, 29.8 (3 signals), 29.7 (2 signals), 29.6 (2 signals), 29.4 (2 signals), 29.3, 29.2, 27.1, 
26.3, 26.2, 26.1, 25.8, 25.6 (2 signals), 22.9, 14.3. HRMS (ESI) calcd for C40H72N2O9SNa (M+Na)+ 
779.4851, found 779.4841.  
 
 
6-O-Undecyl mannose-butenolide-DUPA conjugate (4.10) 
Under a N2 atmosphere, 4.35a (16 mg, 0.021 mmol) was dissolved in MeOH (0.5 mL) and NaOMe (0.1 




solution of 4.35a (18 mg, 0.031 mmol) in methanol (0.5 mL) was added to the reaction mixture. The 
reaction was stirred for 18 h, then, the solvent was removed in vacuo. FCC of the residue (15-20% 
MeOH/DCM) afforded 4.10 (20 mg, 80%). 1H NMR (MeOD, 600 MHz) δ 7.20 (s, 1H), 4.97 (m, 1H), 4.61 
(partially buried s, 1H), 4.60 (m, 1H), 4.25 (t, J = 6.3 Hz, 2H), 4.06 (m, 2H), 3.67-3.20 (m, 9H), 3.11 (m, 
3H), 2.84 (t, J = 6.3 Hz, 2H), 2.64 (t, J = 7.3 Hz, 2H), 2.26 (m, 4H), 2.15 (m, 2H), 2.13 (m, 2H), 1.88 (m, 
2H), 1.40 (m, 14H), 1.28 (partially buried d, J = 6.7 Hz, 3H), 1.24 (m, 18H), 1.31-1.19 (m, 25H), 0.80 (t, J 
= 6.7 Hz, 3H); 13C NMR (MeOD, 600 MHz) δ 176.4, 156.7, 152.4, 134.7, 106.8, 101.7, 80.2, 70.8, 73.5, 
72.9, 72.8, 72.3, 71.9, 69.1, 68.8, 66.7, 40.5, 39.8, 38.4, 35.4 (2 signals), 33.3, 31.5, 31.0 (2 signals), 
30.8, 30.7 (2 signals), 30.6, 30.5, 30.4 (2 signals), 30.2 (2 signals), 29.3, 28.7, 27.7, 27.5, 27.4, 26.5, 
26.4, 23.9, 23.1, 19.4, 14.6. HRMS (ESI) calcd for C57H100N3O19S2 (M+H)+ 1194.6387, found 1194.6299.  
 
 
Annonacin-DUPA conjugate (4.14) 
Following the procedure for the synthesis of 4.10, 4.40/4.41 (9 mg, 0.01 mmol) was transformed to 4.14 
(5 mg, 41%). 1H NMR (CDCl3, 600 MHz) δ 7.16 (s, 1H), 4.86 (m, 1H), 4.45 (m, 3H), 4.15 (t, J = 6.2 Hz, 
2H), 3.93 (m, 5H), 3.59 (m, 2H), 3.45 (m, 2H), 3.21 (m, 2H), 3.03 (m, 8H), 2.75 (t, J = 6.2 Hz, 2H), 2.54 (t, 
J = 7.1 Hz, 2H), 2.49 (m, 2H), 2.34 (m, 4H), 2.23-2.10 (m, 16H), 1.87-1.06 (m, 44H), 0.71 (t, J = 6.8 Hz, 
3H). HRMS (ESI) calcd for C57H100N3O17S2 (M+H)+ 1162.6489, found 1162.6495.  
 
 




A solution of L-glutamic acid di-tertbutyl ester hydrochloride 4.16 (1.0 g, 3.38 mmol) and Et3N (1.54 mL, 
11.09 mmol) in DCM (30 mL) was cooled to -78 oC. A solution of triphosgene (0.34 g, 0.34 mmol) in DCM 
(10 mL) was added dropwise via a syringe over 30 min. The reaction was stirred and allowed to warm to 
rt for 1 h. Then, 4.17 (0.7 g, 2.03 mmol) and Et3N (3 mL, 2.03 mmol) were succesively added and the 
reaction was stirred at rt for 16 h. The reaction mixture was then diluted with DCM and washed with H2O, 
dried (Na2SO4) and concentrated under reduced pressure. FCC (80% EtOAc/hexanes) delivered 4.18 
(1.0 g, 51%). Rf = 0.67 (50% EtOAc/hexanes). 1H NMR (CDCl3, 600 MHz) δ 7.33 (br s, 5H), 5.23 (s, 2H), 
5.09 (m, 1H), 4.98 (m, 1H), 4.43 (m, 1H), 4.26 (m, 1H), 2.24 (m, 4H), 2.11 (m, 2H), 1.80 (m, 2H), 1.51 (s, 
9H), 1.40 (s, 9H), 1.36 (s, 9H); 13C NMR (CDCl3, 600 MHz) δ 172.9, 172.7, 172.5, 172.1, 156.9, 135.6, 
128.8, 128.6, 128.5, 82.3, 82.3, 80.9, 80.8 (2 signals), 67.4, 53.3, 52.9, 31.8, 31.7, 28.3, 28.3, 28.2. 
HRMS (ESI) calcd for C30H46N2O9Na (M+Na)+ 601.3096, found 601.3091. The NMR data was essentially 





Compound 4.18 (1.0 g, 1.7 mmol) was dissolved in ethyl acetate (30 mL). The mixture was purged with 
N2 and Pd/C catalyst (0.1 g, 10%) was added. Then, the reaction was stirred under H2 overnight. The 
mixture was then purged with N2 and filtered over Celite, and the filtrate concentrated under reduced 
pressure. FCC of the residue yielded 4.19 (0.7 g, 82%). Compound did not show well on TLC, so the 
reaction was followed by NMR. 1H NMR (CDCl3, 600 MHz) δ 5.29 (br s, 1H), 5.22 (br s, 1H), 4.43 (m, 1H), 
4.29 (m, 1H), 2.28 (m, 4H), 2.02 (m, 2H), 1.84 (m, 2H), 1.43 (s, 9H), 1.40 (m, 18H); 13C NMR (CDCl3, 500 
MHz) δ 172.5, 172.0, 156.8, 82.0, 80.5, 53.0, 31.6, 28.4, 28.1, 28.0. HRMS (ESI) calcd for C23H40N2O9Na 







6-Aminohexyl-4-methylbenzenesulfonate hydrochloride (4.20) 
6-((tert-butoxycarbonyl)amino)hexyl 4-methylbenzenesulfonate111 (5.0 g, 0.013 mol) was stirred in a 
solution of 4 M HCl in dioxane at rt for 16 h. After that, it was concentrated in vacuo to provide 4.20 as a 
solid (4.13 g, quantitative). 1H NMR (C5H5N, 500 MHz) δ 8.01 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 
4.07 (t, J = 6.4 Hz, 2H), 3.18 (t, J = 7.5 Hz, 2H), 2.24 (s. 3H), 1.90 (m, 2H), 1.50 (m, 2H), 1.23 (m, 2H), 






To a mixture of 4.19 (0.7 g, 1.43 mmol) and DCM (70 mL) at 0 oC under N2, 4.20 (0.64 g, 2.11 mmol), 
EDCI (0.81 g, 4.24 mmol), Et3N (0.73 mL, 5.72 mmol) and DMAP (5 mg, 0.043 mmol) were added. The 
reaction was warmed slowly to rt and then stirred for 16 h. FCC (70% EtOAc/hexanes) delivered 4.19 
(0.38 g, 44%). Rf = 0.3 (30 % EtOAC/hexanes). 1H NMR (CDCl3, 500 MHz) δ 6.61 (br s, 1H), 5.90 (m, 
1H), 5.45 (m, 1H), 4.27 (m, 1H), 4.24 (m, 1H), 3.45 (m, 2H), 3.19 (m, 2H), 2.34 (m, 1H), 2.20 (m, 3H), 
1.98 (m, 2H), 1.80 (m, 2H), 1.70-1.27 (m, 33H); 13C NMR (CDCl3, 500 MHz) δ 173.5, 172.6, 172.3, 172.1, 
157.3, 82.2, 81.1, 80.8, 53.7, 53.2, 45.2, 39.6, 32.6, 32.1, 31.7, 29.5, 28.5, 26.7, 26.3.  
 




Compound 4.21 (0.38 g, 0.65 mmol) was dissolved in dry DMSO (2 mL). KSAc (0.22 g, 1.9 mmol) and 
18-crown-6 ether (17 mg, 0.064 mmol) were added and the mixture stirred at rt for 2 h. The solvent was 
evaporated in vacuo. FCC of the residue provided 4.22 (0.13 g, 31%). Rf = 0.3 (20 % EtOAC/hexanes). 
1H NMR (CDCl3, 600 MHz) δ 6.48 (m, 1H), 5.50 (br s, 1H), 5.05 (m, 1H), 4.30 (m, 1H), 4.19 (m, 1H), 3.22 
(m, 2H), 2.82 (t, J = 7.3 Hz, 2H), 2.40 (m, 1H), 2.29 (s, 3H), 2.40 (m, 1H), 2.24 (m, 1H), 2.03 (m, 1H), 1.84 
(m, 1H), 1.48-1.20 (m, 35H); 13C NMR (CDCl3, 600 MHz) δ 195.5, 173.5, 172.6, 172.2, 172.1, 157.3, 82.2, 
81.1 (2 signals), 53.7, 53.2, 39.5, 32.1, 31.7, 30.9, 29.5, 29.4, 29.1, 28.5, 28.4 (2 signals), 28.3 (2 
signals), 28.2, 26.4. HRMS (ESI) calcd for C31H55N3O9SNa (M+Na)+ 668.3551, found 668.3543.  
 
 
(14S,18S)-2,11,16-Trioxo-3-thia-10,15,17-triazaicosane-14,18,20-tricarboxylic acid (4.23) 
4.22 (25 mg, 0.037 mmol) was stirred in TFA (0.25 mL), DCM (0.25 mL) and TIBS (0.02 mL) at rt for 1.5 
h. The solution was then concentrated in vacuo. FCC of the residue (25% MeOH/DCM to 
HOAc:MeOH:DCM, 0.1:2:8) yielded 4.23 (20 mg, quantitatve). Rf = 0.3 (30% MeOH/DCM). 1H NMR 
(MeOD, 400 MHz) δ 4.30 (m, 1H), 4.20 (m, 1H), 3.21 (m, 2H), 2.88 (t, J = 7.2 Hz, 2H), 2.38 (m, 4H), 2.32 
(s, 3H), 2.16 (m, 1H), 2.04 (m, 1H), 1.81 (m, 1H), 1.77 (m, 2H), 1.52 (m, 4H), 1.39 (m, 4H); 13C NMR 
(CDCl3, 400 MHz) δ 197.8, 176.8, 174.7, 160.0, 54.7, 54.0, 40.4, 31.4, 30.8, 30.6, 30.3, 29.9, 29.6, 29.5, 
29.0, 27.5. HRMS (ESI) calcd for C19H32N3O9S (M+H)+ 478.1854, found 478.1843.  
 
 
4-Nitrophenyl (2-(pyridin-2-yldisulfaneyl)ethyl) carbonate (4.24) 
To a solution of 4.27 (0.50 g, 2.7 mmol), pyridine (0.3 mL, 4 mmol) and DCM (10 mL) at rt was added 




mixture was stirred overnight, then was washed with water (3x). The organic phase was dried (Na2SO4), 
filtered and evaporated under reduced pressure. FCC (15% EtOAc/hexanes) of the residue yielded 4.24 
(0.71 g, 76%). Rf = 0.45 (20% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 8.47 (m, 1H), 8.34 (m, 2H), 
8.14 (m, 2H), 7.55 (m, 2H), 7.32 (m, 2H), 7.14 (m, 1H), 4.58 (t, J = 1.7 Hz, 2H), 3.10 (t, J = 6.2 Hz, 2H); 
13C NMR (CDCl3, 500 MHz) δ 159.1, 155.4, 152.2, 149.9, 137.2, 126.3, 125.0, 123.2, 122.1, 120.2, 115.7, 
66.7, 36.7. HRMS (ESI) calcd for C14H13N2O5S2 (M+H)+ 352.0188, found 352.0187. The NMR data 





Sulfuryl chloride (50 mL, 1M solution in DCM) was added over a period of 20 min to a stirred solution of 2-
mercaptopyridine, 4.28 (5.0 g, 0.045 mol) in dry DCM (50 mL) at 0-5 oC under a nitrogen atmosphere. 
The mixture was stirred for 2 h and concentrated in vacuo. The yellow granular solid was taken up in dry 
DCM (200 mL) and cooled to 0 oC. To this stirred suspension at 0-5 oC was added a solution of 2-
mercaptoethanol 4.25 (3.4 mL, 0.048 mol) in DCM (10 mL) dropwise over 5 min. Within 15-20 min a 
yellow solid started to separate. The mixture was stirred at rt overnight. The product was filtered, washed 
with DCM, and dried under high vacuum. The residue was resuspended in DCM and DMAP (5.50 g, 
0.045 mmol) was added. The suspension was filtered and concentrated in vacuo. FCC of the residue 
(10% EtOAc/hexanes) yielded 4.27 (3.4 g, 40%). Rf = 0.16 (20% EtOAc/hexanes). 1H NMR (CDCl3, 
500MHz) δ 8.53 (d, J = 3.8 Hz, 1H), 7.41 (m, 1H), 7.32 (m, 1H), 7.19 (m, 1H), 3.78 (m, 2H), 2.93 (m, 2H); 
13C NMR (CDCl3, 500MHz) δ 159.1, 149.8, 136.9, 122.0, 121.6, 58.2, 42.8; HRMS (ESI) calcd for 







Alcohol 4.30 (0.40 g, 0.96 mmol) was dissolved in DCM (16 mL), MOMCl (0.29 mL, 3.81 mmol), DIPEA 
(0.86 mL, 0.006 mmol) were added at 0 oC and the solution was stirred overnight. The reaction was then 
quenched with water and extracted with DCM. The organic phase was dried Na2SO4, concentrated in 
vacuo and purified via FCC (25% EtOAc/hexanes) to afford compound 4.31 (0.3 g, 68%). Rf = 0.62 (20% 
EtOAc/hexanes). 1H NMR (CDCl3, 600 MHz) δ 5.87 (m, 1H), 5.26 (m, 1H), 5.17 (m, 1H), 5.65 (s, 1H), 
4.86 (d, J = 5.3 Hz, 1H), 4.65 (d, J = 5.2 Hz, 1H), 4.19 (m, 1H), 4.11 (m, 1H), 3.98 (m, 1H), 3.66 (m, 3H), 
3.57 (m, 1H), 3.48 (m, 1H), 3.42 (m, 4H), 1.55 (m, 4H), 1.50 (s, 3H), 1.31 (partially buried s, 3H), 1.30-
1.22 (m, 21H), 0.86 (t, J = 5.8 Hz, 3H).; 13C NMR δ 133.6, 117.8, 109.3, 96.3, 96.2, 78.4, 75.9, 73.2, 71.8, 
69.7, 68.3, 67.9, 56.0, 31.9, 29.8, 29.7, 29.6, 29.5, 29.3, 27.9, 26.4, 26.2, 22.7, 14.2. HRMS (ESI) calcd 




4-O-Methoxymethyl-6-O-undecyl mannoside-butenolide-alkene (4.33) 
A mixture of 4.31 (0.3 g, 0.65 mmol) and 4.32 (0.18 g, 0.33 mmol) in dry CH2Cl2 (3.3 mL) was purged with 
nitrogen. Grubbs I catalyst (26 mg, 0.03 mmol) was then added and the mixture purged with nitrogen, 
then heated at reflux for 6 h. At that time the mixture was cooled to rt and DMSO (0.05 mL) was added. 
After 1 h the mixture was concentrated in vacuo. FCC (30% EtOAc/hexanes) of the residue afforded 4.33 
(0.27 g, 42%). Rf = 0.53 (20% EtOAc/hexanes). 1H NMR (CDCl3, 500 MHz) δ 7.37 (m, 4H), 7.33 (m, 6H), 
6.95 (s, 1H), 5.62 (m, 1H), 5.48 (m, 1H), 5.05 (s, 1H), 4.97 (m, 1H), 4.86 (m, 1H), 4.66 (d, J = 6.3 Hz, 1H), 




1.90 (m, 2H), 1.50-1.20 (m, 45H), 1.00 (s, 9H), 0.85 (t, J = 7.2 Hz, 3H). HRMS (ESI) calcd for C58H93O10SI 
(M+H)+ 976.6460, found 976.6454.  
 
 
4-O-Methoxymethyl-6-O-undecyl mannoside-butenolide (4.33a) 
Compound 4.33 (0.27 g, 0.27 mmol) and TsNHNH2 (1.8 g, 9.67 mmol) were dissolved in DME (60 mL). At 
reflux, a solution of NaOAc (2.1 g, 25.6 mmol) in H2O (63 mL) was added dropwise over a 4 h period. The 
mixture was then cooled, diluted with ethyl acetate, and washed with water. The organic phase was dried 
(Na2SO4), filtered and concentrated in vacuo. FCC in 1-5% (acetone/DCM) delivered 4.33a. Rf = 0.5 (2% 
acetone/DCM). 1H NMR (CDCl3, 600 MHz) δ 7.64 (m, 4H), 7.33 (m, 6H), 6.93 (m, 1H), 4.99 (s, 1H),  4.97 
(m, 1H), 4.86 (d, J = 6.2 Hz, 1H), 4.66 (d, J = 6.2 Hz, 1H),  4.17 (m, 1H), 4.07 (m, 1H), 3.66 (m, 5H), 3.58 
(m, 1H), 3.46 (m, 1H), 3.40 (m, 2H), 3.38 (s, 3H), 2.40 (s, 1H), 2.22 (m, 2H), 1.50 (m, 17H), 1.24 (m, 6H), 
1.21 (m, 18H), 1.19 (m, 8H), 1.01 (s, 9H), 0.87 (m, 3H). HRMS (ESI) calcd for C58H92O10Si (M+Na)+ 






Compound 4.33a was then dissolved in a mixture of pyridine (1 mL) and HF/pyridine (1 mL) at 0 oC. The 
mixture was stirred for 16 h, then diluted with water and extracted with ethyl ether. FCC of the residue 




(m, 1H), 4.86 (d, J = 6.2 Hz, 1H), 4.66 (d, J = 6.3 Hz, 1H), 4.17 (m, 1H), 4.07 (d, J = 5.6 Hz, 1H), 3.68 (m, 
5H), 3.56 (m, 2H), 3.47 (m, 1H), 3.38 (m, 4H), 2.41 (m, 1H), 1.60-1.32 (m, 51H), 0.86 (t, J = 6.9 Hz, 3H); 
13C NMR (CDCl3, 600 MHz) δ 174.1, 149.1, 134.5, 109.4, 97.1, 95.5, 78.7, 76.2, 73.4, 72.1, 72.0, 69.9, 
68.4, 67.6, 56.2, 37.7 (2 signals), 32.1, 29.9, 29.8, 29.7 (2 signals), 29.6, 29.5 ( 2 signals), 29.3, 28.0, 






DMAP (12 mg, 0.11 mmol) was added to a solution of 4.34 (50 mg, 0.07 mmol) and linker 4.24 (40 mg, 
0.11 mmol) in DCM (1 mL). The reaction was monitored by TLC, and quenched with water after 16 h, on 
disappearance of 4.24. The solvent was evaporated and FCC of the residue (20% EtOAc/hexanes) 
yielded 4.35 (30 mg, 50%). Rf = 0.3 (20% EtOAc/hexanes). 1H NMR (CDCl3, 600 MHz) δ 8.45 (d, J = 4.7 
Hz, 1H), 7.63 m, 2H), 7.07 (m, 1H), 6.95 (m, 1H), 4.98 (s, 1H), 4.96 (m, 1H), 4.85 (d, J = 6.2 Hz, 2H), 4.35 
(m, 2H), 4.15 (t, J = 6.1 Hz, 1H), 4.10 (m, 1H), 4.05 (m, 1H), 3.56 (m, 4H), 3.55 (m, 1H), 3.48 (m, 1H), 
3.45 (m, 1H), 3.37 (m, 4H), 3.04 (t, J = 6.1 Hz, 2H), 2.22 (m, 2H), 1.52 (m, 10H), 1.49 (s, 3H), 1.37 (d, J = 
6.8 Hz, 3H), 1.29 (s, 3H), 1.27-1.21 (m, 26H), 0.84 (t, J = 6.9 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 
174.1, 159.7, 155.0, 149.9, 149.1, 137.3, 134.4, 121.1, 120.0, 109.4, 97.1, 96.5, 79.6, 78.6, 76.2, 73.3, 
72.0, 69.8, 68.3, 67.6, 65.2, 56.2, 37.2, 34.2, 32.1, 29.9, 29.8, 29.7, 29.5, 29.4, 29.3 (2 signals), 28.0, 





   
[1-(5-Methyl-2-oxo-2,5-dihydrofuran-3-yl)-pentadecan-8-yl-(2-(pyridin-2-
yldisulfaneyl)ethyl)carbonate]-15-yl-6-O-undecyl-α-D-mannopyranoside (4.35a) 
Compound 4.35 (30 mg, 0.03 mmol) was dissolved in CH2Cl2 (2 mL) and treated with 5% AcCl in MeOH 
(0.5 mL). The reaction was stirred for 16 h and then quenched with a saturated solution of NaHCO3 in 
methanol. The mixture was filtered, and the filtrate concentrated in vacuo. FCC of the residue (5% 
MeOH/DCM) afforded 4.35a (18 mg, 69%). 1H NMR (CDCl3, 500 MHz) δ 8.51 (d, J = 4.5 Hz, 1H), 7.69 
(m, 2H), 7.14 (m, 1H), 7.01 (s, 1H), 5.02 (m, 1H), 4.85 (s, 1H), 4.60 (m, 1H), 4.41 (t, J = 6.5 Hz, 2H), 3.94 
(br s, 1H), 3.85-3.45 (m, 6H), 3.54 (m, 2H), 3.43 (m, 1H), 3.10 (t, J = 6.5 Hz, 2H), 2.28 (t, J = 8.2 Hz, 2H), 
1.59 (m, 18H), 1.40 (d, J = 5.8 Hz, 3H), 1.28 (m, 27H), 0.90 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3, 500 
MHz) δ 174.2, 160.0, 155.0, 149.9, 149.2, 137.3, 134.4, 121.1, 120.1, 99.7 (2 signals), 79.6, 72.3, 71.9, 
71.8, 70.8, 70.6, 69.0 (2 signals), 68.0 (2 signals), 65.2, 53.6, 51.1, 37.2, 34.2, 32.1, 29.9, 29.8, 29.7, 
29.6, 29.5 (2 signals), 29.4 (2 signals), 29.3 (2 signals), 27.5, 26.2 (3 signals), 25.3 (2 signals), 22.9, 19.4, 




4-O-Methoxymethyl-6-O-undecyl mannoside-thiophene alkene (4.37) 
A mixture of 4.31 (160 mg, 0.35 mmol) and 4.36 (0.56 g, 0.93 mmol) in dry CH2Cl2 (10 mL) was purged 
with nitrogen. Grubbs I catalyst (43 mg, 0.05 mmol) was then introduced and the mixture heated at reflux 




was concentrated in vacuo. FCC (40% EtOAc/hexanes) of the residue afforded compound 4.37 (245 mg, 
68%). Rf = 0.53 (20% EtOAc/hexanes). 1H NMR (CDCl3, 600 MHz) δ 7.64 (m, 4H), 7.46 (m, 1H), 7.44 (m, 
1H), 7.34 (m, 6H), 7.04 (m, 1H), 5.05 (br s, 1H), 4.86 (d, J = 6.3 Hz, 1H), 4.66 (d, J = 6.2 Hz, 1H), 4.18 
(m, 1H), 4.10 (m, 2H), 3.86 (m, 1H), 3.66 (m, 3H), 3.58 (m, 1H), 3.48 (m, 1H), 3.39 (m, 6H), 1.91 (m, 2H), 
1.55 (m, 6H), 1.37 (s, 3H), 1.37-1.12 (m, 41H), 1.02 (s, 9H), 0.86 (t, J = 5.1 Hz, 3H); 13C NMR (CDCl3, 
600 MHz) δ 162.0, 139.3, 136.1 (2 signals), 135.0, 134.9, 129.8, 129.6 (2 signals), 128.0, 127.7, 127.6, 
125.1, 109.4, 96.5, 96.0, 78.6, 76.2, 73.4, 73.3, 72.0, 69.9, 68.4, 67.8, 56.1, 40.2, 36.5, 35.3, 32.4, 32.1, 
29.9 (2 signals), 29.8, 29.7 (2 signals), 29.6, 29.5 (2 signals), 29.2, 28.0, 27.3, 27.1, 26.6, 26.4, 25.0, 
24.7, 22.9, 19.6, 14.3. HRMS (ESI) calcd for C60H95NO9SSiNa (M+Na)+ 1056.6389, found 1056.6389. 
 
 
4-O-Methoxymethyl-6-O-undecyl mannoside-thiophene (4.37a) 
A solution of compound 4.37 (245 mg, 0.23 mmol) in EtOH (10 mL) and Pd/C (150 mg, 10% wt) was 
purged with N2 for 30 min. Then, the mixture was stirred under a hydrogen atmosphere (balloon) for 12 h. 
Additional Pd/C was then added (50 mg, 10% wt) and stirring continued for additional 24 h. The reaction 
was then purged with N2 and filtered through a bed of Celite to yield 4.37a (0.2 g, 82 %). 1H NMR (CDCl3, 
600 MHz) δ 7.64 (m, 4H), 7.43 (m, 1H), 7.38 (m, 1H), 7.34 (m, 6H), 7.04 (m, 1H), 5.92 (br s, 1H), 5.00 (s, 
1H), 4.86 (d, J = 6.3 Hz, 1H), 4.66 (d, J = 6.2 Hz, 1H), 4.18 (m, 1H), 4.07 (m, 1H), 3.68 (m, 6H), 3.64 (m, 
1H), 3.47 (m, 1H), 3.37 (m, 7H), 1.56 (m, 6H), 1.55 (s, 3H), 1.37 (m, 4H), 1.32 (partially buried s, 3H), 
1.09-1.26 (m, 35H), 1.02 (s, 9H), 0.85 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 600 MHz)  δ 162.0, 139.4, 
136.2, 135.0, 129.9, 129.8, 129.6, 128.0, 127.9, 127.8, 127.6, 109.5, 97.1, 96.5, 78.7, 76.3, 73.4, 72.0, 
69.9, 68.4, 67.8, 56.2, 40.3, 36.5, 32.1, 30.0, 29.9 (2 signals), 29.8 (2 signals), 29.7 (2 signals), 29.6 (2 






6-O-undecyl mannoside-2-(pyridin-2-yldisulfaneyl)ethyl)carbonate-thiophene (4.37b) 
4.37a (200 mg, 0.19 mmol) was dissolved in pyridine (2 mL) and HF/pyridine (10%, 1 mL) was added. 
The reaction was stirred at 45 oC for 24 h and then at rt for additional 24 h. The product was isolated and 
purified following the procedure used for 4.33b to afford the derived alcohol (91 mg, 65%). Rf = 0.4 (40% 
EtOAc/hexanes). A mixture of this material (90 mg, 0.11 mmol), linker 4.24 (80 mg, 0.23 mmol) and 
DMAP (30 mg, 0.25 mmol) in DCM (1 mL) was stirred at rt for 16 h.  The solvent was then evaporated, 
and the residue subject to FCC. The partially purified product (Rf = 0.4 (40% EtOAc/hexanes). was 
dissolved in DCM (4 mL) and  5% AcCl in MeOH (0.6 mL) was added. The reaction mixture was then 
evaporated under reduced pressure at rt.  FCC of the residue afforded 4.37b (76 mg, 73% after two 
steps) Rf = 0.42 (8% MeOH/DCM). 1H NMR (CDCl3, 600 MHz) δ 8.41 (m, 1H), 7.61 (m, 1H), 7.59 (m, 
1H), 7.41 (m, 1H), 7.38 (m, 1H), 7.19 (m, 1H), 7.05 (m, 1H), 5.99 (br s, 1H), 4.75 (s, 1H), 4.62 (m, 1H), 
4.31 (t, J = 6.5 Hz, 2H), 3.84-3.58 (m, 7H), 3.44 (m, 2H), 3.33 (m, 3H), 3.01 (t, J = 6.3 Hz, 2H), 1.56 (m, 
12H), 1.27 (m, 37H), 0.81 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 600 MHz) δ 162.1, 159.7, 155.0, 149.9, 
139.3, 137.3, 129.8, 128.0, 127.7, 121.1, 120.1 (2 signals), 99.7, 79.6, 72.3, 71.9, 71.8 (2 signals), 70.7 
(2 signals), 69.4 (2 signals), 68.0, 67.9, 65.2, 40.2, 37.3, 34.1 (2 signals), 32.1, 29.8 (3 signals), 29.7, 
29.6, 29.5 (3 signals), 29.4 (2 signals), 27.1, 26.2 (2 signals), 25.3, 22.9, 14.3. HRMS (ESI) calcd for 









Annonacin 4.13 (0.25 g, 0.412 mmol), was dissolved in 6 mL of a DCM: pyridine mixture (9:1) under N2. 
Nitrophenylcarbonate 4.24 (0.13 g, 0.37 mmol) and DMAP (50 mg, 0.41 mmol) were added and the 
reaction monitored by TLC. After 16 h, methanol (0.05 mL) was added and after 30 min stirring the 
mixture was concentrated in vacuo. The residue was purified by multiple FCC (see text for details), to give 
4.38 (6 mg, 2% yield), 4.39 (3 mg, 1% yield), 4.40 (or 4.41) (9 mg, 3%), an unseparated mixture of 4.40 
and  4.41 (45 mg, 12%) and recovered 4.13 (0.1, 29%). For 4.38: Rf = 0.6 (8% MeOH/DCM). 1H NMR 
(CDCl3, 500 MHz) δ 8.46 (m, 1H), 7.64 (m, 2H), 7.17 (br s, 1H), 7.09 (m, 1H), 5.04 (m, 1H), 4.67 (m, 1H), 
4.36 (t, J = 6.5 Hz, 2H), 3.80 (m, 3H), 3.37 (m, 2H), 3.05 (t, J = 6.5 Hz, 2H), 2.52 (m, 1H), 2.32 (m, 5H), 




calcd for C45H76NO9S2 (M+H)+ 838.4956, found 838.4927. For 4.39: Rf = 0.5 (8% MeOH/DCM). 1H NMR 
(CDCl3, 500 MHz) δ 8.46 (m, 1H), 7.64 (m, 2H), 7.11 (br s, 1H), 7.03 (m, 1H), 4.99 (m, 1H), 4.91 (m. 1H), 
4.37 (t , J = 6.7 Hz, 2H), 3.78 (m, 2H), 3.56 (br s, 1H), 3.38 (br s, 2H), 3.04 (t, J = 6.5 Hz, 2H), 2.57 (m, 
2H), 2.31 (m, 1H), 2.27 (m, 1H), 1.97 (m 4H), 1.54-1.36 (m, 8H), 1.37 (partially buried d, J = 6.9 Hz, 3H), 
0.34 (m, 3H). For 4.40 (or 4.41): Rf = 0.6 (8% MeOH/DCM). 1H NMR (CDCl3, 500 MHz) δ 8.40 (m, 1H), 
7.60 (m, 2H), 7.12 (s, 1H), 7.06 (m, 1H), 4.99 (m, 1H), 4.6 (m, 1H), 4.32 (m, 2H), 3.92 (m, 1H), 3.75 (m, 
2H), 3.51 (br s, 1H), 3.28 (m, 1H), 2.99 (m, 2H), 2.47 (m, 1H), 2.34 (m, 2H), 2.28 (m ,1H), 1.91 (m, 3H), 


































The cytotoxicity of naturally occurring THF-ACGs and unnatural analogues against a broad range of 
human tumor cell lines has been widely studied.12, 63 The MTT assay is the most common assay used. 
However, because studies have been performed at different timelines and against different cell lines, it is 
often difficult to compare the data. This is particularly important as the activity of certain analogues has 
been shown to vary with the length of time that the cells are incubated with the drug.62 Herein, the activity 
of our synthetic compounds in the MTT assay at 16 and 48 h is presented.  
The cell lines evaluated were the prostate cancer (PCa) cells, PC-3 and LNCaP, MCF-7 (MDR breast), 
MDA-MB-231 (breast) and HTC116 (colon). This panel was chosen to test activity against different tumor 
types and to evaluate activity of parent drugs and their DUPA-linked conjugates against PSMA (prostate 
specific membrane antigen) positive and negative cells. LNCaP is known to overexpress PSMA which 
binds DUPA with high specificity and affinity, whereas wild-type PC-3, and the non-PCa lines do not 
present PSMA.103a, b, 110 Therefore, the DUPA-drug conjugate of a given parent drug is expected to be 
more active than the parent drug against LNCaP cells, and other PSMA positive cells compared to PSMA 
negative cells. 
 
5.2. Results  
 
Activities are reported as the half maximal inhibitory concentration (IC50). As it was not possible to 
calculate an IC50 for analogues with low activity, the % cell viability at 12.5 µM and 25 µM is also reported 
to give a measure of the relative activity of all test compounds. Compounds were first assayed at 16 h at 
1-25 µM against MCF-7, MDA-MB-231, HTC116, PC-3 and LNCaP. Analogues with significant activity or 
of structure activity significance were advanced to a 48 h assay starting at a wider range of 
concentrations. 
For comparison of the data, the test compounds are grouped according to structural similarity: (a) THF 




10); (c) Hybrid analogues with both THF and butenolide substitutes (11, 12, 13, 14), including the 
‘chameleon’ analog, 14. The results for each subgroup are discussed in the following sections.  
5.2.1. THF with butenolide or butenolide substitutes (1, 2, 3, 4, 5) 
This group comprises the naturally occurring THF-butenolides 4-DAN, 1 and annonacin, 2, and 3, 4 and 
5, THF analogues in which the butenolide is replaced with O-n-butyl, N-linked piperazine and thiophene-
2-carboxamide moieties, respectively (Table 5.1). In the 16 h MTT assay, all analogues except 3 showed 
less than 50% cell viability at concentrations lower than 25 M against at least four of the five cell lines. 
The four active analogues 1, 2, 4 and 5 were further evaluated at lower concentrations over 48 h (Table 
5.2, Figure S5-I). 






HTC116 LNCaP PC-3 MCF-7 
12.5 25 12.5 25 12.5 25 12.5 25 12.5 25 
 
75 60 40 30 10 10 45 40 45 35 
 
80 70 55 45 30 30 40 30 50 50 
 
80 75 ND ND 70 55 80 75 ND ND 
 
75 60 60 40 20 20 40 30 35 25 
 










HTC116 LNCaP PC-3 MCF-7 
16    48  16  48  16  48  16  48  16  48  
 
ND 1.5 <0.1 0.2 <0.1 0.01 4 0.2 9 0.8 
 
ND ND 14 ND 7 5 15 4 24 ND 
 
ND ND ND ND <0.1 5 ND ND ND ND 
 
ND ND 17 1.5 <0.1 0.1 3 3 4 ND 
 
<0.1 2 6 0.2 <0.1 0.6 <0.1 0.2 <0.1 0.4 
 
 
As discussed earlier, and noted in other studies, in certain cases the IC50s values at 16 and 48 h were 
noticeably different, but no clear trends emerged for 1, 2, 4 and 5.  For example, in MCF-7, the IC50s for 1 
at 16 and 48 h are 9 µM and 0.8 µM respectively. In contrast, compound 5 was more active at 16 than at 
48 h (IC50s: 0.1 vs 2 µM).   
The epimeric mixture of 4-DAN 1, and thiophene 5, showed similar activity across the five cell lines and 
were the most potent compounds, at both 16 and 48 h. Compound 2, annonacin, structurally very similar 
to 1 except for the presence of an additional hydroxyl group at C-4, was somewhat lower in potency than 




5.2.2. Butenolide analogues with sugar substitutes for the THF (6, 7, 8, 9, 10)  






HTC116 PC-3 MCF-7 
12.5 25 12.5 25 12.5 25 12.5 25 
 
95 80 65 60 55 55 80 60 
 
75 50 ND ND 75 55 ND ND 
 
80 80 65 65 60 60 60 60 
 
70 65 60 40 55 50 75 65 
 
60 55 80 75 60 50 65 55 
 
Analogues 6, 7, 8, 9 and 10 probed the effect of replacing the THF with a sugar residue and the length 
and position of a hydrocarbon chain on the sugar. An initial evaluation was performed at 16 h against four 
cell lines (MBA-MD-231, HTC116, PC-3 and MCF-7). Several cases of close to 50% inhibition in the 10-
25 M range were observed, but as a group these compounds were noticeably less active than the THF 
containing compounds against the four cell lines. Specific instances of high potency and selectivity were 
observed but no clear SAR trends regarding the effect of alkyl chain length and position emerged. In 




MCF-7 with close to 50% inhibition at less than 5 M. Of these, 6 was selected for further examination at 
48 h and at lower concentrations (cell viability at 5 µM: MBA-MD-231: 90%; HTC116: 60%; LNCaP: 60%; 
PC-3: 75%; MCF-7: 80%) as it showed broader activity across the different cell lines than the others. As 
discussed for the THF-butenolide and butenolide replacement compounds in Section 5.2.1, for the case 
of compound 6, there is no clear trend in increase or decrease in activity at 16 vs 48 h.  
 
5.2.3. Hybrid analogues with THF and butenolide substitutes (11, 12, 13, 14)  
These compounds were investigated to evaluate effects of substituting the THF and butenolide moieties 
in the natural compounds with sugar residues and other heterocycles respectively. 





HTC116 LNCaP PC-3 MCF-7 
12.5 25 12.5 25 12.5 25 12.5 25 12.5 25 
 
80 55 50 40 75 55 50 40 40 10 
 
55 40 65 55 75 50 40 45 70 70 
 
ND ND ND ND 45 40 40 35 ND ND 
 
ND ND ND ND 50 35 40 40 ND ND 
 
The sugar-piperazine analogues 11 and 12 were evaluated at both 16 and 48 h against the five cell lines. 




latter being the more active and comparable in activity to 1. Both compounds were more active at 16 h 
than 48 h (Table 5.5, S5-III). The thiophene analogues 13 and 14 were only evaluated against PCa cell 
lines. The 6-O-undecyl derivative 13 exhibited IC50s of less than 1 M and was more active than the 
parent THF-butenolide, 1. This compound remains to be further examined at lower concentrations and 
longer incubation times (Table 5.5, Figure S5-III). Compound 14, the 2-carbamoyl analog of 13, preserves 
most of the activity despite the structural modification. 





HTC116 LNCaP PC-3 
MCF-
7 
16 16 16 48 16 48 16 
 
ND 25 ND ND 4 ND 3 
 
25 ND 24 ND <0.1 ND ND 
 
ND ND ND <0.1 2 0.1 ND 
 
ND ND ND <0.1 12 6 ND 
 
 
Based on the limited data for these hybrid molecules replacement of the THF and butenolide segments of 
the natural occurring ACGs with sugar and N-linked piperazine or thiophene-2-carboxamide residues 
respectively, delivered analogues with comparable potency to the parent THF-butenolide. Of all the 
analogues tested the approximate order of activity appears to be: THF-thiophene/piperazine ~ THF-





As determination of IC50s was not possible for the entire panel of test compounds, to allow for a more 
complete comparison of activities, Table S5-II summarizes activities at 12.5 and 25 mM for all analogues. 
Our SAR observations are generally consistent with previous studies (Figure 5.1).12,69 Thus, the 
observation that replacement of the butenolide with thiophene or a piperazine leads to analogues with 
comparable activity to the THF-butenolide parent, agrees with earlier results by Kojima42, 44, 56, 112 and 
Yao.41 However, in contrast to other studies, substitution of the butenolide with a simple n-butyl chain led 
to considerable loss in activity.113 
 
Figure 5.1. SAR conclusion based on cytotoxicity assays 
 
Substitution of the THF ring by a mannose delivered compounds with activity in the 25 µM range, which 
was somewhat lower than the THF-butenolide parent, and in line with earlier results from this laboratory.79 
No clear trend emerged regarding the effects of the length and location of the hydrocarbon chain on the 
sugar, as individual analogues with specific chain lengths and positions all displayed significant activity. 





There have been contradicting reports of the effect that the hydroxyl group in the hydrocarbon spacer has 
on activity.67, 70,70 In this context, 11, the C6-undecyl-mannose-piperazine and 12, its C10-deoxygenated 
counterpart both showed high potency, but their relative toxicity was dependent on the cell line studied. In 
a similar vein, we also found that annonacin 2, was less active than 4-DAN, 1, the 4-deoxy congener of 2. 
The most interesting compounds resulted from replacing both the THF and butenolide segments of the 
naturally occurring ACGs with sugar and N-piperazine or thiophene-2-carboxamide residues. These 
hybrid structures are appealing in that they are of comparable potency to the parent THF-butenolide 
parents but are considerably more synthetically accessible. The piperazine analogues are of additional 
interest in that the secondary amine allows for straightforward conjugation to imaging entities or tumor 
vectors. In the latter context, sugar hybrids such as the 3-O-carbamoyl derivative, 14 have additional 
appeal in that the sugar residue, following from the tumor selectivity of the bleomycins, is an “in-built” 
potential tumor vector.93c, 99-100 
 
5.4. Prodrug studies  
 
 
Figure 5.2. Structure of compound 6 and its prodrug 15 
 
Our hypothesis is that conjugation of a cytotoxic entity to a tumor-specific vector leads to a drug that is 
more toxic to tumor cells that overexpress the receptor than cells that do not. To test this hypothesis for 




PSMA positive prostate cell line, LNCaP, and the PSMA negative cells, PC-3 (prostate), MCF-7 (MDR 
breast), MDA-MB-231 (breast) and HTC116 (colon). Cytotoxicity data was collected over 16 and 48 h. 
 
5.4.1. Cytotoxicity data for 6 and 15 against LNCaP 
 
Over 16 h the prodrug 15 was an order of magnitude more active against LNCaP than the parent drug 6 
(IC50: 2.5 vs 24 µM, Figure 5.3) This increase in potency of 15 is consistent with the presence of PSMA on 
LNCaP and the notion that PSMA is an internalizing receptor than facilitates uptake of DUPA conjugates, 
thereby leading to increase drug uptake and potency.103a, b Similar trends in activity for 6 and 15 were 



















































5.4.2 Cytotoxicity data for 6 and 15 against PSMA negative cells 
































































































































































Compounds 6 and 15 showed a similar activity profile against the PSMA negative cells MBA-MB-231, 
HTC116 and MCF-7 (Figure 5.4). At 16 h, whereas the prodrug 15 was significantly more active than 6 
against LNCaP (ca 20 vs 50% cell viability at 25 M), the activity of 6 and 15 against the three PSMA 
negative cell lines was similar (ca 70-90% cell viability at 25 M).  
 
As a crude measure of selectivity, the activity at 5 M of 15 at 16 h against LNCaP vs the PSMA negative 
cell lines are compared in Table 5.6. The relatively higher toxicity against LNCaP vs the PSMA negative 
cells, albeit modest, supports our hypothesis that the DUPA conjugated prodrug 15 should be more 
selective for PSMA than PSMA negative cell lines.  
 
Table 5.6. Comparison of activity (% cell viability) of 15 for LNCaP vs PSMA negative cell lines at 5 M 
 
MBA-MB-231 HTC116 PC-3 LNCaP MCF-7 
% viability at 
5 M and 16 h 
80 80 80 40 80 
% viability PSMA (–) 
% viability LNCaP 
2 2 2 1 2 
 
It is also noteworthy that 15 was subtly but consistently lower in activity than 6 against the three PSMA 
negative cell lines (ca 90 vs 70% cell viability at 5 M). This may be an indication that in the absence of 
the PSMA transporter, the more polar DUPA-conjugate 15 is internalized more slowly than 6. For the 48 h 
assay, the activities of 6 and 15 against these three PSMA negative cell lines, were essentially the same 
compared to the data at 16 h.  
 
In contrast to data for the three previously discussed PSMA negative cell lines, the 16 and 48 h data 
against PC-3, which is also PSMA negative, is conflicting. The 16 h data for PC-3 is in line with our 
hypothesis and the observations for the other PSMA negative cell lines in that both 6 and 15 show 
similarly modest activity (ca 70 - 90% cell viability at 5 M). However, the activity of 6 and 15 in the 48 h 
assay seemingly disagrees with our hypothesis in that the prodrug 15 is significantly more active than the 




was predicted to be similar, as was the case for the other three PSMA negative cell lines at 48 h. In 
comparison, the activity of 6 in the 16 and 48 h assay was relatively unchanged.  
 
5.4.3. Annonacin prodrugs 
To evaluate the generality of the behavior of ACGs and their DUPA conjugates against LNCaP and PC-3 
cells, the cytotoxicity of annonacin 2 and its prodrug 16 was evaluated (Figure 5.5). These data indicate 
similar trends in activity against LNCaP and PC-3 as for 6 and 15.  
 
Figure 5.5. Structure of annonacin, 2, and annonacin prodrug, 16 
 
At 16 h, the prodrug 16 was more active against LNCaP than PC-3 (40 vs 60% viability at 5 M, Figure 
5.6). However, it should be noted that the difference in selectivity against the two cell lines is somewhat 
lower than for 6 and 15, which may be a consequence of the higher intrinsic toxicity of parent drug 2 
compared to 6.  Similar to the behavior of 6 and 15, at 48 h, prodrug 16 is significantly more active than 2 
against PC-3. This unexpected activity of DUPA-conjugated prodrugs 15 and 16 against PC-3 suggest 






Figure 5.6. Cytotoxicity at 16 and 48 hours of compounds 2 and 16 in prostate cancer cells 
 
5.5. Summary and future directions 
 
These cytotoxicity studies have revealed that ACG mimetics in which the THF and butenolide residues 
are replaced with sugar and thiophene or piperazine moieties respectively, have comparable or more 
potent activities than their THF-butenolide parents. The relatively easy synthetic access to these novel 
mimetics makes them attractive as leads for clinical development. In this context, studies were performed 
on prodrug constructs comprising a sugar-butenolide and DUPA, a validated vector to PSMA expressing 
tumors. Our preliminary assessment of prodrug selectivity albeit modest is consistent with the notion that 
selectivity is connected to DUPA-PSMA recognition. In an alternative tumor targeting approach, a sugar-
thiophene analog containing the 3-O-carbamoyl residue that has been implicated in the selectivity of the 
 















































































bleomycin family of antitumor agents, was also synthesized. This molecule showed activities in the 0.1-10 
M range against the prostate tumor cell lines LNCaP and PC-3; its tumor selectivity remains to be 
investigated.  
More detailed studies will be performed to probe the selectivity observed for our ACG-DUPA prodrugs. 
First, to confirm that the toxicity of the prodrug is due primarily to the drug entity and not the DUPA vector, 
activity of the disulfide of the vector (i.e the DUPA ligand), and prodrugs with inactive “drug” entities To 
improve selectivity prodrugs with drug entities of varying potencies such as the parent THF-butenolide, 
THF-thiophene and sugar-thiophene analogues will be screened. Along these lines, it will be also 
interesting to evaluate sugar residues with shorter hydrocarbon chains, as this may decrease non-specific 
drug uptake. To determine whether the selectivity of these conjugates is in fact due to binding to PSMA, 
competitive inhibitory experiments using 2-(phosphonomethyl)pentanedioic acid (PMPA) - an inhibitor of 
DUPA – can be performed.103a These studies will lay the groundwork for ACG derived prodrugs with other 
established tumor vectors, such as folate and less explored entities as the 3-O-carbamoyl subunit of the 
bleomycins. 
The activity against a wider range of tumor cells will further inform on selectivity. The prostate cell lines 
MDA-PCA-2b and RWPE-1, are of particular interest. The first is highly prevalent among African 
Americans and is relevant to health disparities; the second is a normal prostate epithelial cell line and is 
needed for evaluating selectivity. More detailed mechanistic studies will require fluorescently labeled 
analogues to determine surface binding, and the uptake and intracellular distribution of the compounds. In 
this context, the C-10 alcohol, the amine in piperazine analogues and the 6-O-alkyl chain are practical 
positions for incorporation of these labels. Animal experiments using xenografts will be the prelude to 









The MTT assay was used to determine metabolic activity of cells growing in monolayers by measuring 
using a microplate reader (PowerWave HT Microplate Spectrophotometer) their ability to reduce the 
yellow- colored MTT to a colored formazan. The data is expressed in percentage of control (i.e. optical 
density of formazan from control cells). 
HTC-116 colon cancer cell line, MCF-7 breast cancer, MDA-MB-231 triple negative breast cancer, PC-3, 
and LNCaP prostate cancer were obtained from the American Type Culture Collection (ATCC, Manassas, 
VA, USA). All batches of culture media were supplemented with 10% (v/v) of fetal bovine serum (Life 
Technologies, Carlsbad, CA, USA), 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL 
amphotericin B (Sigma). HCT116 colon cancer cells, MCF-7, and MDA-MB-231 breast cancers were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma), LNCaP was cultured in RPMI-1640, 
and PC-3 in F-12K Medium (Kaighn's Modification of Ham's F-12 Medium). All cells were maintained at 
37 oC in a 5% CO2 humidified atmosphere. Briefly, 20000 cells were plated on sterile 96-well plates (100 
µL of medium per well) and left undisturbed for 48 h. Then, cells were treated with different 
concentrations of compounds and incubated for 16 and 48 hours, respectively. After the incubation, cell 
viability was evaluated and quantified.  
The values of percentage of cell viability presented correspond to the mean of 3 independent experiments 
with error bars corresponding to the standard deviation of the mean. The IC50s were estimated using 
















































































































































































































































































































formula weight 440.38 









temperature (K) 130(2) 
radiation (, Å) 0.71073 
 (calcd.) g cm-3 1.415 
 (Mo K), mm-1 1.561 
 max, deg. 39.510 
no. of data collected 37955 
no. of data 12055 
no. of parameters 213 
R1 [I > 2 (I)] 0.0292 
wR2 [I > 2 (I)] 0.0639 
R1 [all data] 0.0391 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S5-I. List of compounds evaluated in Chapter 5 
 
THF-butenolide or butenolide 
substitutes 
Sugar analogues with butenolide 
Hybrid analogues with THF and 
butenolide substitutes 








































































































































Figure S5-I. Cytotoxicity at 16 and 48 h of THF containing compounds 1, 2, 3, 4 and 5 (Compound 3 at 
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HTC116 LNCaP PC-3 MCF-7 
12.5 25 12.5 25 12.5 25 
12.
5 
25 12.5 25 
 
75 60 40 30 10 10 45 40 45 35 
 
80 70 55 45 30 30 40 30 50 50 
 
80 75 ND ND 70 55 80 75 ND ND 
 
75 60 60 40 20 20 40 30 35 25 
 
30 25 30 20 10 0 30 30 45 40 
 
95 80 65 60 55 55 ND ND 80 60 
 
75 50 ND ND 75 55 ND ND ND ND 
 





70 65 60 40 55 50 ND ND 75 65 
 
60 55 80 75 60 50 ND ND 65 55 
 
80 55 50 40 75 55 50 40 40 10 
 
55 40 65 55 75 50 40 45 70 70 
 
ND ND ND ND 45 40 40 35 ND ND 
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